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Abstract	
Exacerbations	of	airway	disease	are	significant	causes	of	morbidity	and	mortality.	They	
are	 often	 associated	 with	 viral	 infections,	 most	 commonly	 rhinovirus.	 Rhinoviral	
infection	 of	 airway	 epithelial	 cells	 initiates	 several	 signalling	 pathways,	 including	 the	
MAPK	pathways,	leading	to	the	production	of	inflammatory	cytokines.	It	is	of	extreme	
importance	that	these	pathways	are	regulated	to	prevent	excessive	inflammation.	Dual	
specificity	 phosphatases	 (DUSPs)	 are	 known	 to	 negatively	 regulate	 the	 MAPKs	 in	
bacterial	infection	of	macrophages.	I	hypothesised	that	DUSPs	would	play	an	important	
role	in	regulating	the	inflammatory	response	to	rhinoviral	infection.		
The	 response	 of	 primary	 bronchial	 epithelial	 cells	 (PBECs)	 to	 rhinoviral	 infection,	
stimulation	 with	 the	 synthetic	 double-stranded	 RNA	 poly(I:C),	 or	 the	 inflammatory	
cytokine	IL-1b,	was	characterised.	Stimulation	or	infection	of	PBECs	led	to	production	of	
inflammatory	 cytokines,	 which	 was	 reduced	 by	 p38	 or	 JNK	 inhibitors.	 Two	 DUSPs	
previously	found	to	regulate	these	pathways,	DUSPs	1	and	10,	were	expressed	in	PBECs.	
Interestingly,	DUSP1	expression	was	not	regulated	in	response	to	viral	infection	but	was	
increased	at	the	mRNA	level	by	poly(I:C).		All	stimuli	induced	phosphorylation	of	DUSP1.	
In	contrast,	DUSP10	expression	was	 found	to	be	decreased	rapidly	and	transiently	 in	
response	to	infection	with	the	minor	group	virus	RV1B,	but	not	by	the	major	group	virus	
RV16,	or	poly(I:C),	or	IL-1b.	
siRNA	knock	down	of	DUSP10	did	not	show	a	direct	role	in	the	regulation	of	cytokine	
production	in	response	to	rhinovirus	or	poly(I:C).	However,	DUSP10	knock	down	cells	
consistently	 produced	 higher	 CXCL8	 in	 response	 to	 IL-1b	 stimulation,	 an	 important	
molecule	 in	 communication	 between	 macrophages	 and	 epithelial	 cells.	 Rhinovirus	
replicated	well	 in	monocytes,	and	transfer	of	supernatants	from	monocytes	to	PBECs	
induced	CXCL8	production,	which	was	increased	when	DUSP10	was	knocked	down.		
These	data	 suggest	 that	 the	MAPK	proteins	p38	and	 JNK	play	 important	 roles	 in	 the	
inflammatory	response	to	rhinovirus.	DUSPs	1	and	10	are	both	expressed	in	PBECs,	and	
DUSP10	plays	an	important	role	in	regulating	the	inflammatory	response	to	IL-1b,	and	
thus,	airway	inflammation.	This	study	identified	DUSP10	as	a	potential	target	for	future	
therapeutics	aimed	at	limiting	the	inflammation	caused	by	rhinoviral	infection.	
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1 Chapter	one:	Introduction	
1.1 Asthma	and	Chronic	Obstructive	Pulmonary	Disease	
Inflammatory	airway	diseases	are	major	causes	of	morbidity	and	mortality.	Asthma	and	
chronic	obstructive	pulmonary	disease	(COPD)	are	becoming	more	and	more	prevalent,	
with	COPD	affecting	over	a	million	people	in	the	UK,	causing	around	23,000	deaths	per	
year,	while	asthma	causes	around	1,000	deaths	per	year	(Darnton,	2014,	Holton,	2012).	
There	are	also	large	costs	associated	with	these	diseases:	asthma	is	estimated	to	cost	
the	NHS	one	billion	pounds	per	 year	 (Holton,	 2012).	 Furthermore,	 current	 therapies	
have	significant	side	effects,	and	are	poorly	effective	as	they	ease	symptoms	but	do	not	
address	the	underlying	mechanisms	of	the	disease	(Mallia	et	al.,	2011).			
Both	diseases	are	characterised	by	inflammation	and	airway	obstruction;	but	while	the	
inflammation	 in	 asthma	 is	 reversible	 and	 variable,	 in	 COPD	 it	 is	 irreversible	 and	
progressive	(Barnes,	2008).	COPD	refers	to	a	group	of	related	progressive	lung	diseases,	
the	main	two	being	emphysema,	characterised	by	abnormal	dilation	of	the	alveoli	and	
the	destruction	of	alveolar	walls,	and	chronic	bronchitis,	characterised	by	inflammation	
of	 the	 bronchi	 (Reviewed	 in:	 Barnes	 et	 al.,	 2003).	 Each	 of	 these	 diseases	 leads	 to	
decreased	 air	 flow	with	 common	 symptoms	of	 breathlessness	 and	persistent	 cough.	
COPD	 is	 thought	 to	 be	 most	 commonly	 caused	 by	 components	 of	 cigarette	 smoke	
activating	the	immune	system,	eventually	leading	to	chronic	inflammation,	although	it	
does	not	only	affect	smokers	(Sabroe	et	al.,	2007).	
1.1.1 Exacerbations	
The	 major	 cause	 of	 hospitalisations	 and	 mortality	 in	 asthma	 and	 COPD	 are	 acute	
exacerbations	where	inflammation	causes	obstruction	of	the	small	airways	(Gern,	2010).	
This	 leads	 to	cough,	wheezing,	 shortness	of	breath,	 chest	 tightness	and	decreases	 in	
expiratory	air	flow	(Fuhlbrigge	et	al.,	2012).		
Asthma	exacerbations	can	be	triggered	by	atmospheric	and	environmental	 factors	as	
well	as	allergens	(Johnston	and	Sears,	2006).	One	of	the	main	triggers	of	exacerbations	
is	 respiratory	 viral	 infections.	 Several	 studies	 have	 examined	 the	 prevalence	 of	
respiratory	 viruses	 in	 acute	 exacerbations	 of	 asthma	 and	 COPD.	 In	 asthma,	 the	
percentage	 of	 cases	 of	 acute	 exacerbations	 where	 respiratory	 viruses	 were	 present	
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ranges	from	62%	to	85%;	of	these	infections,	60%	were	rhinoviruses	(Atmar	et	al.,	1998,	
Heymann	et	al.,	2004,	 Johnston	et	al.,	2005,	 Johnston	et	al.,	1995,	Khetsuriani	et	al.,	
2007,	 Kling	 et	 al.,	 2005,	Miller	 et	 al.,	 2016,	Wark	 et	 al.,	 2002).	 In	 COPD,	 respiratory	
viruses	were	found	in	37-56%	of	acute	exacerbations,	64%	of	which	were	rhinoviruses	
(McManus	 et	 al.,	 2008,	 Rohde	 et	 al.,	 2003).	 In	 COPD,	 these	 exacerbations	 are	more	
severe	and	frequent	than	non-virally	 induced	exacerbations	(Seemungal	et	al.,	2001).	
Asthma	 morbidity	 correlates	 with	 the	 isolation	 of	 human	 rhinoviruses	 from	 the	
community,	with	peaks	in	September	and	spring	(Johnston	et	al.,	2006).		
Asthma	and	COPD	patients	do	not	 catch	 respiratory	 viral	 infections	more	 frequently	
than	healthy	controls,	but	the	infections	are	more	likely	to	progress	and	spread	to	the	
lower	respiratory	tract,	becoming	much	more	severe.	Rhinovirus	is	initially	detected	in	
nasal	lavage	2	days	post	inoculation,	then	in	bronchoalveolar	lavage	(BAL)	and	bronchial	
brushings	by	4	days	(Message	et	al.,	2008,	Mosser	et	al.,	2005).	The	viral	load	detectable	
in	BAL	is	higher	in	asthmatic	patients	(Message	et	al.,	2008).	This	greater	susceptibility	
to	more	severe	illness	could	be	due	to	damaged	epithelium	being	more	easily	infected	
by	virus	(Gern,	2010,	Jakiela	et	al.,	2008),		and	the	structural	changes	to	the	airways	that	
occur	in	asthma	have	also	been	implicated.	For	example,	a	study	in	2010	showed	that	
goblet	cells	are	particularly	susceptible	to	rhinovirus	infection	(Lachowicz-Scroggins	et	
al.,	2010);	one	of	the	features	of	asthmatic	airways	is	an	increase	in	goblet	cells,	and	
thus	 mucus	 production,	 along	 with	 an	 increase	 in	 smooth	 muscle	 and	 airway	
remodelling	with	deposition	of	collagen	and	fibronectin	under	the	epithelial	basement	
membrane	 (Lambrecht	 and	 Hammad,	 2012).	 Rhinovirus	 itself	 can	 also	 damage	 the	
airway	 epithelium,	 infection	 has	 been	 demonstrated	 to	 increase	 vascular	 leakage	
through	the	disruption	of	tight	junctions	(Sajjan	et	al.,	2008).		
It	has	been	suggested	that	asthmatics	have	deficient	immune	responses,	although	this	
is	controversial.	Several	studies	have	suggested	that	primary	bronchial	epithelial	cells	
from	asthmatics	 secrete	 reduced	amounts	of	 type	 I	 and	 type	 III	 interferons	 (IFNs)	 in	
response	to	infection	with	two	serotypes	of	rhinovirus,	RV16	and	RV1B,	in	comparison	
to	cells	from	healthy	donors	(Contoli	et	al.,	2006,	Edwards	et	al.,	2013,	Wark	et	al.,	2005).	
This	deficiency	was	also	associated	with	an	 increase	 in	viral	 replication,	although	the	
secretion	 of	 pro-inflammatory	 cytokines	 was	 no	 different	 between	 asthmatic	 and	
healthy	cells	(Wark	et	al.,	2005).	However,	two	studies	utilising	similar	methods	and	cell	
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types	found	no	significant	difference	between	the	levels	of	viral	replication	or	of	IFNs	
secreted	in	response	to	rhinoviral	infection	in	asthmatics	and	non-asthmatics	(Bochkov	
et	al.,	2010,	Lopez-Souza	et	al.,	2009).	The	reasons	for	these	differences	remain	to	be	
fully	understood	but	could	be	dependent	on	the	asthma	phenotype,	with	more	severe	
atopic	asthma	having	a	greater	IFN	deficiency	(Sykes	et	al.,	2012,	Sykes	et	al.,	2014).	As	
well	 as	 IFN	 deficiency,	many	 asthmatics	 have	 a	 skewed	 adaptive	 immune	 response,	
towards	the	T	helper	2	(Th2)	axis,	leading	to	allergic	eosinophilic	inflammation	(Message	
et	al.,	2008,	Woodruff	et	al.,	2009).	This	eosinophilic	response	has	been	correlated	to	
lower	 lung	 function	 and	 greater	 lower-respiratory-tract	 symptoms	 in	 rhinoviral	
infection,	and	levels	of	Th2	cytokines	correlate	with	the	severity	of	asthma	exacerbation	
(Message	et	al.,	2008,	Zambrano	et	al.,	2003).		
1.2 Rhinovirus	
Rhinovirus	(RV)	causes	the	common	cold;	while	the	majority	of	people	will	recover	from	
infections	 relatively	 quickly,	 RV	 can	 cause	 exacerbations	 in	 asthmatics	 and	 COPD	
patients	which	lead	to	hospitalisations	and,	in	rare	cases,	death.	
Human	rhinoviruses	belong	to	the	family	Picornaviridae	and	genus	Enterovirus.	They	are	
non-enveloped,	icosahedral,	positive	sense,	single	stranded	RNA	viruses	enclosed	within	
a	protein	capsid	composed	of	four	proteins,	VP1	to	VP4.	Over	150	serotypes	have	been	
identified	so	far	(Bochkov	and	Gern,	2012,	Palmenberg	et	al.,	2009).	These	serotypes	are	
grouped	 into	 RV-A,	 RV-B	 and	 RV-C	 based	 on	 phylogenetic	 analysis.	 Group	 C	 was	
discovered	 in	 2007	 (Lau	 et	 al.,	 2007),	 but	 poor	 culture	 methods	 have	 limited	
investigation	into	this	group	(Hao	et	al.,	2012).	Rhinoviruses	can	also	be	classified	based	
on	the	receptor	they	utilise	to	infect	cells.	The	major	group,	which	includes	most	of	RV-
A	and	all	of	RV-B,	binds	the	receptor	intracellular	adhesion	molecule	1	(ICAM-1)	(Greve	
et	al.,	1989)	while	some	serotypes	in	RV-A	bind	low	density	lipoprotein	receptor	(LDLR),	
very-LDLR	 (VLDLR)	and	LDLR-related	protein	1	 (LRP1)	and	are	 classified	as	 the	minor	
group	(Hofer	et	al.,	1994,	Marlovits	et	al.,	1998).	RV-C	has	recently	been	found	to	bind	
cadherin	related	family	member	3	(CDHR3)	(Bochkov	et	al.,	2015).		
1.2.1 Rhinovirus	Life	Cycle	
Rhinovirus	replicates	within	the	epithelial	cells	 lining	the	respiratory	tract.	Rhinovirus	
replicates	best	at	33oC	and	is	therefore	usually	infects	the	nasal	passages	in	the	upper	
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respiratory	tract.	However,	studies	have	shown	the	ability	of	rhinovirus	to	replicate	well	
at	37oC	 (Papadopoulos	et	al.,	1999)	and	 in	experimental	 infection	of	human	subjects	
rhinovirus	 has	 been	 recovered	 from	 the	 lower	 respiratory	 tract	 (Gern	 et	 al.,	 1997).	
Rhinovirus	binds	to	receptors	on	the	surface	of	epithelial	cells,	ICAM-1,	LDLR	or	CDHR3,	
triggering	 receptor	 mediated	 internalisation.	 This	 internalisation	 can	 be	 via	 clathrin	
dependent	 or	 independent	 endocytosis,	 or	 micropinocytosis,	 depending	 on	 the	
serotype	 (Ganjian	et	al.,	 2017,	Grassme	et	al.,	 2005,	Khan	et	al.,	 2010,	 Snyers	et	al.,	
2003).	Conformational	changes	of	the	rhinovirus	capsid	then	occur,	in	the	major	group	
viruses	these	changes	are	induced	by	binding	to	ICAM-1	and	in	the	minor	group	they	are	
induced	by	the	low	pH	environment	within	the	endosome	(Garriga	et	al.,	2012,	Xing	et	
al.,	2003).	These	changes	release	the	VP4	protein	from	the	capsid	which	forms	pores	in	
the	endosomal	membrane,	allowing	the	viral	RNA	to	move	into	the	cytoplasm	(Davis	et	
al.,	2008,	Panjwani	et	al.,	2014).	Once	within	the	cytoplasm,	the	RNA	is	translated	into	
a	polyprotein.	This	polyprotein	is	then	cleaved	by	the	viral	protease	2A	into	P1	and	P2/3.	
P1	is	cleaved	again	into	the	structural	proteins	VP1,	VP3	and	VP0.	Another	viral	protease,	
3C,	then	cleaves	P2/3	into	the	non-structural	proteins	(Dreschers	et	al.,	2007).	The	virus	
then	 forms	 replication	 complexes	 within	 the	 cytoplasm	 where	 the	 genomic	 RNA	 is	
replicated	by	the	viral	RNA	dependent	RNA	polymerase	 (Love	et	al.,	2004).	The	virus	
then	assembles,	and	VP0	is	cleaved	into	VP2	and	VP4	in	the	maturation	step	(Lee	et	al.,	
1993).	The	cell	then	lyses	to	release	the	nascent	virus	particles.	This	is	summarised	in	
figure	1.1.		
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Figure	1.1	The	life	cycle	of	rhinovirus.		
Rhinoviral	particles	bind	to	receptors	on	the	cell	surface	triggering	receptor	mediated	
endocytosis.	The	viral	RNA	then	escapes	from	the	endosome	and	is	translated	into	viral	
polyprotein.	 The	 polyprotein	 is	 then	 cleaved	 into	 viral	 proteins.	 The	 virus	 forms	
replication	complexes	where	the	RNA	is	replicated	and	the	virus	particles	assemble.	The	
VP0	 protein	 is	 cleaved	 in	 the	maturation	 step	 and	 the	 cell	 is	 lysed.	 (Adapted	 from:	
Dreschers	et	al.,	2007,	Whitton	et	al.,	2005).		
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1.3 Innate	Immune	Response	to	Viruses	in	the	Airway	
The	 respiratory	 tract	 needs	 to	 be	 protected	 from	 the	 constant	 influx	 of	 inhaled	
pathogens.	A	 layer	of	sticky	mucus	covers	the	epithelium,	trapping	pathogens	before	
they	 are	 able	 to	 reach	 the	 cells	 below.	 This	mucus	 is	 constantly	moved	 upwards	 by	
beating	cilia	on	the	epithelial	surface,	removing	any	trapped	pathogens.	This	mucus	also	
contains	immune	factors,	such	as:	secreted	antibodies,	and	collectins,	which	bind	and	
aggregate	pathogens,	enhancing	their	phagocytosis	by	resident	immune	cells	(Bell	et	al.,	
1981,	Vaniwaarden	et	al.,	1990).	These	resident	cells	include	macrophages,	which	are	
split	into	two	populations:	alveolar	macrophages,	on	the	alveolar	epithelial	surface,	and	
interstitial	macrophages	within	the	alveolar	walls	(Franke-Ullmann	et	al.,	1996).	These	
macrophages	 are	 capable	 of	 phagocytosing	 and	 killing	 pathogens,	 and	 secreting	
inflammatory	mediators.	However,	the	epithelial	cells	lining	the	airways	are	often	the	
first	line	of	defence.	These	cells	express	pattern	recognition	receptors	(PRRs),	both	on	
the	 plasma	membrane	 and	 within	 the	 cell	 in	 the	 cytoplasm	 and	 endosomes,	 which	
recognise	 pathogen-associated	 molecular	 patterns	 (PAMPs)	 and	 damage-associated	
molecular	patterns	(DAMPs)	(Section	1.3.1)	(Sha	et	al.,	2004).	This	gives	these	cells	the	
ability	to	monitor	both	the	external	and	internal	environment.	Binding	of	ligands	to	PRRs	
initiates	 signalling	 pathways	 (Section	 1.3.2)	 which	 lead	 to	 the	 secretion	 of	 many	
different	molecules:		IFNs;	cytokines,	including	chemotactic	cytokines	(chemokines);	and	
adhesion	molecules	(Newton	and	Dixit,	2012).	The	secretion	of	these	molecules	initiates	
inflammation,	attracting	immune	cells	towards	the	site	of	infection	(Figure	1.2).		
	
	
	 7	
	
Figure	1.2	The	initiation	of	an	inflammatory	response	to	rhinoviral	infection.		
Rhinovirus	 particles	 infect	 epithelial	 cells	 through	 binding	 to	 either	 ICAM-1,	 LDLR	 or	
CHDR-3.	This	induces	epithelial	cells	to	secrete	cytokines	including	chemokines	and	IFN.	
Immune	cells	 then	move	towards	the	site	of	 infection	through	chemotaxis.	 (Adapted	
from:	Ritchie	et	al.,	2016,	Saraya	et	al.,	2014).	
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1.3.1 Pattern	Recognition	Receptors	
The	major	family	of	PRRs	is	the	Toll-like	receptor	(TLR)	family.	In	humans,	this	consists	
of	ten	type	I	transmembrane	proteins,	each	of	which	recognises	a	different	PAMP	(Table	
1.1).	 When	 activated	 by	 a	 ligand,	 the	 TLRs	 oligomerise	 and	 form	 multi-subunit	
complexes	 which	 initiate	 signalling	 cascades	 leading	 to	 the	 activation	 and	 nuclear	
translocation	of	a	variety	of	 transcription	 factors,	 including	NF-κB,	AP-1,	CREB,	c/EBP	
and	 IRF3	 (Section	 1.3.2)	 (Newton	 and	Dixit,	 2012).	 A	 study	 in	 2004	 found	 that	 both	
primary	cells	and	cell	lines	derived	from	airway	epithelium	express	mRNA	for	TLRs	1-10	
(Sha	et	al.,	2004).	Of	relevance	to	viral	recognition,	three	of	these	receptors,	TLRs	3,	7	
and	8,	recognise	RNA	viruses	and	are	present	on	endosomal	membranes	(Lund	et	al.,	
2004,	Matsumoto	et	al.,	2003).	Here	they	can	detect	viruses	entering	the	cell	through	
endocytosis.	
Table	1.1:	Primary	ligands	recognised	by	toll-like	receptors	
	
	
	
	
	
	
	
	
RIG-I	 like	 receptors	 (RLRs),	 another	 virus-specific	 family	 of	 PRRs,	 are	 present	 in	 the	
cytosol	where	they	can	detect	the	double	stranded	RNA	(dsRNA)	produced	by	actively	
replicating	viruses	and	5’-triphosphorylated	single	stranded	RNA	(ssRNA)	 (Kato	et	al.,	
2008,	Hornung	et	 al.,	 2006).	 This	 family	 consists	 of	 three	proteins:	 RIG-I,	MDA5	and	
LGP2.	 Like	 TLRs	 3,	 7	 and	 8,	 RIG-I	 and	 MDA5	 bind	 viral	 RNA	 and	 initiate	 signalling	
pathways,	leading	to	the	activation	of	the	transcription	factors	NF-κB	and	IRF3	(Section	
1.3.2)	(Yoneyama	et	al.,	2004).	They	are	present	 in	most	cell	 types	at	 low	levels,	and	
their	expression	is	induced	by	type	I	IFNs	in	response	to	viral	infection	(Kang	et	al.,	2004).	
TLR	 Primary	Ligand	 Reference	
TLR1	 Triacyl	lipopeptides	 (Takeuchi	et	al.,	2002)	
TLR2	 Peptidoglycan	
Lipoproteins	
Lipoteichoic	acid	
(Yoshimura	et	al.,	1999)	
(Hirschfeld	et	al.,	1999)	
(Schwandner	et	al.,	1999)	
TLR3	 dsRNA	 (Alexopoulou	et	al.,	2001)	
TLR4	 Lipopolysaccharide	(LPS)	 (Hoshino	et	al.,	1999)	
TLR5	 Flagellin	 (Hayashi	et	al.,	2001)	
TLR6	 Diacyl	lipopeptides	 (Takeuchi	et	al.,	2001)	
TLR7	 ssRNA	 (Heil	et	al.,	2004)	
TLR8	 ssRNA	 (Heil	et	al.,	2004)	
TLR9	 CpG	dinucleotides	in	DNA	 (Hemmi	et	al.,	2001)	
TLR10	 Ligand	unknown,	potential	
co-receptor	for	TLR2	
(Guan	et	al.,	2010)	
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LGP2	lacks	the	caspase	activation	and	recruitment	domain	(CARD)-like	domain	which	is	
essential	for	RIG-I	and	MDA5	signalling,	and	is	thought	to	act	as	a	positive	regulator	of	
these	two	proteins	(Satoh	et	al.,	2010).		
Both	TLRs	and	RLRs	are	thought	to	detect	rhinovirus	infection	but	there	is	debate	over	
which	receptors	are	involved.	Two	studies	have	used	small	interfering	RNA	(siRNA)	to	
silence	 different	 PRRs	 in	 rhinovirus	 infection	 and	 determined	 the	 effect	 on	 IFN	 and	
cytokine	production	(Wang	et	al.,	2009,	Slater	et	al.,	2010).	Both	groups	found	that	TLR3	
and	MDA5	play	important	roles	in	the	detection	of	rhinovirus	but	they	disagreed	on	the	
role	 of	 RIG-I.	 Wang	 et	 al	 found	 no	 difference	 in	 the	 cell	 response	 when	 RIG-I	 was	
silenced,	whereas	Slater	et	al.	found	that	knockdown	of	RIG-I	decreased	the	amount	of	
IFN	secreted	and	also	led	to	a	higher	viral	load	(Wang	et	al.,	2009,	Slater	et	al.,	2010).	
These	differences	may	be	due	to	the	cell	type	used	in	each	study,	Wang	et	al.	used	a	cell	
line	derived	from	human	bronchial	epithelium	(BEAS-2B)	and	Slater	et	al.	used	primary	
human	 bronchial	 epithelial	 cells.	 In	 addition,	 the	 study	 by	 Slater	 et	 al.	 found	 that	
expression	 of	 RIG-I	 and	MDA5	was	 low	 at	 baseline	 and	 increased	 by	 four	 days	 post	
infection	(Slater	et	al.,	2010).	Furthermore,	when	the	TLR3	pathway	was	inhibited,	RIG-
I	and	MDA5	expression	decreased	(Slater	et	al.,	2010).	This	suggests	that	TLR3	 is	 the	
initiator	of	the	response	to	rhinovirus	and	induces	expression	of	RIG-I	and	MDA5	which	
then	contribute	to	the	antiviral	signalling	pathways.		
A	later	study	by	Triantafilou	et	al.	had	very	different	findings	(Triantafilou	et	al.,	2011).	
They	 suggest	 that	TLR2,	TLR7	and	TLR8	play	a	major	 role	 in	 rhinoviral	 recognition	 in	
primary	human	bronchial	 epithelial	 cells.	However,	 several	other	 studies	have	 found	
that	airway	epithelial	cells	are	unresponsive	to	the	synthetic	TLR7/8	ligands	R848	and	
Gardiquimod	(Parker	et	al.,	2008,	Slater	et	al.,	2010,	Morris	et	al.,	2006,	Sadik	et	al.,	
2009).	These	differences	could	be	partly	due	to	the	fact	that	the	Triantafilou	study	only	
included	primary	cells	from	one	donor	and	one	serotype	of	RV,	RV6	(Triantafilou	et	al.,	
2011).	
Macrophages	are	capable	of	recognising	rhinovirus	through	TLR2	binding	the	rhinoviral	
capsid.	The	inflammatory	response	of	bone	marrow	derived	macrophages	(BMDMs)	to	
rhinovirus	and	UV-inactivated	rhinovirus	is	comparable,	suggesting	that	replication,	and	
therefore	dsRNA,	 is	unnecessary	for	recognition	of	the	virus	(Saba	et	al.,	2014).	TLR2	
knock	out	mice	have	much	lower	inflammatory	cell	influx	in	response	to	RV1B	infection	
	10	
compared	to	wild-type,	and	BMDMs	taken	from	these	mice	have	decreased	mRNA	levels	
of	 inflammatory	cytokines,	such	as	TNFa	 (Han	et	al.,	2016,	Saba	et	al.,	2014).	Recent	
evidence	has	suggested	that	epithelial	cells	are	also	capable	of	recognising	RV	through	
TLR2.	BEAS-2B	cells	infected	with	RV16	or	RV39	release	comparable	levels	of	CXCL8	to	
cells	 infected	with	UV-inactivated	virus.	This	secreted	CXCL8	is	reduced	when	treated	
with	TLR2	siRNA,	although	the	reduction	is	not	as	dramatic	as	that	seen	in	macrophages	
(Ganesan	et	al.,	2016,	Unger	et	al.,	2012).		
1.3.2 Signalling	Pathways	Induced	by	Viral	Infection	
Binding	of	a	ligand	to	TLRs	causes	the	receptor	to	hetero-	or	homodimerise	(Liu	et	al.,	
2008b).	 The	 Toll/IL-1	 receptor	 (TIR)	 domain	 then	 binds	 to	 TIR	 domains	 in	 adaptor	
proteins.	All	TLRs	use	the	adaptor	MyD88	with	the	exception	of	TLR3	which	utilises	the	
adaptor	TRIF	(Yamamoto	et	al.,	2003).	Binding	of	TRIF	to	TLR3	leads	to	the	induction	of	
two	main	signalling	pathways:	figure	1.3.	The	first	pathway	is	initiated	by	TRIF	forming	
a	complex	with	TRAF3,	TBK1	and	IKKi.	TBK1	and	IKKi	phosphorylate	and	activate	IRF3	
(Fitzgerald	et	al.,	2003)	which	dimerises	and	translocates	to	the	nucleus	(Yoneyama	et	
al.,	1998).	TBK1	and	IKKi	are	also	capable	of	activating	IRF7	in	the	same	way,	however	
this	is	cell	type	dependent	(Sharma	et	al.,	2003).	Transcription	of	IRF7	is	also	induced	by	
interferon	stimulation	through	the	JAK-STAT	pathway	in	a	positive	feedback	mechanism.	
IRF3	and	IRF7	induce	the	transcription	of	interferons,	proteins	extremely	important	in	
inducing	an	antiviral	state	in	surrounding	cells	and	limiting	viral	spread	(Section	1.4.1).			
The	second	signalling	pathway	induced	by	TRIF	is	mediated	by	TRIF	binding	TRAF6	(Sato	
et	al.,	2003).	TRAF6	ubiquitinates	and	activates	TAK1	(Sato	et	al.,	2005),	which	activates	
IKKα	 and	 IKKβ	 by	 phosphorylation	 (Wang	 et	 al.,	 2001).	 IKKβ	 subsequently	
phosphorylates	p105	and	 IκBα,	 targeting	 them	for	polyubiquitination	by	SCFβ-TrCP	and	
proteosomal	 degradation	 (Yaron	 et	 al.,	 1998).	 p105	 is	 degraded	 leaving	 a	 smaller	
protein,	p50,	which	after	 release	 from	 inhibition	by	 the	 IκBα	degradation,	binds	p65	
forming	the	transcription	factor	NF-κB	(Fan	and	Maniatis,	1991).	Degradation	of	p105	
also	releases	Tpl2	from	inhibition	leading	to	activation	of	the	mitogen-activated	protein	
kinase	(MAPK)	pathways	(Section	1.3.3).		
As	mentioned	above,	all	TLRs	other	than	TLR3,	utilise	a	different	adaptor,	MyD88.	TLR4	
is	capable	of	signalling	through	both	adaptors	MyD88	and	TRIF.	Binding	of	MyD88	to	TLR	
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leads	to	the	recruitment	of	IRAK4,	which	autophosphorylates,	allowing	for	the	binding	
of	IRAK1	and	IRAK2	(Lin	et	al.,	2010).	The	formation	of	this	complex	leads	to	recruitment	
of	TRAF6,	which	 then	 induces	activation	of	NF-kB	and	 the	MAPKs	 through	 the	 same	
pathway	as	described	above	for	TLR3	signalling	(Gohda	et	al.,	2004).	However,	unlike	
TLR3	signalling,	MyD88	recruitment	does	not	lead	to	activation	of	the	IRF3	pathway	and	
induction	of	IFNs.		
The	 RLRs	 initiate	 signalling	 pathways	 through	 the	 adaptor	 protein	 mitochondrial	
antiviral	signalling	protein	(MAVS)	(Meylan	et	al.,	2005).	Binding	of	RIG-I	to	RNA	causes	
a	conformational	change	which	exposes	the	CARD	domain	(Kowalinski	et	al.,	2011).	The	
CARD	domain	binds	polyubiquitin	chains	generated	by	TRIM25	which	enables	MAVS	to	
bind	(Zeng	et	al.,	2010).	Activated	MAVS	forms	large	aggregates	(Hou	et	al.,	2011)	which	
are	able	to	bind	TRAF3	and	the	IKK	proteins	(Meylan	et	al.,	2005,	Saha	et	al.,	2006).	This	
leads	 to	 the	 induction	of	 the	 same	 signalling	 pathways	 as	 described	 above	 for	 TRIF-
mediated	signalling	(Figure	1.3).	
1.3.3 Mitogen-Activated	Protein	Kinases	
TLRs	also	activate	the	mitogen-activated	protein	kinase	(MAPK)	pathways	(Figure	1.3).	
These	pathways	consist	of	a	three-tier	kinase	cascade	of	a	MAPK	kinase	kinase	(MKKK)	
phosphorylating	 a	 MAPK	 kinase	 (MKK)	 which	 then	 phosphorylates	 a	 MAPK	 on	 two	
residues,	threonine	and	tyrosine.	The	MAPK	then	phosphorylates	and	activates	a	range	
of	substrates,	including	transcription	factors	and	other	kinases.	There	are	three	families	
of	MAPKs	involved	in	innate	immune	signalling:	p38,	JNK	and	ERK.	
Both	the	JNK	and	p38	pathways	are	activated	by	the	MKKK	TAK1.	TAK1	phosphorylates	
MKK3	or	6	and	MKK4	or	7,	which	in	turn	phosphorylate	p38	and	JNK,	respectively	(Wang	
et	al.,	2001).	p38	and	JNK	then	translocate	to	the	nucleus	and	activate	transcription	of	
a	variety	of	genes.	Other	MKKKs	can	also	lead	to	p38	and	JNK	activation;	for	example,	
ASK1,	 MLK3,	 MEKK1	 and	 MEKK3	 have	 all	 been	 shown	 to	 induce	 JNK	 activation	 in	
response	to	inflammatory	stimuli,	but	TAK1	is	thought	to	be	the	most	widely	utilised	in	
the	immune	system	(Tobiume	et	al.,	2001,	Brancho	et	al.,	2005,	Xia	et	al.,	2000,	Huang	
et	al.,	2004).		
The	JNK	pathway	is	the	main	activator	of	the	AP-1	transcription	factors.	AP-1	refers	to	a	
group	of	transcription	factors	that	bind	to	the	AP-1	binding	site	on	DNA.	They	are	hetero-	
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or	homodimers	composed	of	Jun,	Fos	or	ATF	subunits	(Curran	and	Franza,	1988).		c-Jun	
is	the	central	component	of	all	AP-1	complexes	and	is	phosphorylated	by	JNK1	and	JNK2	
(Hibi	et	al.,	1993).	This	phosphorylation	increases	its	stability	and	transcriptional	activity	
(Musti	et	al.,	1997,	Smeal	et	al.,	1994).	JNK	can	also	phosphorylate	other	AP-1	subunits,	
including	JunD	and	ATF2,	but	less	efficiently	(Gupta	et	al.,	1995,	Kallunki	et	al.,	1996).	
The	genes	of	many	inflammatory	proteins	contain	AP-1	binding	sites,	including:	IL-2,	IL-
3,	IL-4,	IL-5	and	TNFα	(Duncliffe	et	al.,	1997,	Jain	et	al.,	1993,	Rooney	et	al.,	1995,	Stranick	
et	al.,	1997,	Tsai	et	al.,	1996).	
There	 are	 four	 proteins	 in	 the	p38	 family:	 p38α,	 p38β,	 p38γ	 and	p38δ.	Not	much	 is	
known	 about	 the	 role	 of	 p38γ	 and	 p38δ	 in	 innate	 immune	 signalling,	 as	 most	 p38	
chemical	inhibitors	do	not	affect	them,	but	it	has	recently	been	suggested	they	may	have	
a	role	in	maintaining	Tpl2	stability	(Risco	et	al.,	2012).	p38α	is	thought	to	have	the	largest	
role	in	innate	immune	signalling	pathways	as	knockout	of	p38α	in	mice	protects	them	
from	 lipopolysaccharide	 (LPS)	 induced	endotoxic	shock	and	decreases	 the	amount	of	
inflammatory	cytokines	produced	by	peritoneal	macrophages	from	these	mice	in	vitro,	
including	TNFα,	IL-12	and	IL-18	(Kang	et	al.,	2008).	p38α	also	has	a	role	in	inducing	anti-
inflammatory	 molecules,	 such	 as	 IL-10	 and	 dual	 specificity	 phosphatase	 1	 (DUSP1)	
(Section	1.5.1),	in	negative	feedback	mechanisms	(Kim	et	al.,	2008).	p38β	is	thought	to	
have	less	of	a	role,	as	knocking	out	the	gene	in	mice	has	no	effect	on	LPS	stimulated	
cytokine	production	(Beardmore	et	al.,	2005).		
As	well	 as	 directly	 phosphorylating	 transcription	 factors,	 p38α	mediates	 some	 of	 its	
functions	through	activating	other	kinases,	such	as	MAPK-activated	protein	kinase	2	and	
3	(MK2	and	3)	and	mitogen	and	stress	activated	protein	kinase	1	and	2	(MSK1	and	2).	
MK2	and	3	are	produced	by	 immune	cells,	such	as	macrophages,	and	are	thought	to	
have	a	role	in	maintaining	the	stability	of	TNFα	(Kotlyarov	et	al.,	1999).	MSK1	and	2	can	
be	activated	by	both	p38α	and	the	ERK	proteins	ERK1	and	2.	They	are	nuclear	proteins	
which	phosphorylate	and	activate	the	transcription	factors	ATF1	and	CREB	(Ananieva	et	
al.,	 2008).	 These	 transcription	 factors	 bind	 to	 promoters	 in	 the	 DNA	 and	 induce	
transcription	of	the	anti-inflammatory	proteins	IL-10	and	DUSP1.	Dual	knockout	of	MSK1	
and	2	in	mice	made	them	highly	susceptible	to	LPS-induced	endotoxic	shock	(Ananieva	
et	al.,	2008)	suggesting	they	have	important	roles	in	regulating	inflammatory	responses.		
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ERK1	 and	 2	 also	 have	 roles	 in	 inducing	 pro-inflammatory	 cytokines.	 ERK1	 and	 2	 are	
activated	by	phosphorylation	by	the	MKK	MEK1,	which	is	activated	by	Tpl2	(Beinke	et	
al.,	 2004).	 Peritoneal	 macrophages	 isolated	 from	 Tpl2	 knockout	 mice	 produce	
significantly	 less	 TNFα	 in	 response	 to	 LPS	 stimulation.	 The	 same	 result	 is	 seen	when	
MEK1	is	inhibited	in	macrophages	from	wild	type	mice	pharmacologically	(Dumitru	et	
al.,	2000).	
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Figure	 1.3	 Innate	 immune	 signalling	 pathways	 initiated	 by	 viral	 infection	 of	 an	
epithelial	cell.	
TLR3	 binds	 dsRNA	 within	 the	 endosome.	 TLR3	 recruits	 TRIF	 which	 mediates	 two	
pathways.	TRIF	interacts	with	TRAF3,	TBK1	and	IKKi.	TBK1	and	IKKi	phosphorylate	the	
transcription	 factor	 IRF3	which	 dimerises	 and	 translocates	 to	 the	 nucleus.	 TRIF	 also	
interacts	with	TRAF6	and	RIP-1.	TRAF6	activates	the	TAK1/TAB2/TAB3	complex	which	
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activates	the	IKK	complex.	This	complex	phosphorylates	IκBα	and	p105	leading	to	their	
breakdown	by	the	proteasome.	p105	is	broken	down	leaving	p50	which	binds	p65,	after	
release	from	inhibition	by	IκBα,	to	form	NF-κB	which	translocates	to	the	nucleus,	binds	
DNA	and	activates	transcription	of	many	genes.	Breakdown	of	p105	also	releases	Tpl2	
from	 its	 inhibition,	 which	 phosphorylates	 MEK1,	 a	 MKK.	 Other	 MKKs,	 MKK3/6	 and	
MKK4/7,	 are	 phosphorylated	 by	 TAK1.	 The	 MKKs	 phosphorylate	 the	 MAPKs	 which	
translocate	 to	 the	 nucleus	 and	 phosphorylate	 and	 activate	 a	 variety	 of	 transcription	
factors.	 RIG-I	 and	 MDA5	 recognise	 both	 double	 and	 single	 stranded	 RNA	 in	 the	
cytoplasm	and	activate	the	IRF3	pathway	and	the	IKK	complex	(Adapted	from:	Kawai	
and	Akira,	2007,	Newton	and	Dixit,	2012).	
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1.3.4 MAPKs	in	Rhinoviral	Infection	
Many	viruses	have	been	shown	to	induce	phosphorylation	and	activation	of	the	MAPK	
proteins	 upon	 infection,	 including	 influenza	 virus,	 simian	 immunodeficiency	 virus,	
vaccinia	virus,	human	cytomegalovirus	and	murine	coronavirus	(Mizumura	et	al.,	2003,	
Popik	and	Pitha,	1998,	Andrade	et	al.,	2004,	Johnson	et	al.,	2000,	Banerjee	et	al.,	2002).	
Infection	with	RV	causes	a	time	and	dose	dependent	increase	in	the	phosphorylation	of	
the	MAPKs	(Griego	et	al.,	2000,	Schuler	et	al.,	2014).	Gern	et	al.	studied	the	effect	of	
TLR3	 activation	 on	 the	 MAPKs	 using	 a	 synthetic	 double	 stranded	 RNA	 molecule:	
polyinosinic:polycytidylic	 acid	 (poly(I:C)).	 Poly(I:C)	 is	 composed	 of	 one	 strand	 of	
polyinosine	base	paired	to	a	strand	of	polycytidine	forming	a	synthetic	dsRNA	molecule	
which	activates	TLR3	and	the	RLRs.	Stimulation	of	primary	bronchial	epithelial	cells	with	
poly(I:C)	led	to	a	gradual	increase	of	phospho-p38	which	peaked	at	70	minutes	(Gern	et	
al.,	2003).		
Rhinovirus	has	also	been	found	to	activate	p38	through	signalling	pathways	other	than	
TLR3,	 triggered	 by	 the	 viral	 internalisation	 pathway.	 In	 2006,	 p38	 was	 found	 to	 be	
activated	by	RV14	infection	of	HeLa	cells	through	the	G-protein	RhoA	(Dumitru	et	al.,	
2006).	However,	this	study	has	limitations,	for	example	the	use	of	HeLa	cells,	which	are	
not	representative	of	the	airway	epithelium,	and	only	one	strain	of	rhinovirus.	Other	
studies	 have	 demonstrated	 early,	 TLR3	 independent,	 p38	 activation	 induced	 by	
rhinoviral	infection;	with	RV16	binding	to	ICAM-1	leading	to	activation	of	p38	through	
the	protein	kinase	Syk	(Wang	et	al.,	2006).	Again,	this	research	was	done	in	a	cell	line,	
BEAS-2B,	and	only	used	one	rhinovirus	serotype,	from	the	major	group.	In	addition,	Syk	
activation	was	demonstrated	to	induce	PI3K	signalling	in	response	to	RV16	infection	of	
BEAS-2B	 cells	 (Lau	 et	 al.,	 2008),	 and	 treatment	 of	 BEAS-2B	 cells	with	 PI3K	 inhibitors	
decreased	the	release	of	inflammatory	cytokines	in	response	to	RV16	infection	(Ismail	
et	al.,	2014).	PI3K	was	also	shown	to	be	activated	by	infection	of	the	airway	epithelial	
cell	line	16HBE14o-	with	another	major	group	rhinovirus,	RV39,	and	this	activation	was	
reported	to	be	responsible	for	a	significant	proportion	of	the	CXCL8	released	(Bentley	et	
al.,	2007).	The	PI3K	pathway	has	previously	been	associated	with	the	MAPK	pathways,	
for	example,	the	PI3K/Akt	pathway	can	directly	activate	Tpl2,	the	MKKK	associated	with	
ERK	 activation	 in	 TLR3	 signalling	 (Kane	 et	 al.,	 2002).	 Furthermore,	 PI3K	 signalling	
activates	the	JNK	pathway	in	response	to	growth	factor	receptor	activation	(Kraus	et	al.,	
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2003).	Of	note,	minor	group	rhinoviruses,	such	as	RV1B,	do	not	bind	ICAM-1	and	do	not	
activate	 this	 pathway,	 although	 they	 may	 activate	 similar	 kinases	 through	 different	
means.	For	example,	Newcomb	et	al	demonstrated	that	 infection	of	a	human	airway	
epithelial	 cell	 line	with	 RV1B,	 a	minor	 group	 rhinovirus,	 induced	 activation	 of	 Akt,	 a	
downstream	 target	 of	 PI3K,	 and	 mice	 treated	 with	 a	 PI3K	 inhibitor	 had	 decreased	
inflammatory	cytokine	release	in	response	to	RV1B	(Newcomb	et	al.,	2008).		The	various	
possible	pathways	leading	to	MAPK	activation	in	RV	infection	are	summarised	in	figure	
1.4.		
Pyridinyl	imidazole	compounds,	such	as	SB203580,	inhibit	p38	by	blocking	its	catalytic	
activity,	possibly	by	competing	with	ATP	for	its	binding	site	(Young	et	al.,	1997).	Griego	
et	al.	used	two	pyridinyl	imidazole	p38	inhibitors,	SB203580	and	SB239053,	to	examine	
the	role	of	p38	in	cytokine	and	chemokine	production	by	the	BEAS-2B	human	bronchial	
epithelial	cell	line	in	response	to	infection	with	the	major	group	virus	RV39	(Griego	et	
al.,	 2000).	 They	 found	 that	 infection	with	 RV39	 caused	 a	 time	 and	 dose	 dependant	
increase	in	p38	phosphorylation.	Treatment	with	either	inhibitor	prior	to	infection	led	
to	a	 significant	decrease	 in	 the	 secretion	of	 all	 cytokines	and	chemokines	examined,	
including	CXCL8,	growth-related	oncogene-α	 (GRO-α),	granulocyte	colony-stimulating	
factor	(G-CSF)	and	granulocyte-macrophage	colony-stimulating	factor	(GM-CSF),	all	of	
which	have	important	roles	in	neutrophilia	(Griego	et	al.,	2000).		
The	role	of	the	ERK	pathway	in	rhinoviral	infection	was	examined	by	Liu	et	al.	in	2008.	
The	BEAS-2B	cell	line	was	treated	with	the	ERK1/2	inhibitor	U0126	before	infection	with	
RV16.	U0126	inhibits	the	ERK1/2	pathway	by	blocking	the	activation	of	the	MKKs	MEK1	
and	MEK2	(Davies	et	al.,	2000).	Treatment	with	this	drug	reduced	the	secretion	of	CXCL8	
by	 the	 cells	 in	 response	 to	 RV16,	 returning	 it	 to	 baseline	 levels	 (Liu	 et	 al.,	 2008a).	
Together,	these	studies	demonstrate	that	the	MAPK	proteins	play	an	important	role	in	
the	production	of	cytokines	in	response	to	RV	infection	of	airway	epithelial	cells.		
As	MAPKs	have	roles	in	many	different	cellular	processes,	they	may	also	affect	stages	of	
the	viral	life	cycle.	For	example,	Ilnytska	et	al.	have	shown	that	enteroviruses	utilise	the	
host	 cell	 endocytosis	 machinery,	 mainly	 the	 protein	 Rab11,	 to	 traffic	 cholesterol	 to	
replication	organelles	(Ilnytska	et	al.,	2013).	p38	has	been	shown	to	have	a	role	in	the	
endocytosis	 pathway:	 it	 phosphorylates	 and	 activates	 guanyl-nucleotide	 dissociation	
inhibitor	 (GDI),	 a	 protein	 which	 facilitates	 cycling	 of	 Rab	 proteins	 between	 the	
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membrane	and	the	cytosol	(Cavalli	et	al.,	2001).	This	suggests	MAPKs	may	affect	more	
aspects	of	viral	infection	than	just	innate	immune	signalling	and	affect	viral	replication.		
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Figure	1.4	Activation	of	the	MAPK	pathways	by	RV	infection.		
Major	group	RV	bind	to	receptor	ICAM-1	which	initiates	phosphorylation	of	Syk	and	the	
PI3K	pathway.	RV	can	be	recognised	by	various	PRRs:	TLR2	recognises	RV	capsid,	TLR7/8	
recognise	 ssRNA,	TLR3	and	RLRs	 recognise	dsRNA	and	 the	RLRs	also	 recognise	5’	 tri-
phosphorylated	RNA.	All	of	these	pathways	converge	on	the	TRAF6	pathway	which	leads	
to	MAPK	activation.		
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1.4 Cytokine	Signalling	
Epithelial	 cells	 have	 been	 demonstrated	 to	 secrete	 many	 cytokines	 in	 response	 to	
rhinoviral	infection	(Schroth	et	al.,	1999,	Spurrell	et	al.,	2005,	Zhu	et	al.,	1996,	Zhu	et	al.,	
1997).	Each	has	a	different	role	in	the	immune	response	to	RV.	In	this	thesis,	I	will	be	
focusing	on	the	following	cytokines:	type	I	IFN,	IL-1b,	CCL5	and	CXCL8.		
1.4.1 Interferon	
Interferons	play	an	important	role	in	controlling	viral	infections.	As	discussed	in	section	
1.3.2,	activation	of	the	IRF	pathways	in	response	to	viral	infection	leads	to	induction	and	
secretion	of	interferon.	Secreted	interferon	acts	in	an	autocrine	manner	to	signal	danger	
to	 the	 surrounding	 cells	 by	 binding	 to	 IFN	 receptors	 on	 the	 surface.	 This	 triggers	
activation	of	the	JAK-STAT	pathway,	where	the	protein	tyrosine	kinases	JAK1	and	Tyk2	
phosphorylate	STAT1	and	STAT2	which	heterodimerise	and	translocate	to	the	nucleus	
(Darnell	et	al.,	1994,	Muller	et	al.,	1993).	Within	the	nucleus,	they	bind	IRF9	forming	the	
complex	IFN-stimulated	gene	factor	3	(ISGF3)	(Fu	et	al.,	1990).	ISGF3	binds	to	promotors	
for	interferon-stimulated	genes	(ISGs)	inducing	transcription	(Sato	et	al.,	1998).	These	
ISGs	prime	the	cell	for	enhanced	virus	detection	and	inhibit	productive	viral	replication.	
Examples	of	ISGs	include	the	RLRs,	enabling	enhanced	detection	of	viral	RNA,	and	PKR	
which	phosphorylates	and	inhibits	eIF-2a,	blocking	protein	synthesis	(Der	and	Lau,	1995,	
Kang	et	al.,	2004).		
Type	I	and	III	IFNs	have	important	roles	in	the	response	to	RV.	The	predominant	type	I	
IFNs	 are	 IFN-a	 and	 IFN-b.	 IFN-a	 and	 b	 have	 similar	 structures	 and	 bind	 the	 same	
receptor:	a	complex	of	two	subunits	 IFN-a,	b	and	w	 receptor	(IFNAR)-1	and	IFNAR-2.	
Infection	of	primary	bronchial	epithelial	cells	with	RV1B	or	RV16	was	shown	to	induce	
production	 of	 IFN-a	 and	 b	 (Khaitov	 et	 al.,	 2009),	 and	 exogenous	 IFN-b	 suppressed	
replication	of	RV1B	(Cakebread	et	al.,	2011).	Clinical	trials	have	been	conducted,	with	
some	success,	using	inhaled	IFN-b	to	prevent	exacerbations	in	asthmatics	after	the	onset	
of	cold	symptoms	(Djukanovic	et	al.,	2014).		
Type	 III	 IFN,	 IFN-l,	 have	 similar	 properties	 to	 type	 I	 and	 their	 production	 is	 induced	
through	the	IRF	pathways,	although	the	promotor	also	contains	binding	sites	for	NF-kB	
(Onoguchi	et	al.,	2007).	Most	cell	types	produce	IFN-l	 in	response	to	TLR	stimulation	
but	only	certain	cells	respond	due	to	limited	expression	of	the	receptor,	IL-28Ra.	The	
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cell	types	known	to	express	IL-28Ra	include	epithelial	cells	and	plasmacytoid	dendritic	
cells	(Ank	et	al.,	2008).	Binding	of	IFN-l	to	IL-28Ra	activates	the	same	signalling	pathway	
as	type	I	IFN	(Kotenko	et	al.,	2003).	In	2007,	Zhou	et	al.	used	a	gene	expression	array	to	
compare	the	response	of	the	B	lymphocyte	cell	line	Raji	to	type	I	and	type	III	IFNs.	Type	
I	and	III	IFN	induced	a	similar	subset	of	genes,	with	no	genes	upregulated	only	by	type	
III	 (Zhou	et	al.,	2007).	 IFN-l	mRNA	production	has	been	shown	to	be	upregulated	 in	
PBECs	 in	 response	 to	 infection	with	RV16	or	 RV1B	 (Khaitov	 et	 al.,	 2009).	 Exogenous	
treatment	of	nasal	epithelial	cells	with	IFN-l	suppressed	replication	of	RSV	(Okabayashi	
et	al.,	2011).		
1.4.2 Inflammatory	Cytokines	
Some	of	the	cytokines	secreted	in	response	to	infection	signal	to	surrounding	epithelial	
cells	to	induce	defences	against	infection,	including	IL-1b.	IL-1β	binds	to	the	receptor	IL-
1RI	on	the	cell	surface	which	dimerises	with	IL-1RAcP.	This	recruits	the	adaptor	protein	
MyD88	 and	 induces	 activation	 of	 the	 TRAF6	 signalling	 pathway	 (Section	 1.3.2)	
(Medzhitov	et	al.,	1998).	IL-1β	has	been	shown	to	have	an	important	role	in	inducing	
cytokine	 release	 in	 rhinoviral	 infection,	 as	 treatment	 of	 BEAS-2B	 cells	 with	 the	 IL-1	
receptor	 antagonist	 (IL-1Ra)	 significantly	 reduces	 CXCL8	 expression	 in	 response	 to	
infection	(Stokes	et	al.,	2011).		
One	ISG	was	examined	in	this	study,	CCL5.	CCL5	is	transcriptionally	induced	by	IRF3	and	
secreted	by	epithelial	cells	in	response	to	rhinoviral	infection	(Lin	et	al.,	1999).	CCL5	then	
acts	 as	 a	 chemokine,	 attracting	many	 cell	 types	 to	 the	 site	of	 infection,	 in	particular	
eosinophils	(Alam	et	al.,	1993).		
CXCL8	is	an	inflammatory	cytokine,	transcriptionally	induced	by	NF-kB.	It	is	secreted	by	
cells	in	response	to	rhinoviral	infection	and	acts	as	a	neutrophil	chemoattractant	(Zhu	
et	al.,	1997).	Asthma	is	associated	with	increased	neutrophilic	inflammation	in	response	
to	respiratory	viral	infection	(Jarjour	et	al.,	2000,	Ordonez	et	al.,	2000,	Wark	et	al.,	2002)	
and	this	neutrophilia	can	induce	epithelial	necrosis	and	damage	the	airway	(Wang	et	al.,	
1998).	 Indeed,	 higher	 levels	 of	 CXCL8	 have	 been	 found	 to	 correlate	 with	 symptom	
severity	 in	 rhinoviral	 infection	 (Turner	 et	 al.,	 1998,	 Ordonez	 et	 al.,	 2000)	 and	 nasal	
challenge	 with	 CXCL8	 alone	 can	 induce	 cold	 symptoms	 (Douglass	 et	 al.,	 1994).	 As	
rhinovirus	itself	only	infects	a	small	percentage	of	the	epithelial	cells	within	the	airway	
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(Arruda	et	al.,	1995,	Mosser	et	al.,	2002,	Mosser	et	al.,	2005),	the	damage	seen	in	RV	
infections	is	likely	due	to	these	infiltrating	immune	cells.		
1.5 Regulation	of	Inflammation	by	DUSPs	
In	 order	 to	 stop	 overproduction	 of	 inflammatory	 markers	 and	 immune	 mediated	
damage,	 pro-inflammatory	 signalling	 pathways	 are	 heavily	 regulated.	 A	 family	 of	
proteins	called	dual-specificity	phosphatases	(DUSPs)	have	roles	in	regulating	signalling	
pathways	by	dephosphorylating	both	the	threonine	and	tyrosine	residues	within	one	
substrate	simultaneously	(Denu	and	Dixon,	1995).	Sixty-one	DUSP	proteins	have	been	
identified	so	far	with	roles	in	many	different	processes,	including	the	regulation	of:	actin	
polymerisation,	 cell	 cycle	 progression	 and	 DNA	 damage	 checkpoints	 (Reviewed	 in:	
Patterson	et	al.,	2009).	
A	subset	of	the	DUSP	family,	called	MAPK	phosphatases	(MKPs),	regulates	the	MAPK	
pathways	triggered	by	the	 innate	 immune	response	(see	figure	1.5).	So	far	ten	MKPs	
have	 been	 found,	 four	 of	 which	 have	 been	 shown	 to	 have	 roles	 in	 innate	 immune	
signalling.	In	this	chapter	I	will	be	focussing	on	these	four	MKPs:	DUSP1,	DUSP2,	DUSP4	
and	DUSP10	(Figure	1.5	and	Table	2).		
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Table	1.2:	Properties	of	DUSPs	with	roles	in	innate	immune	signalling.	
Name	 Alternative	
Names	
Molecular	
Mass	(kDa)	
Substrate	
Specificity	
Subcellular	
Localisation		
Reference	
DUSP1	 MKP-1	 39.30	 p38	and	JNK	 Nuclear	 (Zhao	et	al.,	2005)	
DUSP2	 PAC-1	 34.40	 JNK	 Nuclear	 (Jeffrey	et	al.,	
2006)	
DUSP4	 MKP-2	 42.95	 ERK	 Nuclear	 (Cornell	et	al.,	
2010)	
DUSP10	 MKP-5	 52.64	 p38	and	JNK	 Nuclear	and	
Cytoplasmic	
(Zhang	et	al.,	2004)	
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Figure	 1.5	 Regulation	 of	 the	MAPK	 pathways	 by	 DUSP	 proteins	 in	 innate	 immune	
signalling.		
The	MAPKs	 are	 activated	 by	 a	 phosphorylation	 cascade:	 the	MKKKs	 TAK1	 and	 Tpl2	
phosphorylate	the	MKKs	MKK4/7,	MKK3/6	and	MEK1	which	phosphorylate	the	MAPKs	
which	 then	 translocate	 to	 the	 nucleus	 and	 activate	 transcription	 factors	 and	 other	
kinases.	Two	kinases	activated	by	p38	and	ERK1/2	are	MSK1	and	MSK2.	These	activate	
transcription	 factors	 NF-κB	 and	 CREB/ATF.	 CREB/ATF	 then	 induces	 transcription	 of	
DUSPs	1,	2	and	4.	The	DUSP	proteins	inhibit	these	pathways	by	dephosphorylating	the	
MAPKs:	DUSP1	and	DUSP10	dephosphorylate	p38	and	JNK1/2,	DUSP2	dephosphorylates	
JNK1/2	 and	 DUSP4	 dephosphorylates	 ERK1/2.	 DUSP1	 is	 also	 activated	 by	
phosphorylation	by	ERK	(Adapted	from:	Arthur	and	Ley,	2013,	Newton	and	Dixit,	2012).	
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1.5.1 DUSP1	
The	 most	 well-studied	 of	 the	 DUSP	 proteins	 is	 the	 nuclear	 protein	 DUSP1.	 DUSP1	
preferentially	dephosphorylates	p38	and	JNK,	but	is	capable	of	dephosphorylating	ERK	
(Chi	et	al.,	2006,	Franklin	and	Kraft,	1997).	Studies	from	knockout	mice	have	shown	the	
importance	of	DUSP1	 in	 the	 immune	 system	 (Chi	 et	 al.,	 2006,	Hammer	 et	 al.,	 2006,	
Frazier	et	al.,	2009).	For	example,	mice	lacking	DUSP1	are	very	susceptible	to	endotoxic	
shock	when	their	 immune	systems	are	activated	by	stimuli	such	as	LPS,	and	DUSP1-/-	
BMDMs	overexpress	many	inflammatory	mediators,	such	as	TNFα,	IL-1,	IL-6,	CCL3,	CCL4	
and	 CXCL2,	when	 challenged	with	 LPS,	 or	 live	 bacteria,	 in	 vitro	 (Frazier	 et	 al.,	 2009,	
Hammer	et	al.,	 2006,	Talwar	et	al.,	 2017).	 In	each	 study	 this	excessive	 inflammatory	
response	 was	 associated	 with	 increased	 and	 prolonged	 activation	 of	 p38	 and	 JNK	
MAPKs.	 Loss	 of	 DUSP1	 also	 correlated	 with	 an	 increased	 release	 of	 the	 anti-
inflammatory	protein	IL-10,	BMDMs	from	knock	out	mice	producing	5	to	10	times	more	
than	wild	type	in	response	to	LPS	stimulation	(Chi	et	al.,	2006,	Hammer	et	al.,	2006).	This	
effect	was	negated	when	treated	with	p38	 inhibitors	 (Chi	et	al.,	2006).	Furthermore,	
overexpression	 of	 DUSP1	 in	 murine	 alveolar	 macrophages	 has	 been	 shown	 to	
significantly	decrease	the	release	of	TNFα	in	response	to	LPS	(Zhao	et	al.,	2005).	DUSP1	
has	also	been	implicated	in	the	regulation	of	interferon	production;	DUSP1	knock	out	
BMDMs	produce	much	higher	levels	of	IFN-β	in	response	to	LPS	than	wild-type	(McGuire	
et	 al.,	 2017).	 This	 indicates	 that	 regulation	 of	 p38	 and	 JNK	 signalling	 in	 response	 to	
bacteria	by	DUSP1	is	extremely	important	in	minimising	the	amount	of	damage	caused	
by	inflammation.		
DUSP1	may	also	be	able	 to	positively	 regulate	expression	of	 some	genes.	During	 the	
course	 of	 this	 thesis,	 Shah	 et	 al.	 performed	 a	 gene	 expression	 array,	 comparing	 the	
response	of	A549	cells,	with	and	without	DUSP1	overexpression,	to	IL-1b	stimulation.	
Several	gene	transcripts	were	found	to	be	upregulated	in	DUSP1	overexpressing	cells,	
including	STAT5A,	the	interferon-stimulated	genes	IFIT1	and	IFIT3,	and	the	transcription	
factor	IRF1.	Treatment	of	the	lung	epithelial	cell	line	A549	with	DUSP1	siRNA	was	found	
to	decrease	IRF1	expression	in	response	to	IL-1b	(Shah	et	al.,	2016a).	This	study	suggests	
that	DUSP1	may	have	a	positive	regulatory	role	in	the	interferon	pathways,	however,	
overexpression	 studies	 must	 be	 interpreted	 carefully,	 as	 they	 create	 a	 synthetic	
environment.				
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DUSP1	may	regulate	cytokine	expression	both	pre-	and	post-transcriptionally;	a	study	in	
2011	found	that	DUSP1	can	also	induce	cytokine	mRNA	decay	(Yu	et	al.,	2011).	The	half-
lives	of	several	cytokine	mRNAs	were	increased	in	BMDMs	from	DUSP1	knockout	mice	
compared	 to	wild	 type,	 and	 this	was	 associated	with	 a	 decrease	 in	 translocation	 of	
ARE/Poly(U)	 binding	 degradation	 factor	 1	 (AUF1),	 a	 protein	 which	 binds	mRNA	 and	
recruits	degradation	machinery,	from	the	nucleus	to	the	cytoplasm	(Yu	et	al.,	2011).	This	
may	 be	 an	 additional	 result	 of	 p38	 dephosphorylation,	 as	 it	 has	 been	 found	 that	
treatment	 with	 another	 imidazole	 p38	 inhibitor,	 SK&F	 86002,	 promotes	 AUF1-
dependant	mRNA	decay	in	primary	human	monocytes	(Sirenko	et	al.,	1997).	DUSP1	also	
activates	tristetraprolin	 (TTP),	another	mRNA	destabilising	factor,	which	binds	to	and	
induces	the	decay	of	mRNA	for	several	 inflammatory	cytokines.	TTP	 is	 inactivated	by	
phosphorylation	 by	 p38;	 therefore,	 DUSP1	 dephosphorylation	 of	 p38	 prevents	 TTP	
inhibition	(Prabhala	et	al.,	2016).	TTP	has	also	been	shown	to	destabilise	DUSP1	mRNA	
in	a	negative	feedback	mechanism	(Emmons	et	al.,	2008).	
1.5.2 DUSP1	and	Viruses	
Much	of	the	literature	discussed	above	has	examined	the	role	of	DUSP1	in	response	to	
LPS,	a	component	of	bacterial	cell	membranes,	not	present	in	viruses.	Recently,	its	role	
in	the	response	to	viral	infection	has	begun	to	be	investigated.	DUSP1	has	been	shown	
to	be	induced	by	the	synthetic	viral	mimic,	poly(I:C),	in	a	human	airway	epithelial	cell	
line,	NCI-H292	(Golebski	et	al.,	2014).	Knockdown	of	the	DUSP1	protein	in	NCI-H292	cells	
using	 siRNA	 significantly	 increased	 both	 induction	 and	 secretion	 of	 two	 pro-
inflammatory	cytokines,	CXCL8	and	IL-6,	in	response	to	poly(I:C)	(Golebski	et	al.,	2015).	
DUSP1	is	also	induced	by	infection	with	viruses:	Ebola	infection	of	the	human	hepatoma	
cell	 line	 Huh7,	 human	 immunodeficiency	 virus	 (HIV)	 infection	 of	 human	 alveolar	
macrophages,	and	infectious	bronchitis	virus	(IBV)	infection	of	NCI-H1299	cells	(a	lung	
epithelial	cell	 line),	 increased	DUSP1	expression	(Holzer	et	al.,	2016,	Liao	et	al.,	2011,	
Tachado	et	al.,	2005).	This	increase	in	response	to	HIV	was	diminished	when	infected	
with	virus	lacking	the	NS1	protein,	suggesting	that	the	virus	may	be	targeting	DUSP1	as	
a	mechanism	to	dampen	down	the	immune	response	(Tachado	et	al.,	2005).	Vaccinia	
virus	has	also	been	shown	to	upregulate	DUSP1	mRNA	and	protein	levels	in	HeLa	cells,	
and	 knockout	 mice	 infected	 with	 this	 virus	 had	 increased	 TNFα	 release,	 and,	
interestingly,	increased	viral	titres	(Caceres	et	al.,	2013).			
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Surprisingly,	silencing	DUSP1	in	Huh7	cells	inhibited	the	replication	of	hepatitis	C	virus	
(HCV).	 This	 was	 found	 to	 be	 due	 to	 increased	 STAT1	 activation	 and	 induction	 of	
interferon	 stimulated	 genes,	 suggesting	DUSP1	dephosphorylates	 STAT1	 (Choi	 et	 al.,	
2015).	
1.5.3 Regulation	of	DUSP1	
DUSP1	 is	 transcriptionally	 induced	 by	 a	 negative	 feedback	mechanism:	 p38	 and	 ERK	
activate	the	kinases	MSK1	or	MSK2	which	phosphorylate	the	transcription	factors	CREB	
and	 ATF1,	 which	 then	 bind	 to	 the	 promoter	 of	 the	 gene	 for	 DUSP1	 and	 initiate	 its	
transcription	 (Ananieva	 et	 al.,	 2008).	 DUSP1	 has	 been	 shown	 to	 be	 transcriptionally	
induced	in	response	to	inflammatory	cytokines,	such	as	TNFα,	and	by	ligands	for	TLRs	2,	
3,	4	and	9:	Pam3CSK4,	poly(I:C),	LPS	and	CpG	(Chi	et	al.,	2006,	Manetsch	et	al.,	2012).	It	
is	also	upregulated	by	IL-1b	 in	primary	airway	smooth	muscle	cells	(Issa	et	al.,	2007).	
This	induction	is	through	either	the	MyD88	or	TRIF	mediated	pathways,	with	knock	out	
mice	 for	 either	unable	 to	upregulate	DUSP1	 (Chi	 et	 al.,	 2006).	However,	 it	 has	been	
suggested	that	pretreatment	of	macrophages	with	IFN-γ	can	decrease	the	induction	of	
DUSP1	by	LPS	(Zhao	et	al.,	2005).	DUSP1	is	also	regulated	by	the	stability	of	its	mRNA,	
inhibition	 of	 the	 pro-inflammatory	 cytokine	 macrophage	 migration	 inhibitory	 factor	
(MIF)	has	been	found	to	increase	DUSP1	mRNA	stability	in	the	RAW	264.7	macrophage	
cell	 line	 (Gao	 et	 al.,	 2017).	 DUSP1	 protein	 stability	 can	 also	 be	 regulated:	
phosphorylation	 at	 two	 serine	 residues,	 Ser359	 and	 Ser364,	 stabilises	 the	 protein,	
prolonging	its	half-life.	The	MAPK	ERK	has	been	shown	to	do	this	in	a	negative	feedback	
mechanism	(Brondello	et	al.,	1999).	However,	sustained	ERK	activation	has	been	shown,	
in	cancer	cells,	to	phosphorylate	DUSP1	at	two	alternative	serine	residues,	Ser296	and	
Ser323,	which	 induces	 ubiquitination	 of	 DUSP1	 by	 SCF-SKP2	 leading	 to	 proteosomal	
degradation	(Lin	et	al.,	2003).	Similarly	to	other	phosphatases,	oxidation	of	the	catalytic	
site	by	reactive	oxygen	species	(ROS)	can	inhibit	DUSP1	activity	(Kamata	et	al.,	2005,	Kim	
et	al.,	2012,	Tephly	and	Carter,	2007).	The	catalytic	activity	of	DUSP1	is	increased	when	
bound	to	substrates	(Hutter	et	al.,	2000),	and	the	affinity	of	DUSP1	for	its	substrates	is	
increased	by	acetylation	of	a	lysine	residue	in	the	substrate	binding	domain	(Cao	et	al.,	
2008).	This	is	summarised	in	figure	1.6.	
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Figure	1.6	Regulation	of	DUSP1.		
The	 various	 factors	 impacting	 DUSP1	 mRNA	 or	 protein	 are	 depicted.	 Blue	 arrows	
indicate	a	positive	regulation	and	red	arrows	a	negative	regulation.	DUSP1	mRNA	can	
be	transcriptionally	 induced	by	LPS	or	steroids,	or	inhibited	by	IFN-γ.	Once	translated	
into	protein,	DUSP1	can	be	phosphorylated	by	ERK,	which	is	either	stabilising	or	leads	
to	degradation,	depending	on	the	serine	residue.	ROS	can	oxidise	DUSP1,	inhibiting	the	
catalytic	 activity.	 PCAF/p300	 can	 acetylate	 DUSP1	 which	 increases	 its	 affinity	 for	
substrates.	DUSP1	can	activate	TTP,	which	destabilises	DUSP1	mRNA.	(Adapted	from:	
Lloberas	et	al.,	2016).	
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1.5.4 DUSP10	
DUSP10	has	a	very	similar	role	to	DUSP1,	as	 it	has	also	been	shown	to	attenuate	the	
inflammatory	response	by	dephosphorylating	p38	and	JNK	(Tanoue	et	al.,	1999).	 It	 is	
thought	that	DUSP10	may	have	more	affinity	for	JNK,	but	activity	towards	p38	has	also	
been	demonstrated	(Qian	et	al.,	2009,	Zhang	et	al.,	2004).	It	is	expressed	ubiquitously	in	
both	the	nucleus	and	cytoplasm	(Tanoue	et	al.,	1999),	but	is	upregulated	in	response	to	
innate	immune	signalling	(Zhang	et	al.,	2004).	DUSP10	is	stabilised	by	phosphorylation	
by	the	kinase	mTORC2	in	glioblastoma	cells	(Benavides-Serrato	et	al.,	2014).	mTORC2	is	
a	regulator	of	cell	growth	but	there	may	be	other	kinases	involved	in	the	innate	immune	
signalling	pathways	that	are	also	able	to	phosphorylate	DUSP10.	Moreover,	DUSP10-/-	
mice	suffer	from	lung	tissue	damage	when	challenged	with	LPS,	and	BMDMs	isolated	
from	these	mice	produced	higher	amounts	of	cytokines	 in	response	to	LPS	than	wild	
type,	which	was	associated	with	 increased	p38	and	JNK	activation	 (Qian	et	al.,	2009,	
Qian	et	al.,	2012,	Zhang	et	al.,	2004).	DUSP10	knock	out	peritoneal	macrophages	also	
produce	 higher	 levels	 of	 inflammatory	 cytokines,	 including	 IL-6	 and	 TNFα,	 to	
peptidoglycan,	 Listeria	monocytogenes,	 and	 poly(I:C)	 (Zhang	 et	 al.,	 2004).	 	 Adoptive	
transfer	of	knock	out	BMDMs	caused	much	more	severe	lung	inflammation	in	response	
to	LPS	stimulation	than	transfer	of	BMDMs	taken	from	wild-type	mice	(Qian	et	al.,	2012).	
BMDMs	taken	from	DUSP10	knock	out	mice	have	also	been	found	to	be	skewed	towards	
a	pro-inflammatory	M1	phenotype	(Zhang	et	al.,	2015).	This	indicates	that,	like	DUSP1,	
DUSP10	plays	an	extremely	important	role	in	regulating	the	inflammatory	response	to	
bacterial	infection,	through	inactivating	p38	and	JNK	MAPKs.		
DUSP10	expression	can	also	be	upregulated	by	viral	infection:	ebola	infection	of	Huh7	
cells	and	influenza	infection	of	murine	BMDMs	upregulate	DUSP10	expression	(Holzer	
et	 al.,	 2016,	 James	 et	 al.,	 2015).	 When	 DUSP10	 knockout	 mice	 were	 infected	 with	
influenza	 virus,	 production	 of	 the	 inflammatory	 cytokine	 IL-6	 was	 increased	 in	
comparison	to	wild-type	mice.	The	knock	out	mice	were	also	found	to	have	less	severe	
disease	and	lower	viral	titres;	this	correlated	with	increased	IFN-α	and	IFN-β	release	in	
BMDMs	isolated	from	these	mice.	As	they	were	able	to	co-immunoprecipitate	DUSP10	
and	IRF3,	the	authors	suggest	this	is	due	to	the	ability	of	DUSP10	to	dephosphorylate	
and	inactivate	IRF3	(James	et	al.,	2015).		
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1.5.5 DUSP2	
DUSP2	is	a	nuclear	protein,	which	has	so	far	only	been	detected	in	human	leukocytes	
(Jeffrey	et	al.,	2006).	It	is	upregulated	in	response	to	LPS	via	the	ERK	pathway	in	a	range	
of	B	cell	lines	and	in	response	to	human	T-cell	leukaemia	virus	type	1	(HTLV-1)	in	T	cells	
(Grumont	 et	 al.,	 1996,	 Pise-Masison	 et	 al.,	 2002).	 When	 knocked	 out	 in	 mice	 the	
inflammatory	 signalling	 in	 response	 to	 LPS	 is	 decreased,	 suggesting,	 in	 contrast	with	
DUSP1	and	DUSP10,	a	positive	rather	 than	negative	regulatory	role	 for	DUSP2	 in	 the	
immune	response.	In	mast	cells	and	macrophages	taken	from	these	mice,	the	decreased	
release	of	 inflammatory	markers	was	associated	with	an	 increase	 in	phosphorylation	
and	activity	of	JNK,	but	a	decrease	in	p38	and	ERK,	which	the	authors	proposed	was	due	
to	cross-talk	between	 the	 JNK	and	ERK	pathways	 (Jeffrey	et	al.,	2006).	This	model	 is	
supported	by	an	earlier	study	showing	that	JNK	activity	blocked	the	phosphorylation	of	
ERK	 by	 MEK1,	 and	 that	 this	 inhibition	 was	 dependant	 on	 c-Jun	 mediated	 gene	
transcription.	 This	 implies	 JNK	 activation	 leads	 to	 induction	 of	 an	 unknown	 protein,	
through	activation	of	AP-1,	which	blocks	ERK	phosphorylation	(Shen	et	al.,	2003).	In	this	
model	DUSP2	would	inactivate	JNK,	stopping	activation	of	AP-1,	the	unknown	protein	
which	 blocks	 ERK	 phosphorylation	 is	 therefore	 not	 expressed,	 and	 thus	 the	 pro-
inflammatory	activity	of	ERK	is	increased.		
Contrastingly,	 DUSP2	 has	 been	 suggested	 to	 negatively	 regulate	 production	 of	 the	
inflammatory	cytokine	IL-6	in	endometriotic	stromal	cells,	as	overexpression	of	DUSP2	
in	this	setting	led	to	a	significant	decrease	in	IL-6	mRNA	expression	(Hsiao	et	al.,	2017).	
1.5.6 DUSP4		
DUSP4	is	a	nuclear	protein	also	induced	by	the	ERK	pathway	(Brondello	et	al.,	1997).	Like	
DUSP1	 it	 can	 be	 phosphorylated	 by	 ERK	 at	 Ser386	 and	 Ser391,	 which	 stabilises	 the	
protein	 (Crowell	 et	 al.,	 2014).	 Two	 groups	 have	 performed	 studies	 using	 DUSP4	
knockout	mice	and	produced	conflicting	results.	Cornell	et	al.	showed	that	mice	lacking	
DUSP4	have	decreased	pro-inflammatory	cytokines	present	in	BAL	fluid	after	challenge	
with	LPS	in	comparison	to	wild	type	mice	(Cornell	et	al.,	2012).	BMDMs	isolated	from	
these	 mice	 showed	 this	 decrease	 was	 associated	 with	 an	 increase	 in	 ERK	 activity,	
decreases	 in	 p38	 and	 JNK	 activity,	 and	 increased	 induction	 of	DUSP1	protein.	When	
DUSP1	was	knocked	down,	using	siRNA,	in	these	DUSP4	knock	out	BMDMs,	the	release	
of	 pro-inflammatory	 cytokines	 increased	 (Cornell	 et	 al.,	 2010).	 The	 authors	 suggest	
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these	 results	 indicate	 that	 DUSP4	 inactivates	 ERK,	 which	 leads	 to	 a	 decrease	 in	 the	
expression	and	stabilisation/activation	of	DUSP1,	thereby	increasing	the	activity	of	p38	
and	JNK,	and	the	associated	release	of	inflammatory	mediators.		
In	contrast,	a	study	by	Al-Mutairi	and	colleagues	used	similar	methods	but	found	the	
opposite;	BMDMs	isolated	from	DUSP4	knockout	mice	released	increased	amounts	of	
pro-inflammatory	cytokines	 in	response	to	LPS	(Al-Mutairi	et	al.,	2010).	Furthermore,	
they	found	increased	levels	of	JNK	and	p38	phosphorylation,	and	no	change	in	the	level	
of	ERK	phosphorylation	(Al-Mutairi	et	al.,	2010).	It	is	currently	not	clear	why	the	results	
of	these	studies	should	differ	as	they	both	studied	the	same	cell	types:	BMDMs	taken	
from	DUSP4	 knockout	mice.	 One	 possible	 explanation	 could	 be	 the	 use	 of	 different	
strains	of	mice.			
1.5.7 DUSPs	and	Asthma	
It	is	possible	that	several	of	the	DUSPs	may	be	dysregulated	in	people	with	asthma.	This	
could	 partially	 account	 for	 the	 excessive	 inflammatory	 response	 to	 respiratory	
infections.	A	study	 in	2008	 isolated	nasal	epithelial	cells	 from	healthy	 individuals	and	
patients	with	house	dust	mite	allergy,	a	common	allergy	associated	with	asthma.	They	
performed	 a	 microarray	 to	 determine	 any	 gene	 expression	 changes	 in	 response	 to	
stimulation	with	house	dust	mite.	In	non-allergic	controls,	DUSP1	mRNA	expression	was	
upregulated	 in	 response	 to	 house	 dust	mite	 challenge,	 however,	 in	 allergic	 patients	
DUSP1	expression	did	not	alter	(Vroling	et	al.,	2008).	DUSP10	may	also	have	differential	
expression	 in	 asthmatic	 patients.	 A	 transcriptional	 profile	 of	 Th2	 cells	 taken	 from	
asthmatic	and	healthy	subjects	showed	lower	baseline	mRNA	expression	of	DUSP10	in	
the	asthmatic	cells	than	the	healthy	cells	(Seumois	et	al.,	2016).		
Interestingly,	 a	 study	 in	 2012	 looking	 for	 genetic	 determinants	 for	 severe	 asthma	
suggested	 there	may	be	 a	 single	 nucleotide	polymorphism	 (SNP)	 in	 the	DUSP4	 gene	
linked	to	asthma,	however	the	result	was	not	statistically	significant,	possibly	due	to	the	
limited	number	of	patients	in	the	study	(Wan	et	al.,	2012).		
As	of	yet,	the	expression	of	DUSPs	in	COPD	patients	and	any	differences	with	healthy	
controls,	has	not	been	explored.		
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1.6 Corticosteroids	
Exacerbations	of	asthma	and	COPD	are	treated	with	corticosteroids	(Cutrera	et	al.,	2017,	
Rosenberg	 and	 Kalhan,	 2017).	 Steroids	 act	 to	 limit	 inflammation	 by	 interacting	with	
glucocorticoid	receptors	(GRs)	in	the	cytosol,	this	causes	a	conformational	change	in	the	
GR	which	allows	 it	 to	 translocate	 to	 the	nucleus,	where	 it	 interacts	with	and	 inhibits	
transcription	factors,	such	as	AP-1	and	NF-κB	(Heck	et	al.,	1994,	Ray	and	Prefontaine,	
1994).	More	recent	evidence	suggests	that	glucocorticoids	mediate	many	of	their	anti-
inflammatory	 actions	 through	 DUSP1.	 Treatment	 of	 cells	 with	 the	 glucocorticoid	
dexamethasone	causes	an	 increase	 in	DUSP1	expression	 in	many	different	cell	 types,	
including:	primary	peripheral	blood	neutrophils;	primary	airway	smooth	muscle	cells;	
murine	BMDMs;	 the	epithelial	 cell	 lines	A549,	BEAS-2B,	 and	HeLa	 cells;	 the	RBL-2H3	
basophil	line	and	the	NIH-3T3	fibroblast	cell	line	(Kassel	et	al.,	2001,	Keranen	et	al.,	2017,	
King	et	al.,	2009,	Lasa	et	al.,	2002,	Prabhala	et	al.,	2016,	Rahman	et	al.,	2016,	Wang	et	
al.,	 2016).	 Knock	 out	mice	 have	 shown	 the	 importance	of	DUSP1	 in	 dexamethasone	
treatment.	Bone-marrow	macrophages	taken	from	these	mice	show	that	the	inhibitory	
effect	of	dexamethasone	treatment	on	p38	and	JNK	activation,	 in	response	to	LPS,	 is	
impaired	when	DUSP1	is	not	present	(Abraham	et	al.,	2006).	The	suppressive	effect	of	
dexamethasone	 on	 inflammatory	 cytokine	 expression	 in	 response	 to	 LPS	 was	 also	
negated	in	the	DUSP1	knock	out	cells	(Abraham	et	al.,	2006).	Bone-marrow	derived	mast	
cells	 taken	 from	 DUSP1	 knock	 out	 mice	 had	 higher	 levels	 of	 MAPK	 activation	 in	
dexamethasone	 treated	 cells.	 However,	 the	 expression	 of	 inflammatory	 cytokines	 in	
response	to	IgE	crosslinking	did	not	differ	significantly	between	wild-type	and	knock	out	
cells	 (Maier	 et	 al.,	 2007).	 The	 authors	 suggest	 this	 may	 be	 due	 to	 compensatory	
mechanisms,	 a	 theory	 supported	 by	 the	 fact	 that	 dexamethasone	 treatment	 also	
increased	 expression	 of	 other	 phosphatases,	 including	 DUSPs	 2	 and	 4	 (Maier	 et	 al.,	
2007).	This	suggests	that	the	actions	of	DUSPs	may	differ	depending	on	the	cell	type.	
DUSP1	has	also	been	knocked	down	in	the	airway	epithelial	cell	line	A549	using	siRNA.	
Knock	down	of	DUSP1	blocked	the	anti-inflammatory	action	of	dexamethasone	on	IL-1β	
induced	MAPK	activation	and	inflammatory	cytokine	expression	(Newton	et	al.,	2010,	
Shah	et	al.,	2014).		
Exacerbations	 of	 asthma	 and	 COPD	 caused	 by	 infection	with	 respiratory	 viruses	 are	
more	resistant	to	glucocorticoid	treatment	(Xia	et	al.,	2017).	Rhinoviral	infections	have	
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been	found	to	impair	their	anti-inflammatory	actions,	partly	through	reducing	nuclear	
translocation	of	 the	GR	(Papi	et	al.,	2013).	RV16	 infection	of	A549	cells	 impaired	the	
dexamethasone-mediated	suppression	of	inflammatory	cytokines	induced	by	IL-1β,	and	
also	the	upregulation	of	DUSP1	mRNA	(Papi	et	al.,	2013).	Bacterial	 infection	has	also	
been	demonstrated	to	cause	steroid	resistance	(Goleva	et	al.,	2009).	Treatment	of	A549	
cells	with	the	synthetic	TLR2	 ligand	Pam3CSK4	 induced	steroid	resistance,	but	did	not	
affect	 the	 upregulation	 of	 DUSP1.	 However,	 treatment	 with	 Pam3CSK4	 did	 induce	
oxidative	 stress,	 and	 a	 proportion	 of	 the	 DUSP1	 present	 in	 these	 cells	was	 oxidised	
(Rahman	et	al.,	2016).	As	discussed	in	section	1.5.3,	oxidation	of	the	catalytic	cysteine	
residue	of	DUSP1	inactivates	its	phosphatase	activity.	This	suggests	that	the	resistance	
of	 exacerbations	 caused	 by	 infection	 to	 steroid	 treatment	may	 be	 in	 part	 due	 to	 a	
suppression	of	DUSP1	expression	or	 inactivation	of	 the	DUSP1	protein.	A	study	 from	
2010	has	also	suggested	that	polymorphisms	within	the	DUSP1	gene	are	associated	with	
the	clinical	response	to	steroids	(Jin	et	al.,	2010).	The	roles	of	other	DUSPs	in	steroid	
treatment	remains	to	be	investigated.		
The	fact	that	a	well-established	therapy	acts,	in	part,	through	DUSPs	suggests	that	they	
are	potential	therapeutic	targets.	Corticosteroid	treatment	causes	many	harmful	side	
effects	 (Fernandes	 et	 al.,	 2014).	 Therefore,	 a	 more	 targeted	 therapy,	 aimed	 at	
upregulating	DUSP1,	may	be	preferable.			
1.7 Hypothesis	and	Aims	
The	 literature	 supports	 a	 role	 for	 DUSPs	 in	 regulating	 the	 release	 of	 inflammatory	
cytokines	in	response	to	both	bacteria	and	viruses.	These	studies	also	suggest	roles	for	
DUSPs	in	other	pathways	involved	in	antiviral	control.	However,	the	ability	of	DUSPs	to	
regulate	the	response	of	bronchial	epithelial	cells	to	rhinoviral	infection	has	not	yet	been	
studied.	 I	 hypothesised	 that	 DUSPs	 have	 important	 roles	 in	 regulating	 inflammatory	
cytokine	release	in	epithelial	cells	in	response	to	rhinoviral	infection.	If	this	hypothesis	
is	 correct,	 DUSPs	 could	 be	 a	 potential	 target	 for	 anti-inflammatory	 treatments	 for	
chronic	lung	disease.		
Therefore,	in	the	present	study	I	aimed	to	characterise	the	expression	of	the	four	DUSPs	
discussed	above	in	primary	bronchial	epithelial	cells	(PBECs)	and	determine	their	role	in	
rhinoviral	infection.	This	work	aimed	to:	
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• Characterise	the	response	of	PBECs	to	rhinoviral	infection,	including:	
– Describing	the	activation	and	role	of	the	MAPK	pathways		
– Determining	the	key	DUSPs	expressed	in	PBECs.	
– Assessing	 whether	 the	 expression	 and	 activity	 of	 the	 key	 DUSPs	 are	
regulated	by	infection	with	rhinovirus		
• Knock	down	specific	DUSPs	in	PBECs,	using	siRNA,	and	examine	the	effects	upon	
rhinovirus	infection,	including:	
– Rhinoviral	replication		
– The	 secretion	 of	 inflammatory	 and	 anti-viral	 cytokines	 in	 response	 to	
rhinovirus	
– The	activation	of	the	MAPK	pathways	
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2 Chapter	Two:	Materials	and	Methods	
2.1 Materials	
Table	2.1:	Cell	Culture	Materials		
Name	 Composition	 Application	
BEAS-2B	
complete	media	
RPMI	(Gibco),	supplemented	with	10%	FCS	
(Gibco),	1%	penicillin	and	1%	streptomycin	
(Sigma-Aldrich)	
BEAS-2B	cell	
maintenance	
BEAS-2B	basal	
media	
RPMI	(Gibco),	supplemented	with	1%	penicillin	
and	1%	streptomycin	(Sigma-Aldrich)	
Removing	
serum	prior	to	
infection	
BEAS-2B	2%	
media	
RPMI	(Gibco),	supplemented	with	2%	FCS	
(Gibco),	1%	penicillin	and	1%	streptomycin	
(Sigma-Aldrich)	
Transfection	of	
BEAS-2B	cells	
Airway	
epithelial	cell	
complete	media	
Airway	epithelial	cell	basal	medium	(Promocell)	
supplemented	with	1%	penicillin,	1%	
streptomycin	(Sigma-Aldrich),	0.004	mg/ml	
bovine	pituitary	extract,	10	ng/ml	epidermal	
growth	factor,	5	µg/ml	insulin,	0.5	µg/ml	
hydrocortisone,	0.5	µg/ml	epinephrine,	6.7	
ng/ml	triiodo-L-thyronine,	10	µg/ml	transferrin	
and	0.1	ng/ml	retinoic	acid	(Promocell)	
PBEC	
maintenance	
Airway	
epithelial	cell	
basal	media	
Airway	epithelial	cell	basal	medium	(Promocell)	
supplemented	with	1%	penicillin,	1%	
streptomycin	(Sigma-Aldrich)	
Removing	
serum	prior	to	
infection	
Airway	
epithelial	cell	
recovery	media	
Airway	epithelial	cell	basal	medium	(Promocell)	
supplemented	with	1%	penicillin,	1%	
streptomycin	(Sigma-Aldrich),	10	ng/ml	
epidermal	growth	factor,	5	µg/ml	insulin,	0.5	
µg/ml	hydrocortisone,	0.5	µg/ml	epinephrine,	
6.7	ng/ml	triiodo-L-thyronine,	10	µg/ml	
transferrin	and	0.1	ng/ml	retinoic	acid	
(Promocell)	
Post-PBEC	
infection		
Detach	Kit	 30mM	Hepes,	0.04%	trypsin/EDTA,	trypsin	
neutralising	solution	(Promocell)	
PBEC	
maintenance	
HeLa	Ohio	
complete	media	
DMEM	(Gibco)	supplemented	with	10%	FCS	
(Gibco),	1%	penicillin,	1%	streptomycin	(Sigma-
Aldrich),	1%	non-essential	amino	acids	(Gibco),	
1%	L-Glutamine	(Gibco)	
HeLa	Ohio	
maintenance	
HeLa	Ohio	
infection	media	
DMEM	(Gibco)	supplemented	with	2%	Hepes	
(Gibco),	1%	Bicarbonate	(Gibco),	2%	FCS	
(Gibco),	1	%	penicillin,	1%	streptomycin	(Sigma-
Aldrich)	
HeLa	Ohio	
infection	
PBMC	Basal	
Media		
RPMI	(Gibco),	supplemented	with	1%	penicillin	
and	1%	streptomycin	(Sigma-Aldrich)	
Attachment	of	
monocytes		
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Table	2.1	Continued:	Cell	Culture	Materials		
Name	 Composition	 Application	
MDM	Complete	
Media	
RPMI	(Gibco),	supplemented	with	10%	FCS	
(Gibco),	1%	penicillin	and	1%	streptomycin	
(Sigma-Aldrich)	
MDM	
differentiation	
Monocyte	
Infection	Media	
RPMI	(Gibco),	supplemented	with	2%	FCS	
(Gibco),	1%	penicillin	and	1%	streptomycin	
(Sigma-Aldrich)	
Monocyte	
infection	
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Table	2.2:	Buffers	and	Reagents		
Reagent	 Composition	 Application	
MACS	buffer	 PBS	
0.5%	BSA		
2	mM	EDTA		
Monocyte	
isolation	
Phosphate	lysis	
buffer	
50	mM	Tris	base	(pH7.5)		
1%	Triton		
50	mM	NaF	
1	mM	PMSF		
10	mM	Na3VO4		
50	mM	β-glycerophosphate		
Protease	inhibitor	(Calbiochem)	
Protein	
extraction	
4X	Sample	buffer	 8%	SDS		
0.2	M	DTT		
20%	Glycerol		
0.125	M	Tris-Cl	(pH6.8)		
0.008%	Bromophenol	blue	
Protein	storage	
Agarose	 Agarose	molecular	grade	powder	
(Melford)	
Agarose	gel	
electrophoresis	
50X	TAE	 242	g	Tris	base	
37.2	g	EDTA	
57.1	ml	Acetic	acid	
Agarose	gel	
electrophoresis	
ELISA	coating	buffer	 0.14	M	NaCl	
2.7	mM	KCl	
1.5	mM	KH2PO4		
8.1	mM	Na2HPO4	
ELISA	
ELISA	wash	buffer	 0.5	M	NaCl	
2.5	mM	NaH2PO4	
7.5	mM	Na2HPO4	
0.1%	Tween		
pH	to	7.2	with	NaOH	
ELISA	
10X	running	buffer	 0.26	M	Tris	base		
1.92	M	Glycine		
1%	SDS	
Running	SDS-
PAGE	gels	
10X	transfer	buffer	 0.25	M	Tris	base	
1.93	M	Glycine	
Western	blot	
1X	PBS/Tween	 PBS	tablets	(Oxoid)	
0.2%	Tween		
Western	blot	
1X	TBS/Tween	 6.05	g	Tris	base	
8.76	g	NaCl	
0.1%	Tween		
Western	blot	
Blocking	buffer		 5%	Non-fat	milk	
1X	PBS/Tween	or	1X	TBS/Tween	
Western	blot	
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Table	2.3:	Commercially	Available	Kits		
Name	 Components	 Application	 Supplier	
MAPK	
Inhibitor	
Tocriset	
U0126	
SB203580	
PD98059	
SB202190	
SP600125	
MAPK	inhibitor	 Tocris	(1879)	
DNA-free	 10X	DNase	I	buffer	
rDNase	I		
DNase	inactivation	reagent	
Genomic	DNA	
removal	
during	RNA	
extraction	
Ambion	
(AM1906M)	
High-capacity	
cDNA	reverse	
transcription	
kit	
10X	RT	buffer	
10X	random	primers		
25X	dNTP	mix	
MultiScribe	Reverse	Transcriptase		
RNase	inhibitor	
cDNA	
synthesis	
Applied	
Biosystems	
(4368814)	
GoTaq	Hot	
Start	
Polymerase	
GoTaq	Hot	Start	Polymerase		
5X	Green	GoTaq	Flexi	Buffer	
5X	Colourless	GoTaq	Flexi	Buffer	
MgCl2	
RT-PCR	 Promega	
(M5001)	
q-PCR	
mastermix	
2X	Mastermix	
MgCl2	
qRT-PCR	 Eurogentec	
(RT-	QP2X-03-
075+)	
GoTaq	Probe	
q-PCR	Master	
Mix	
GoTaq	Probe	q-PCR	Master	Mix	
CXR	Reference	Dye	
qRT-PCR	 Promega	
(A6101/2)	
GeneJET	
Plasmid	Mini-
Prep	Kit	
Resuspension	solution	
Lysis	solution	
Neutralisation	solution	
Wash	solution	
RNase	A	
Elution	buffer	
GeneJET	spin	columns	
Collection	tubes	
qRT-PCR	 Thermo	Fisher	
(K0502)	
MACS	Human	
Monocyte	
Isolation	Kit	II	
FcR	Blocking	Reagent	
Monocyte-Biotin	Antibody	
Cocktail	
Anti-Biotin	MicroBeads	
Monocyte	
isolation	
MACS		
(130-091-153)	
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Table	2.3	Continued:	Commercially	Available	Kits		
Name	 Components	 Application	 Supplier	
Human	
Cytokine	
Array	
Human	Cytokine	Array	
Membranes	
Array	Buffer	4	
Array	Buffer	5	
Wash	Buffer	Concentrate	
Detection	Antibody	Cocktail	
Streptavidin-HRP	
Chemi	Reagent	1	
Chemi	Reagent	2	
4-Well	Multi-dish		
Detection	of	
cytokines	in	
cell	culture	
supernatants	
R&D	
(ARY005B)	
Human	IL-1β	
ELISA	DuoSet	
IL-1β	Capture	Antibody		
IL-1β	Standard	
IL-1β	Detection	Antibody	
Streptavidin-HRP	
IL-1β	ELISA	 R&D		
(DY201-05)	
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Table	2.4:	Antibodies		
Antibody	 Isotype	 Application	 Concentration	
Used	
Supplier	
Capture	
antibody,	anti-
human	CXCL8	
Mouse	IgG	 ELISA	 0.3	µg/ml	 R&D	
(MAB208)	
Detection	
antibody,	anti-
human	CXCL8	
Biotinylated	
goat	IgG	
ELISA	 0.32	µg/ml	 R&D	(BAF208)	
Capture	
antibody,	anti-
human	CCL5	
Mouse	IgG	 ELISA	 2	µg/ml	 R&D	
(MAB678)	
Detection	
antibody,	anti-
human	CCL5	
Biotinylated	
goat	IgG	
ELISA	 0.08	µg/ml	 R&D	(BAF273)	
Anti-human	actin	 Rabbit	IgG	 Western	blot	 0.04-0.08	
µg/ml	
Sigma-Aldrich	
(A2066)	
Anti-human	
DUSP1	
Rabbit	IgG	 Western	blot	 1	µg/ml	 Merck	
Millipore		
(07-535)	
Anti-human	
phosphorylated	
DUSP1	
Rabbit	IgG	 Western	blot	 1:500	 Cell-Signalling	
(2857)	
Anti-human	
DUSP10	
Rabbit	IgG	 Western	blot	 0.35	µg/ml	 Abcam	
(ab140123)	
Anti-human	
DUSP4	
Rabbit	IgG	 Western	blot	 2.67	µg/ml	 Abcam	
(ab72593)	
Anti-human	
phosphorylated	
ERK	1/2	
Rabbit	IgG	 Western	blot	 1:1000	 Cell-Signalling	
(9101)	
Anti-human	
activated	p38	
Rabbit	IgG	 Western	blot	 1:2000	 Promega	
(V1211)	
Anti-human	
phosphorylated	
JNK	
Rabbit	IgG	 Western	blot	 1:1000	 Cell-Signalling	
(4668)	
Anti-rabbit	
secondary	
antibody	
Polyclonal	goat	
–	HRP	
conjugated	
Western	blot	 0.125	µg/ml	 Dako	(P0448)	
Anti-rabbit	
secondary	
antibody	
Goat	IgG	–	
HRP	
conjugated	
Western	blot	 1:2000	 Cell-Signalling	
(7074)	
Anti-mouse	
secondary	
antibody	
Polyclonal	goat	
–	HRP	
conjugated	
Western	blot	 0.5	µg/ml	 Dako	(P0447)	
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Table	2.7:	siRNA		
Target	 siRNA	Sequence	Sense	 Supplier	
Control	 5’UCACACAACAUGUAAACCA	 Dharmacon	(D-001810-
01-05)	
DUSP1	#1	 Pool	of:	
5’AAACGCUUCGUAUCCUCCU	
5’UUCGCCUCUGCUUCACAAA	
5’UAGUCCUCAUAAGGUAAGC	
5’UGACCCUCAAAAUGGUUGG	
Dharmacon		
(L-003484-02-0005)	
DUSP1	#2	 Pool	of:	
5’GGUUCAACGAGGCUAUUGA	
5’CGAGGCUAUUGACUUCAUA	
5’GCAAGACAUUUGCUGAACU	
Santa	Cruz	(sc-35938)	
DUSP1	#3	 5’GAGGCGAAGCAUCAUCUC	 Santa	Cruz	(sc-35937)	
DUSP1	#4	 5’CUGUACUAUCCUGUAAAUAUA	 Qiagen	(SI00374808)	
DUSP10	 Pool	of:	
5’CCAUCGUCAUCGCUUACUU	
5’CGAGAAUCCUUACACCAAA	
5’CAGCUUAAGUGGUCUAAGA	
Santa	Cruz	(sc-61048)	
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Table	2.8:	Solutions	for	making	10%	SDS-PAGE	gels		
Solution	 10%	Resolving	
gel	(ml)		
5%	Stacking	gel	
(ml)	
Supplier	
Water	 1.9	 0.68	 	
30%	acrylamide	mix	 1.7	 0.17	 Geneflow	
1.5	M	Tris	(pH	8.8)	 1.3	 0	 BioRad	
1.0	M	Tris	(pH6.8)	 0	 0.13	 BioRad	
10%	SDS	 0.05	 0.01	 Panreac	
10%	ammonium	persulfate	 0.05	 0.01	 Fluka	
TEMED	 0.002	 0.001	 Sigma-Aldrich	
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2.2 Cell	Culture	
2.2.1 BEAS-2B	Cell	Culture		
The	BEAS-2B	lung	epithelial	cell	line	was	purchased	from	ATCC.	Cells	were	maintained	
in	BEAS-2B	complete	media	(Table	2.1)	in	75	cm2	culture	flasks	(Thermo	Fisher).	Flasks	
were	 kept	 in	 a	 humidified	 37oC	 incubator	 with	 5%	 CO2,	 and	 passaged	 at	 80-90%	
confluency	using	cell	dissociation	solution	(Sigma-Aldrich).	Briefly,	media	was	removed	
from	cells	and	replaced	with	2	ml	cell	dissociation	solution.	The	flask	was	then	incubated	
at	37oC,	5%	CO2	for	5	minutes	to	allow	cells	to	detach.	The	cell	dissociation	solution	was	
inactivated	with	complete	media,	and	cells	transferred	to	fresh	75	cm2	culture	flasks.		
2.2.2 HeLa	Ohio	Cell	Culture	
HeLa	Ohio	cells	were	purchased	from	ATCC	and	grown	in	75	cm2	culture	flasks	in	HeLa	
Ohio	complete	media	(Table	2.1)	and	incubated	at	37oC,	5%	CO2	and	passaged	at	80-
90%	confluency	using	cell	dissociation	solution	(Sigma-Aldrich).		
2.2.3 Primary	Bronchial	Epithelial	Cell	Culture	
Primary	bronchial	epithelial	cells	(PBECs)	isolated	from	healthy	human	volunteers	were	
purchased	from	Promocell.	They	were	grown	in	75	cm2	culture	flasks	in	airway	epithelial	
cell	complete	media	(Table	2.1)	and	incubated	in	a	humidified	37oC	incubator	with	5%	
CO2.	The	media	was	removed	and	replaced	with	fresh	media	every	two	to	three	days.	
Cells	were	passaged	at	80-90%	confluency	using	the	Promocell	detach	kit	(Table	2.1)	in	
accordance	with	manufacturer’s	instructions.	
2.2.4 Mycoplasma	Testing	
All	 cells	were	 tested	monthly	 for	 the	 presence	 of	mycoplasma	by	 technicians	 in	 the	
department.	 The	 EZ-PCR	mycoplasma	 test	 kit	 (Geneflow)	was	 used	 according	 to	 the	
manufacturer’s	instructions.		
2.2.5 Peripheral-Blood	Mononuclear	Cell	Isolation		
Peripheral	 venous	 blood	 was	 obtained	 from	 healthy	 human	 volunteers	 with	 fully	
informed	 consent,	 in	 accordance	with	 a	 protocol	 approved	 by	 South	 Sheffield	 Local	
Research	Ethics	Committee.	
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Peripheral-blood	 mononuclear	 cells	 (PBMCs)	 were	 isolated	 from	 blood	 by	 other	
members	of	the	department.	Freshly	drawn	blood	was	added	to	3.8%	tri-sodium	citrate	
(Martingdale	 Pharmaceuticals)	 and	 mixed	 gently	 before	 centrifuging	 at	 350	 g,	 20	
minutes,	 room	 temperature.	 The	 upper	 phase,	 containing	 platelet-rich-plasma,	 was	
transferred	to	a	fresh	50	ml	falcon	tube	and	centrifuged	at	800	g,	20	min,	20oC,	in	order	
to	 remove	platelets.	 The	 supernatant	was	 transferred	 to	a	 fresh	 tube	and	 the	pellet	
discarded.	To	 the	 lower	phase	of	 cells,	 6%	dextran	 (Pharmacosmos)	was	added,	and	
made	up	to	50	ml	with	saline	(Gibco),	before	gently	mixing.	This	was	incubated	at	room	
temperature	for	20	to	30	minutes,	with	the	lid	left	loose,	to	allow	the	dextran	to	bind	
the	red	blood	cells	and	sediment.	The	upper	layer	was	transferred	into	a	fresh	tube	and	
centrifuged	 at	 320	 g,	 6	 min,	 20oC.	 The	 supernatant	 was	 discarded	 and	 the	 pellet	
resuspended	in	2	ml	platelet-poor-plasma.	A	percoll	gradient	was	made,	containing	a	
lower	phase	of	51%	percoll	(GE	Healthcare)	and	49%	platelet-poor-plasma	and	an	upper	
phase	 containing	42%	percoll	 and	58%	platelet-poor-plasma.	The	 cells	were	overlaid	
onto	the	gradient	and	centrifuged	at	320	g,	11	min,	20oC.	The	solution	separated	into	
three	layers,	with	the	PBMCs	in	the	interphase	between	the	upper	and	middle	layers.	
The	PBMC	layer	was	transferred	into	a	fresh	falcon	tube,	and	made	up	to	40	ml	with	1X	
HBSS	(Gibco),	before	centrifuging	320	g,	6	min,	20oC.		
2.2.6 Monocyte-Derived	Macrophage	Culture	
PBMCs	isolated	from	percoll	gradient	centrifugation	(Section	2.2.5)	were	resuspended	
in	monocyte	basal	media	(Table	2.1)	at	4	x	106	cells/ml	and	500	µl	added	to	each	well	of	
a	24-well	 culture	plate	 (Costar).	 Cells	were	 incubated	at	37oC,	5%	CO2	 for	one	hour.	
Media	 was	 then	 replaced	 with	 MDM	 complete	 media	 (Table	 2.1)	 to	 remove	 non-
adherent	cells.	The	remaining	monocytes	were	cultured	for	7	or	14	days	(as	indicated	in	
figure	 legends)	to	allow	differentiation	 into	macrophages,	replacing	media	with	fresh	
MDM	complete	media	every	two	days.		
2.2.7 Monocyte	Isolation	and	Culture	
Monocytes	were	isolated	from	PBMCs	(Section	2.2.5)	using	the	MACS	Human	Monocyte	
Isolation	 Kit	 II	 (Table	 2.3)	 according	 to	 the	 manufacturer’s	 instructions.	 Any	 non-
monocytes	are	magnetically	labelled	and	removed	by	passing	over	a	magnetic	column.	
Briefly,	PBMCs	were	resuspended	in	1	ml	MACS	buffer	(Table	2.2),	transferred	to	a	1.5	
ml	 tube,	and	centrifuged	at	1000	g,	2	min,	 room	temperature.	The	supernatant	was	
	 47	
discarded	and	the	pellet	resuspended	in	30	µl	buffer	per	107	cells.	10	µl	of	FCR	blocking	
reagent,	and	10	µl	of	biotin	antibody	cocktail	were	added	per	107	cells	before	gently	
mixing	and	incubating	at	4oC	for	10	min.	30	µl	of	buffer	per	107	cells	was	then	added.		
The	anti-biotin	beads	were	vortexed	and	20	µl	added	per	107	cells.	The	solution	was	
mixed	gently	and	incubated	at	4oC	for	15	min.	The	solution	was	then	made	up	to	1	ml	
with	MACS	buffer	and	spun	at	300	g,	10	min,	room	temperature.	The	supernatant	was	
discarded	and	the	pellet	resuspended	in	500	µl	MACS	buffer.		
A	MACS	LS	column	was	placed	into	the	field	of	a	MACS	separator.	The	column	was	rinsed	
using	3	ml	MACS	buffer.	The	cell	 suspension	was	added	 to	 the	column	and	 the	 flow	
through,	 containing	 monocytes,	 collected	 in	 a	 50	 ml	 falcon	 tube.	 The	 column	 was	
washed	three	times	using	3	ml	MACS	buffer	and	the	effluent	collected	into	the	same	
falcon	tube.	The	cell	solution	was	centrifuged	at	1000	g,	5	min,	room	temperature,	the	
supernatant	discarded	and	the	pellet	resuspended	in	monocyte	basal	media	(Table	2.1)	
at	4	x	105	cells/ml.	500	µl	was	added	to	each	well	of	a	24	well	plate	and	incubated	at	
37oC,	5%	CO2.	
2.3 	Rhinovirus	
2.3.1 Viral	Propagation	
Confluent	175	cm2	culture	flasks	of	HeLa	Ohio	cells	were	washed	twice	with	HeLa	Ohio	
infection	media	(Table	2.1),	and	7.5	ml	infection	media	and	5	ml	viral	stock,	from	the	
last	batch,	added	to	each	before	incubating	at	37oC,	5%	CO2,	for	one	hour	with	agitation.	
12.5	ml	 infection	media	 was	 added	 before	 overnight	 incubation.	 Once	 around	 90%	
cytopathic	effect	was	observed,	three	cycles	of	freeze-thawing	lysed	the	cells,	and	cell	
debris	was	removed	by	centrifuging	at	4000	g	for	15	minutes.	Supernatant	was	filtered	
through	a	0.22	µm	filter,	and	aliquoted	for	storage	in	liquid	nitrogen.		
2.3.2 Viral	Titration	
50	µl	of	infection	media,	undiluted	RV	or	sample,	or	10-fold	serial	dilutions,	up	to	10-9,	
were	added	to	each	well	of	a	96	well	plate	(Costar),	8	repeats	of	each	dilution.	1.5x104	
HeLa	Ohio	cells	were	seeded	into	each	well	on	top	of	the	virus.	The	plate	was	incubated	
for	4	days	before	the	number	of	wells	with	cytopathic	effect	at	each	viral	dilution	was	
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determined	using	light	microscopy,	and	the	TCID50	calculated	using	the	Spearman	Karber	
formula	(Hamilton	et	al.,	1977).	
2.4 Cell	Stimulation	
PBECs	were	seeded	at	7x105	or	BEAS-2Bs	were	seeded	at	1x106	cells	per	plate	onto	12	
well	culture	plates.	Once	cells	reached	80-95%	confluency	media	was	replaced	with	1	
ml	basal	media	(Table	2.1)	and	incubated	at	37oC,	5%	CO2	overnight.	Media	was	replaced	
with	basal	media	containing	stimulant	as	required	for	each	time	point:	1	-	100	ng/ml	IL-
1β	 (Peprotech)	or	25	µg/ml	poly(I:C)	 (Invivogen).	Supernatant,	mRNA	or	protein	was	
collected	from	each	well	(Section	2.9).	
PBECs	from	at	least	three	different	donors	were	used	for	each	experiment.	Donors	were	
chosen	at	random.	Table	7.1	(Appendix	1)	indicates	which	donors	were	used	for	each	
figure	and	their	characteristics.		
2.5 RV	Infection	
2.5.1 RV	Infection	of	PBECs		
PBECs	 were	 seeded	 at	 7x105	 cells	 per	 plate	 onto	 12	 well	 culture	 plates.	 Once	 cells	
reached	80-95%	confluency	media	was	replaced	with	1	ml	basal	media	(Table	2.1)	and	
incubated	at	37oC,	5%	CO2	overnight.	Media	was	removed,	and	250	µl	of	basal	media,	
RV1B	or	RV16	was	added	as	required	for	each	time	point;	titres	used	are	recorded	in	
figure	legends.	The	plate	was	incubated	at	37oC,	5%	CO2,	for	one	hour,	with	agitation.	
The	wells	were	washed	twice	with	PBS	before	adding	1	ml	PBEC	recovery	media	(Table	
2.1).	Supernatant,	mRNA	or	protein	was	collected	from	each	well	(Section	2.9),	or	cell	
viability	assay	performed	(Section	2.10).	
2.5.2 RV	Infection	of	Monocytes	and	MDMs	
Monocytes	 were	 isolated	 and	 plated	 as	 in	 section	 2.2.	 After	 one	 hour	 incubation	
(monocytes),	or	after	differentiation	(MDMs),	media	was	removed	and	replaced	with	
250	µl	basal	PBMC	media	(Table	2.1)	or	rhinovirus;	serotypes	and	titres	are	recorded	in	
figure	legends.	The	plate	was	incubated	at	37oC,	5%	CO2,	for	one	hour,	with	agitation.	
The	wells	were	washed	twice	with	PBS	before	adding	500	µl	of	basal	media	or	monocyte	
2%	media	(Table	2.1),	as	indicated	in	figure	legends.	Cells	were	incubated	at	37oC,	5%	
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CO2	for	the	indicated	time	point.	Supernatant	or	mRNA	was	collected	from	each	well	
(Section	2.9).	
2.5.3 RV	Controls	
To	determine	that	the	effects	of	the	virus	were	due	to	viral	infection,	two	controls	were	
used,	UV-inactivated	virus	and	virus	filtrate.	UV-inactivated	RV1B	or	RV16	was	obtained	
by	exposing	the	virus	to	1000	mJoules/cm2	UV	light	for	10	minutes.	Filtrate	was	obtained	
by	adding	500	µl	of	 virus	 to	a	 centrifugal	 filter	with	a	membrane	nominal	molecular	
weight	 limit	 of	 30	 kDa	 (Amicon).	 Filters	 were	 centrifuged	 at	 12000	 g,	 5	 min,	 room	
temperature,	and	any	liquid	left	in	the	upper	chamber	discarded.	These	controls	were	
then	used	to	treat	cells	in	the	same	way	as	virus	(Sections	2.5.1	and	2.5.2).		
2.6 Inhibitor	Treatment	
Prior	to	cell	stimulation	(Section	2.4)	or	infection	(Section	2.5)	PBECs	were	treated	with	
20	µM	MAPK	inhibitor	(Table	2.3),	diluted	in	DMSO,	or	vehicle	control	for	one	hour,	or	
with	100	nM	okadaic	acid	(Abcam),	diluted	in	DMSO,	or	vehicle	control	for	30	minutes.		
2.7 Dexamethasone	Treatment		
At	the	same	time	as,	or	4	h	prior	to,	cell	stimulation	(Section	2.4)	or	infection	(Section	
2.5)	(as	indicated	in	figure	legends)	PBECs	were	treated	with	1	-	100	nM	dexamethasone	
(Sigma-Aldrich)	diluted	in	basal	media	(Table	2.1).		
2.8 siRNA	Treatment	
2.8.1 DUSP10	Knock	Down	
Short	 interfering	RNA	 (siRNA)	was	used	 to	knock	down	DUSP10	mRNA	expression	 in	
PBECs.	PBECs	were	seeded	at	7x105	cells	per	plate	onto	12	well	culture	plates	(Costar)	
and	 incubated	 at	 37oC,	 5%	 CO2	 until	 around	 80%	 confluent.	 For	 each	 well	 5	 µl	
Lipofectamine	2000	(Invitrogen)	was	mixed	with	95	µl	Opti-MEM	(Gibco)	and	incubated	
at	room	temperature	for	5	minutes.	5	µl	of	20	µM	DUSP10	or	control	siRNA	(Table	2.7)	
diluted	in	95	µl	Opti-MEM	was	added	to	this	mixture,	and	complexes	allowed	to	form	at	
room	temperature	for	20	minutes.	Media	was	removed	from	cells	and	replaced	with	
800	µl	PBEC	basal	media	(Table	2.1).	200	µl	of	the	siRNA	mixture	was	added	dropwise	
to	 each	well	 and	 plates	were	 incubated	 at	 37oC,	 5%	CO2,	 for	 4	 h	 before	media	was	
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removed	 and	 replaced	 with	 1	 ml	 PBEC	 recovery	 media	 (Table	 2.1).	 	 Plates	 were	
incubated	at	37oC,	5%	CO2	for	48	h.	Cells	were	then	stimulated	(Section	2.4)	or	infected	
(Section	2.5).		
2.8.2 DUSP1	Knock	Down	
siRNA	knock	down	of	DUSP1	was	attempted	in	PBECs,	BEAS-2Bs	and	HeLa	Ohio	cells.	
Cells	were	seeded	into	12	well	culture	plates	and	incubated	at	37oC,	5%	CO2	until	they	
reached	 the	desired	confluency,	 indicated	 in	 figure	 legends.	The	above	protocol	was	
used	 for	 each	 of	 four	 different	 DUSP1	 siRNAs	 (Table	 2.7),	 varying	 the	 final	
concentrations	 of	 siRNA	 and	 Lipofectamine	 2000,	 and	 replacing	 Lipofectamine	 2000	
with	Mission	transfection	reagent	(Sigma-Aldrich).	Knock	down	was	attempted	for	24	
and	48	h.	In	BEAS-2B	cells	knock	down	was	attempted	in	both	basal	and	2%	media	(Table	
2.1).	
Knock	 down	 in	 BEAS-2B	 cells	 was	 also	 attempted	 using	 Viromer	 Blue	 transfection	
reagent	 (Lipocalyx)	 according	 to	 the	 manufacturer’s	 instructions.	 DUSP1	 or	 control	
siRNA	(Table	2.7)	was	diluted	to	2.8	µM	in	10	µl	Buffer	Blue	per	well.	1	µl	of	Viromer	
Blue	was	mixed	with	99	µl	Buffer	Blue	per	well	and	added	to	the	diluted	siRNA,	before	
incubating	at	room	temperature	for	15	min.	Media	was	removed	from	cells	and	replaced	
with	900	µl	BEAS-2B	basal	media	(Table	2.1).	100	µl	of	the	siRNA	solution	was	added	
dropwise	to	each	well	and	plates	incubated	at	37oC,	5%	CO2,	for	4	h	before	media	was	
removed	and	replaced	with	2%	media	(Table	2.1).	Plates	were	incubated	at	37oC,	5%	
CO2	for	48	h	before	cell	lysates	were	collected.		
2.9 Sample	Collection	
2.9.1 Supernatant	Collection	
The	media	from	each	well	was	collected	in	a	1.5	ml	tube	before	being	centrifuged	1000	
g,	2	min,	to	remove	cell	debris;	hereafter	called	supernatant.		Cell-free	supernatant	was	
transferred	 into	 a	 clean	 tube,	 and	 stored	 at	 -80oC.	 Where	 indicated,	 supernatant	
collection	was	performed	under	sterile	conditions.		
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2.9.2 mRNA	Collection	
Cells	were	scraped	and	lysed	in	1	ml	of	Tri	reagent	(12	well	plates)	or	500	µl	Tri	reagent	
(24	well	plates)	(Sigma-Aldrich).	The	sample	was	collected	in	a	1.5	ml	tube,	and	stored	
at	-80oC.		
2.9.3 Protein	Collection	
Cells	were	scraped	and	lysed	in	75	µl	of	phosphate	lysis	buffer	(Table	2.2)	for	15	minutes	
on	ice.	Lysates	were	collected	in	1.5	ml	tubes	and	centrifuged	at	12000	g	for	one	minute;	
the	soluble	fraction	was	transferred	to	fresh	1.5	ml	tubes.	Lysates	were	boiled	for	5	min	
in	1X	sample	buffer	(Table	2.2).	Samples	were	stored	at	-80oC.		
2.10 Cell	Viability	Assay	
Cell-titre	 glo	 viability	 assay	 (Promega)	 was	 performed	 in	 accordance	 with	 the	
manufacturer’s	instructions	24	or	48	h	post	infection	of	PBECs	(Section	2.5.1).	Briefly,	
media	was	removed,	and	200	µl	PBEC	recovery	media	(Table	2.1)	added	to	each	well,	
and	one	empty	well	as	a	control.	Cell	titre	glo	reagent	(Table	2.3)	was	made	by	mixing	
equal	volumes	of	buffer	and	reagent.	200	µl	of	this	mixture	was	added	to	each	well.	The	
plate	was	wrapped	in	foil	and	incubated	at	room	temperature	on	a	shaking	platform	for	
2	min,	and	then	incubated	at	room	temperature	for	10	min.	200	µl	was	then	taken	from	
each	well	and	added	to	a	well	of	a	white	96	well	plate	(Thermo	Fisher),	in	duplicate.	The	
optical	density	at	480	nm	was	read	by	Thermo	Scientific	Varioskan	Flash	plate	reader,	
and	the	reading	for	the	control	wells	deducted	from	each	reading.			
2.11 Supernatant	Transfer	
Cell-free	 supernatant	 was	 collected	 under	 sterile	 conditions	 (Section	 2.9.1)	 from	
monocyte	cultures	from	three	donors	infected	with	RV1B	or	RV16	for	24	or	48	h	(Section	
2.5.2)	and	stored	at	-80oC.	All	samples	were	thawed	and	all	three	donors	pooled	into	
fresh	 bijou	 tubes	 for	 each	 treatment.	 The	 pooled	 supernatant	 was	 filtered	 through	
centrifugal	filters	with	a	membrane	nominal	molecular	weight	limit	of	30	kDa	(Amicon),	
as	in	section	2.5.3,	to	remove	viral	particles.	PBECs	which	had	been	treated	with	control	
or	DUSP10	siRNA	for	48	h	(Section	2.8.1)	were	washed	in	PBS	and	500	µl	PBEC	recovery	
media	 added	 to	 each	well	 (Table	 2.1).	 500	µl	 of	 the	 filtered	 supernatant	 from	 each	
treatment	was	then	added	to	one	well	treated	with	control	siRNA	and	one	well	treated	
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with	DUSP10	siRNA.	Cells	were	incubated	at	37oC,	5%	CO2	for	24	h,	and	supernatant	and	
RNA	collected	(Section	2.9).		
2.12 Reverse	Transcription	PCR	(RT-PCR)	
2.12.1 Primer	Design	
Specific	primer	sequences	for	DUSP1,	DUSP2	and	DUSP10	were	found	in	the	literature	
(Table	2.5).	Primer	sequences	were	designed	for	DUSP4	(gene	ID	1846)	with	NCBI	BLAST	
primer	 design	 (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).	 The	 primers	 were	
synthesised	by	Sigma-Aldrich.	All	primer	sequences,	and	their	associated	conditions,	are	
listed	in	Table	2.5.	
2.12.2 RNA	Extraction	and	Purification	
RNA	was	extracted	using	Tri	reagent	in	accordance	with	the	manufacturer’s	instructions.	
Briefly,	after	sample	collection	(section	2.9.2),	200	µl	of	chloroform	was	added,	mixed	
vigorously,	and	stood	at	room	temperature	for	10	minutes	before	centrifuging	at	4oC	for	
15	minutes	at	12000	g.	The	solution	separates	into	the	upper	aqueous	phase	(containing	
RNA),	interphase	(containing	DNA),	and	the	lower	organic	phase	(containing	protein).	
The	 aqueous	 phase	was	 transferred	 to	 a	 clean	 1.5	ml	 tube.	 500	µl	 isopropanol	was	
added,	and	samples	stood	at	room	temperature	for	10	minutes	before	centrifuging	at	
4oC	for	10	minutes	at	12000	g,	and	discarding	the	supernatant.	The	pellet	was	washed	
in	 70%	 ethanol,	 centrifuged	 at	 4oC	 for	 5	 minutes	 at	 7500	 g,	 and	 the	 supernatant	
discarded.	Once	the	pellet	was	completely	dry	it	was	resuspended	in	20	µl	sterile	water.	
Any	contaminating	genomic	DNA	was	removed	using	the	Ambion	DNase	treatment	kit	
(Table	2.3).	2	µl	of	10X	DNase	I	buffer	and	1	µl	of	rDNase	I	was	added	to	each	sample,	
and	incubated	at	37oC	for	25	minutes.	2.3	µl	of	DNase	Inactivation	Reagent	was	added	
to	 each	 sample,	 before	 centrifuging	 at	 10000	 g	 for	 2	 minutes.	 Supernatant	 was	
transferred	to	fresh	1.5	ml	tubes,	and	the	quantity	and	quality	of	RNA	assessed	using	a	
Nanodrop-1000	spectrophotometer	(Thermo	Fisher).	
2.12.3 cDNA	Synthesis	
High	capacity	cDNA	reverse	transcriptase	kit	(Table	2.3)	was	used	to	convert	1	µg	mRNA	
into	cDNA.	1	µg	mRNA	was	made	up	to	20	µl	with	sterile	water.	To	each	sample	4	µl	10X	
RT	buffer,	1.6	µl	25X	100nM	dNTPs,	4	µl	10X	random	primers,	2	µl	multiscribe	reverse	
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transcriptase,	2	µl	RNase	inhibitors,	and	6.4	µl	of	sterile	water	was	added.	Two	controls	
were	included,	one	Taq	polymerase	negative,	and	one	containing	master	mix	only.	The	
samples	were	reverse	transcribed	using	a	Peltier	Thermal	Cycler	PCR	machine	(25oC	for	
10	minutes,	37oC	for	120	minutes,	and	85oC	for	5	minutes).	
2.12.4 RT-PCR	
PCR	was	 carried	out	 using	 the	Promega	GoTaq	Hot	 Start	 Polymerase	 kit	 (Table	 2.3).	
0.025	µg	of	each	cDNA	sample,	or	1	µl	control,	was	added	to	a	master	mix	containing:	
0.28	µM	of	each	forward	and	reverse	specific	primers,	0.4	mM	of	each	dNTP	(Promega),	
1	unit	Taq	polymerase,	buffer	to	a	final	concentration	of	1x,	1.5	mM	MgCl2,	and	sterile	
water	 to	 25	µl	 total	 volume.	 The	 samples	were	 run	 in	 a	 Bibby	 Scientific	 3Prime	PCR	
machine	(94oC	for	2	minutes,	then	cycled	38	times	through	94oC	for	30	seconds,	52oC	
for	30	seconds,	and	72oC	for	1	minute,	followed	by	72oC	for	5	minutes).		
2.12.5 Agarose	Gel	Electrophoresis	
Samples	(10	µl)	were	electrophoresed	through	a	1.5%	agarose	gel	containing	0.3	µg/ml	
ethidium	bromide	(Sigma-Aldrich)	at	100	V,	and	then	imaged	using	a	Bio-Rad	ChemiDoc	
XRS+.		
2.13 Quantitative	RT-PCR	(qRT-PCR)	
2.13.1 ΔΔCt	qRT-PCR	
Quantitative	RT-PCR	(qRT-PCR)	was	used	to	determine	cellular	mRNA	levels	of	DUSP1,	
DUSP10	and	DUSP4	in	comparison	to	a	control	gene,	GAPDH.	1	µl	of	primer	probe	(Table	
2.6),	10	µl	of	q-PCR	mastermix,	8	µl	of	water	and	0.025	µg	cDNA	sample,	or	control	
(Section	 2.12.3)	was	 added	 to	 each	well	 of	 a	 384	well	 plate.	 Two	different	 qRT-PCR	
mastermix	 were	 used:	 Promega,	 mixed	 with	 0.2	 µl	 CXR	 reference	 dye	 per	 well,	 or	
Eurogentec	(Table	2.3).		Each	sample	was	run	in	duplicate.	The	plate	was	centrifuged	for	
2	minutes	at	689	g	before	running	on	the	ABI	7900HT	Fast	Real-Time	PCR	system	using	
the	ΔΔCT	setting	(50oC	for	2	minutes,	95oC	for	10	minutes,	then	cycled	40	times	through	
95oC	for	15	seconds,	and	60oC	for	1	minute).	Data	was	analysed	using	SDS	2.2.1	software	
(ABI	systems)	to	find	the	fold	change	in	DUSP	mRNA	expression	normalised	to	GAPDH	
expression,	and	the	untreated	control	(Livak	and	Schmittgen,	2001).		
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2.13.2 Absolute	Quantification	qRT-PCR	
2.13.2.1 Plasmid	Preparation	
Standard	 curves	 for	 each	 gene	 of	 interest	 were	made	 using	 plasmid	 DNA.	 Plasmids	
expressing	the	genes	of	interest	and	an	antibiotic	resistance	gene	were	transformed	into	
Escherichia	coli	by	other	members	of	 the	group.	Plasmid	DNA	was	purified	using	 the	
GeneJET	plasmid	mini-prep	kit	(Table	2.3)	according	to	the	manufacturer’s	instructions.	
A	single	colony	of	E.	coli	was	used	to	inoculate	5	ml	LB	media	and	incubated	at	37oC,	
shaking,	 over-night.	 The	 culture	was	 then	 centrifuged	 8000	g,	 10	min,	 4oC,	 and	 the	
supernatant	discarded.	The	pellet	was	resuspended	in	250	µl	resuspension	solution	and	
mixed	 by	 inversion.	 250	µl	 of	 lysis	 solution	 and	 350	µl	 neutralisation	 solution	were	
added	before	centrifuging	12000	g,	5	min,	room	temperature	to	remove	cell	debris	and	
chromosomal	DNA.	The	supernatant	was	transferred	to	the	supplied	spin	column	and	
centrifuged	12000	g,	1	min,	room	temperature	and	flow	through	discarded.	The	column	
was	 washed	 twice	 with	 500	 µl	 wash	 solution,	 centrifuging	 12000	 g,	 1	 min,	 room	
temperature,	and	flow	through	discarded.	50	µl	elution	buffer	was	then	added	to	the	
column	and	incubated	for	2	min	at	room	temperature,	before	centrifuging	at	12000	g,	
2	min,	room	temperature	and	collecting	the	flow	through	in	a	fresh	1.5	ml	tube.	This	last	
step	 was	 repeated	 in	 order	 to	 collect	 the	 maximum	 amount	 of	 plasmid	 DNA.	 The	
quantity	 and	 quality	 of	 plasmid	 DNA	 was	 assessed	 using	 a	 Nanodrop-1000	
spectrophotometer	(Thermo	Fisher)	and	the	DNA	stored	at	-20oC.		
2.13.2.2 qRT-PCR	
Absolute	quantification	qRT-PCR	was	used	to	find	cellular	mRNA	levels	of	CXCL8	and	IFN-
b	 mRNA,	 and	 to	 determine	 viral	 replication	 using	 primers	 specific	 to	 part	 of	 the	
rhinoviral	 genome.	 The	 RNA	 concentration	 of	 each	 sample	 was	 calculated	 from	 a	
standard	curve	made	from	a	sample	of	known	copy	number	per	µl	(plasmid	standard).	
Plasmid	 standards	 were	 diluted	 to	 108	 copies	 per	µl	 and	 then	 a	 serial	 1:10	 dilution	
performed	up	to	100	copies	per	µl.		
For	 CXCL8	 and	 GAPDH	 1	µl	 of	 primer	 probe	 (Table	 2.6),	 10	µl	 of	 q-PCR	mastermix	
(Promega),	0.2	µl	CXR	(Promega),	7.8	µl	of	water	and	0.025	µg	cDNA	sample	or	1	µl	
plasmid	standard	was	added	to	each	well	of	a	384	well	plate.	For	RV	and	IFN-b,	1	µl	of	
each	 of	 diluted	 forward	 and	 reverse	 primers	 and	 probe,	 10	 µl	 q-PCR	 mastermix	
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(Promega),	 0.2	µl	 CXR	 (Promega),	 5.8	µl	 water	 and	 0.025	µg	 cDNA	 or	 1	µl	 plasmid	
standard	or	controls	added	to	each	well	of	a	384	well	plate.	Samples,	standards,	and	
controls	were	run	in	duplicate.	The	plate	was	centrifuged	for	2	minutes	at	689	g	before	
running	on	the	ABI	7900HT	Fast	Real-Time	PCR	system,	using	the	absolute	quantification	
setting	(50oC	for	2	minutes,	95oC	for	10	minutes,	then	cycled	40	times	through	95oC	for	
15	seconds,	and	60oC	for	1	minute).	Data	was	analysed	using	SDS	2.2.1	software	(ABI	
systems)	to	find	the	number	of	copies	per	µg	RNA,	normalised	to	GAPDH.		
2.14 Enzyme-Linked	Immunosorbent	Assay	(ELISA)	
2.14.1 CXCL8	and	CCL5	ELISAs	
Cell-free	 supernatants	 were	 collected	 (section	 2.9.1)	 and	 CXCL8	 or	 CCL5	 generation	
were	determined	by	ELISA.	100	µl	of	coating	antibodies	(Table	2.4)	diluted	in	coating	
buffer	(Table	2.2)	was	added	to	each	well	of	a	96	well	plate	with	high-binding	surface	
(Costar),	 and	 incubated	 at	 room	 temperature	 overnight.	 The	plate	was	washed	 four	
times	with	wash	buffer	(Table	2.2)	using	a	plate	washer	(Labtech	International),	then	
blocked	in	1%	albumin	(from	chicken	egg,	Sigma-Aldrich)	or	1%	BSA	(Sigma-Aldrich)	in	
coating	 buffer	 for	 1	 h	 on	 a	 shaking	 platform	 (300	 rotations/minute)	 at	 room	
temperature.	Plates	were	washed	four	times,	and	100	µl	of	standard	(19.6	to	5000	pg/ml	
for	CXCL8;	39	to	10000	pg/ml	for	CCL5)	or	sample	was	added	in	duplicate	to	each	well.	
The	plate	was	incubated	at	room	temperature	for	1.5	h	on	a	shaking	platform	before	
washing	 four	 times.	 100	µl	 of	 biotinylated	 detection	 antibody	 (Table	 2.4),	 diluted	 in	
wash	buffer,	was	added	to	each	well,	and	incubated	at	room	temperature	on	a	shaking	
platform	for	1.5	h.	The	plate	was	washed	four	times,	and	100	µl	of	Streptavidin-HRP	
(R&D	Systems),	diluted	1:200	in	wash	buffer,	was	added	to	each	well,	and	incubated	in	
the	dark	at	room	temperature	for	20	minutes	on	a	shaking	platform.	After	washing	four	
times,	 100	 µl	 of	 substrate	 solution	 (R&D	 systems)	 was	 added	 to	 all	 wells,	 before	
incubating	in	the	dark	at	room	temperature	for	15-25	minutes	on	a	shaking	platform.	
The	reaction	was	stopped	using	50	µl	of	1M	sulphuric	acid	(Fisher)	per	well.	The	optical	
density	of	each	well	at	450	nm	was	read	by	the	Thermo	Multiscan	EX	plate	reader.	The	
amount	of	CXCL8	or	CCL5	present	in	each	sample,	above	the	minimum	detection	level	
of	 78.125	 pg/ml	 for	 CXCL8	 and	 156.25	 pg/ml	 for	 CCL5,	 was	 determined	 using	 the	
standard	curve	from	the	same	plate.	
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2.14.2 IL-1β	ELISA	
The	 R&D	 Systems	 IL-1b	 ELISA	 duo-set	 (Table	 2.3)	 was	 used	 to	 determine	 IL-1b	
generation	 in	 cell-free	 supernatants	 by	 ELISA,	 according	 to	 the	 manufacturer’s	
instructions.	96	well	plates	(Costar)	were	coated	overnight	using	100	µl	per	well	of	IL-1b	
coating	antibody,	diluted	to	4	µg/ml	in	PBS.	The	plate	was	washed	four	times	with	wash	
buffer	 (Table	 2.2)	 using	 a	 plate	 washer	 (Labtech	 International),	 then	 blocked	 in	 1X	
reagent	diluent	(R&D	Systems)	for	one	hour	on	a	shaking	platform	at	room	temperature.	
Plates	were	washed	four	times	and	100	µl	of	standard	(3.91	to	250	pg/ml)	or	sample	
added	in	duplicate	to	each	well.	The	plate	was	incubated	at	room	temperature	for	1.5	h	
on	 a	 shaking	 platform	 before	 washing	 four	 times.	 100	 µl	 of	 biotinylated	 detection	
antibody,	 diluted	 to	 200	 ng/ml	 in	 1X	 reagent	 diluent,	 was	 added	 to	 each	 well,	 and	
incubated	at	room	temperature	on	a	shaking	platform	for	1.5	h.	The	plate	was	washed	
four	 times,	 and	 100	 µl	 of	 Streptavidin-HRP	 (R&D	 Systems),	 diluted	 1:40	 in	 reagent	
diluent	was	added	to	each	well,	and	incubated	in	the	dark	at	room	temperature	for	20	
minutes	on	a	shaking	platform.	After	washing	four	times,	100	µl	of	substrate	solution	
(R&D	 systems)	 was	 added	 to	 all	 wells,	 before	 incubating	 in	 the	 dark	 at	 room	
temperature	for	15-25	minutes	on	a	shaking	platform.	The	reaction	was	stopped	using	
50	µl	of	1M	sulphuric	acid	(Fisher)	per	well.	The	optical	density	of	each	well	at	450	nm	
was	read	by	the	Thermo	Multiscan	EX	plate	reader.	The	amount	of	IL-1b	present	in	each	
sample,	above	the	minimum	detection	level	of	7.81	pg/ml,	was	determined	using	the	
standard	curve	from	the	same	plate.	
2.15 Cytokine	Array	
Cell-free	supernatants	were	collected	(Section	2.9.1)	and	stored	at	-80oC.	Generation	of	
36	 cytokines	was	 determined	 using	 the	 R&D	 Systems	 cytokine	 array	 (Table	 2.3).	 All	
reagents	 from	 the	 kit	were	 brought	 to	 room	 temperature	 and	 supernatant	 samples	
defrosted	on	ice.	Membranes	were	each	blocked	in	3	ml	array	buffer	4	in	the	supplied	
4-well	multi-dish	on	a	rocking	platform,	at	room	temperature,	for	1	h.	900	µl	of	each	
sample	was	transferred	to	a	fresh	1.5	ml	tube,	and	mixed	with	500	µl	array	buffer	4	and	
100	µl	array	buffer	5.	The	antibody	cocktail	was	reconstituted	in	100	µl	water	and	15	µl	
added	to	each	sample	mixture.	Sample	mixtures	were	inverted	and	incubated	at	room	
temperature	 for	 1	 h.	 Blocking	 buffer	 was	 removed	 from	 the	 dish	 and	 the	 sample	
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mixtures	 added	 to	 each	 well,	 before	 the	 membranes	 were	 incubated	 on	 a	 rocking	
platform,	 at	 4oC,	 overnight.	Membranes	 were	 then	washed	 three	 times	 in	 1X	wash	
buffer	for	10	minutes.	Streptavidin-HRP	was	diluted	1:2000	in	array	buffer	5,	and	3	ml	
added	 to	 each	 membrane.	 This	 was	 incubated	 at	 room	 temperature	 on	 a	 rocking	
platform	for	30	min.	Membranes	were	then	washed	3	times	in	1X	wash	buffer	for	10	
minutes.	Each	membrane	was	then	incubated	for	1	minute	with	Chemi	Reagent	before	
being	imaged	using	a	BioRad	ChemiDoc	XRS+.		
2.16 Western	Blot	
2.16.1 SDS-PAGE	Gel	Electrophoresis	
SDS-PAGE	gel	apparatus	was	set	up	according	to	the	manufacturer’s	instructions.	Gels	
were	prepared	as	in	table	2.8	with	approximately	2.5	cm	of	5%	stacking	gel,	containing	
a	10	or	15	well	comb,	layered	above	the	10%	resolving	gel.	
Gels	were	assembled	 in	a	 running	 tank	 filled	with	1X	 running	buffer	 (Table	2.2).	Cell	
lysates	 (10	 µl)	 (section	 2.9.3)	 and	 prestained	 protein	 ladder	 (GeneFlow)	 were	
electrophoresed	 through	 the	 stacking	 gel	 at	 100	 V,	 increased	 to	 200	 V	 through	 the	
resolving	gel.	
2.16.2 Transfer	
Proteins	 were	 transferred	 onto	 0.22	 µm	 nitrocellulose	 membrane	 (Pall)	 using	 the	
Thermo	Scientific	Pierce	G2	Fast	Blotter.	Filter	paper	and	nitrocellulose	membrane	were	
soaked	 in	 1X	 transfer	 buffer	 (Table	 2.2)	 for	 5	minutes,	 and	 the	 transfer	 sandwiches	
assembled	on	the	Fast	Blotter.	Proteins	were	allowed	to	migrate	for	15	minutes	at	3	A	
and	25	V,	and	membranes	stained	with	1%	Ponceau	S	(Sigma-Aldrich)	to	assess	protein	
transfer.	Ponceau	S	was	washed	off	with	1X	PBS/Tween	or	1x	TBS/Tween	(for	antibodies	
specific	 to	 phosphorylated	 proteins)	 (Table	 2.2),	 and	 the	 membranes	 incubated	 in	
blocking	buffer	(Table	2.2)	for	1	h	at	room	temperature	on	a	rotating	platform.	
2.16.3 Primary	Antibody	
Primary	antibodies	(Table	2.4)	were	diluted	in	blocking	buffer	(Table	2.2)	or	5%	BSA	in	
PBS/Tween,	and	incubated	with	the	membrane	overnight	at	4oC,	rolling.		
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2.16.4 Secondary	Antibody	
Membranes	were	washed	4	times	with	1X	PBS/Tween	or	1X	TBS/Tween	for	5	minutes.	
The	HRP-conjugated	secondary	antibody	(Table	2.4)	was	diluted	in	blocking	buffer,	and	
incubated	with	the	membrane	at	room	temperature	for	one	hour,	rolling.		
2.16.5 Visualising	the	Membrane	
Membranes	were	washed	4	times	with	1X	PBS/Tween	or	1X	TBS/Tween	for	5	minutes.	
The	membranes	were	incubated	with	ECL	substrate	(BioRad)	for	5	minutes	before	being	
imaged	using	a	BioRad	ChemiDoc	XRS+.		
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3 Chapter	Three	–	Results:	Characterising	the	Response	of	
PBECs	to	Rhinoviral	Infection	
3.1 Aims	
Rhinovirus	infection	of	bronchial	epithelial	cells	activates	pattern	recognition	receptors,	
including	TLR3,	which	initiate	a	range	of	different	signalling	pathways,	such	as	the	MAPK	
pathways:	ERK,	p38	and	JNK	 (Slater	et	al.,	2010,	Wang	et	al.,	2009).	These	pathways	
consist	of	a	three-tier	kinase	cascade,	culminating	in	the	phosphorylation	of	the	MAPK	
protein	 on	 two	 residues,	 threonine	 and	 tyrosine.	 The	 phosphorylated	 MAPK	 then	
translocates	to	the	nucleus	and	activates	transcription	factors,	such	as	NF-kB	and	AP-1;	
inducing	cytokine	transcription	(Griego	et	al.,	2000).	Previous	work	has	 identified	the	
MAPKs	as	having	important	roles	in	the	response	to	rhinoviral	infection	(Griego	et	al.,	
2000,	Liu	et	al.,	2008a).		
It	 is	 important	 to	 regulate	 these	 pathways	 to	 limit	 the	 inflammation	 produced	 in	
response	to	the	virus.	A	family	of	proteins	called	DUSPs	have	previously	been	found	to	
regulate	 the	MAPK	pathways	by	dephosphorylating	both	 the	 threonine	 and	 tyrosine	
residues	within	 the	MAPK	proteins	 simultaneously.	However,	much	of	 this	work	has	
been	investigated	in	bacterial	infection	of	macrophages	(Hammer	et	al.,	2006,	Qian	et	
al.,	2012,	Cornell	et	al.,	2012).	The	expression	of	DUSPs	in	epithelial	cells	has	not	been	
well	studied,	and	the	regulation	of	these	proteins	in	response	to	rhinoviral	infection	is	
not	known.		
The	aim	of	this	chapter	was	to	examine	the	role	of	the	three	MAPK	proteins:	ERK,	p38	
and	JNK,	in	the	response	of	primary	bronchial	epithelial	cells	to	rhinoviral	infection	and	
to	characterise	the	expression	of	DUSP	proteins	thought	to	regulate	these	pathways.	
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3.2 The	Role	of	the	MAPK	Pathways	in	the	Response	of	PBECs	to	RV	
Infection	
3.2.1 Cytokine	Release	in	Response	to	Viral	Infection	
It	 is	 well	 documented	 that	 epithelial	 cells	 respond	 to	 viral	 infection	 by	 secreting	
cytokines,	 such	 as	 CXCL8	 and	 CCL5.	 CXCL8	 is	 a	 neutrophil	 chemoattractant,	 its	
transcription	being	induced	by	NF-kB,	whereas	CCL5	production	is	mainly	 induced	by	
the	 IRFs.	 Therefore,	 secretion	 of	 these	 two	 molecules	 indicates	 that	 an	 immune	
response	has	been	 induced	and	can	give	an	 indication	of	which	 transcription	 factors	
have	 been	 activated.	 PBECs	 were	 infected	 with	 rhinovirus	 to	 confirm	 that	 airway	
epithelial	cells	respond	to	rhinoviral	infection	by	secreting	these	cytokines.	Both	major,	
RV16,	and	minor,	RV1B,	group	rhinoviruses	were	utilised	to	further	ascertain	if	the	cells	
respond	differently	to	the	two	serotypes.	Poly(I:C)	was	also	used	to	stimulate	PBECs,	to	
determine	whether	the	response	to	rhinovirus	was	due	to	TLR3	signalling	pathways.	As	
a	positive	control,	IL-1b	was	used,	as	it	is	known	to	activate	the	MAPK	pathways.		
Unstimulated	PBECs	released	around	1	ng/ml	CXCL8	at	baseline	and	the	CCL5	release	
was	below	the	minimum	level	of	detection	(Figure	3.1).	Stimulation	with	poly(I:C)	for	24	
h	induced	significant	secretion	of	both	CXCL8	and	CCL5,	as	measured	by	ELISA	(Figure	
3.1).	Simulation	with	RV1B	consistently	induced	secretion	of	both	cytokines,	however	
this	only	reached	statistical	significance	for	CCL5	release.	Infection	with	RV16	did	not	
upregulate	CXCL8	release,	but	caused	a	consistent,	statistically	significant,	increase	in	
CCL5	 release.	 Stimulation	 of	 PBECs	with	 the	 proinflammatory	 cytokine	 IL-1b	 caused	
release	of	CXCL8	but	not	CCL5,	for	which	two	out	of	six	donors	were	below	the	minimum	
detection	level.	This	was	in	keeping	with	the	literature	and	confirms	that	IL-1b	does	not	
activate	 the	 IRF	 and	 IFN	pathways.	 These	data	 confirm	 that	 under	 these	 conditions,	
stimulation	of	PBECs	with	poly(I:C)	or	 infection	with	 rhinovirus	 leads	 to	activation	of	
both	the	NF-kB	and	IRF	pathways,	whereas	IL-1b	only	induces	the	NF-kB	pathway.	 	
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Figure	3.1	PBECs	respond	to	major	or	minor	rhinoviral	infection	or	stimulation	with	
poly(I:C)	or	IL-1β	by	secreting	pro-inflammatory	cytokines.	
PBECs	were	stimulated	with	 IL-1β	 (100	ng/ml),	poly(I:C)	 (25	µg/ml),	RV1B	(MOI	3)	or	
RV16	(MOI	4)	for	24	hours.	Supernatant	was	collected	and	ELISA	used	to	measure	the	
release	of	CXCL8	(A)	and	CCL5	(B).	Data	shown	are	mean	±	SEM	of	n=4	for	CXCL8,	except	
RV16	n=3,	and	n=6	for	CCL5,	except	poly(I:C)	and	RV16	n=3.	Significance	is	indicated	by	
*	p	≤	0.05,	**	p	≤	0.01,	or	****	p	≤	0.0001	as	measured	by	t-test,	compared	to	media	
control.	 	
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3.2.2 The	Roles	of	the	MAPK	Pathways	in	Cytokine	Release	in	the	Response	
of	PBECs	to	Viral	Infection	
It	is	well	established	that	the	MAPK	pathways	have	roles	in	inducing	cytokine	release.	
To	determine	the	specific	role	of	each	MAPK	pathway	in	the	release	of	cytokines	from	
PBECs	in	response	to	viral	infection	(Figure	3.1),	cells	were	treated	with	a	panel	of	MAPK	
inhibitors	 before	 stimulation	 with	 poly(I:C),	 as	 the	 greatest	 cytokine	 release	 was	
observed	in	response	to	this	stimulant.		
Inhibition	of	either	p38	or	JNK	dramatically	decreased	release	of	both	CXCL8	and	CCL5,	
almost	 to	 the	 level	of	media	 control	 (Figure	3.2).	 This	was	 statistically	 significant	 for	
CXCL8	release	for	both	p38	and	JNK	inhibitors;	and	there	was	a	consistent	decrease	in	
CCL5	release	following	p38	or	JNK	inhibition	in	all	three	PBEC	donors.	Release	of	both	
cytokines	was	unaffected	when	ERK	was	inhibited	(Figure	3.2).			
The	effect	of	MAPK	inhibition	on	CXCL8	mRNA	generation	in	response	to	both	strains	of	
rhinovirus	was	determined	by	qRT-PCR	and	ELISA.	Similarly	to	results	obtained	when	
studying	responses	to	poly(I:C),	at	48	h	inhibition	of	either	p38	or	JNK	decreased	mRNA	
and	secreted	protein	levels	of	CXCL8	in	response	to	RV1B,	whereas	ERK	inhibition	had	
no	effect	(Figure	3.3).	Due	to	the	large	amount	of	donor	variation	in	mRNA	levels,	this	is	
only	statistically	significant	for	p38	inhibition,	however,	the	effect	is	much	clearer	at	the	
secreted	protein	 level.	At	24	h	post	 infection,	RV1B	caused	a	small	 increase	in	CXCL8	
levels	 compared	 to	 the	media	 control,	 which	was	 unaffected	 by	 JNK	 inhibition,	 and	
inhibition	of	p38	caused	only	a	modest	downregulation	of	CXCL8	(Figure	3.3).		
The	response	of	PBECs	to	RV16	infection	was	similar,	with	only	a	small	effect	of	24	h	
RV16	 infection	on	CXCL8	production.	These	data	are	 in	keeping	with	 those	shown	 in	
figure	3.1,	where	no	change	was	seen	in	CXCL8	protein	levels	in	response	to	RV16.	After	
48	h,	the	response	to	RV16	was	larger,	with	a	trend	towards	lower	CXCL8	levels	in	cells	
treated	with	p38	or	JNK	inhibitors,	but	again	no	change	in	response	to	ERK	inhibition.	
However,	 this	 only	 reached	 statistical	 significance	 in	 the	 secreted	 protein	 level	 in	
response	to	SB202190	treatment	(Figure	3.4).	
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Figure	 3.2	 Treatment	of	 PBECs	with	MAPK	 inhibitors	 decreases	 cytokine	 release	 in	
response	to	poly(I:C)	stimulation.		
PBECs	 were	 treated	 with	 MAPK	 inhibitor	 (20	 µM);	 U0126	 (ERK),	 PD98059	 (ERK),	
SB203580	 (p38),	 SB202190	 (p38)	 or	 SP600125	 (JNK);	 vehicle	 control;	 or	 untreated	
(media)	 for	one	hour	prior	 to	24	h	poly(I:C)	stimulation	 (25	µg/ml).	Supernatant	was	
collected	and	ELISA	used	to	measure	the	release	of	CXCL8	(A)	and	CCL5	(B).	Data	shown	
are	mean	±	SEM	of	n=3.	Significance	is	indicated	by	*	p	≤	0.05,	**	p	£	0.01	verses	poly(I:C)	
+	DMSO,	as	measured	by	paired	t-test.	
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Figure	 3.3	 Treatment	of	 PBECs	with	MAPK	 inhibitors	 decreases	 cytokine	 release	 in	
response	to	RV1B	infection.		
PBECs	 were	 treated	with	MAPK	 inhibitor	 (20	µM);	 PD98059	 (ERK),	 SB203580	 (p38),	
SB202190	(p38)	or	SP600125	(JNK);	vehicle	control;	or	untreated	(media)	for	one	hour	
prior	to	RV1B	infection	(MOI	3).	RNA	was	collected	and	qRT-PCR	performed	for	CXCL8	
and	a	GAPDH	control.	Data	shown	mean	±	SEM	of	n=3	normalised	to	the	GAPDH	control	
and	media	control	(A).	Supernatant	was	collected	and	ELISA	used	to	measure	the	release	
of	CXCL8.	Data	shown	are	mean	±	SEM	of	n=3,	normalised	to	media	control.	Significance	
is	indicated	by	*	p	≤	0.05,	****	p	≤	0.0001	verses	RV1B	+	DMSO,	as	measured	by	two-
way	ANOVA,	Dunnett’s	post-test.	
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Figure	 3.4	 Treatment	of	 PBECs	with	MAPK	 inhibitors	 decreases	 cytokine	 release	 in	
response	to	RV16	infection.		
PBECs	 were	 treated	with	MAPK	 inhibitor	 (20	µM);	 PD98059	 (ERK),	 SB203580	 (p38),	
SB202190	(p38)	or	SP600125	(JNK);	vehicle	control;	or	untreated	(media)	for	one	hour	
prior	to	RV16	infection	(MOI	4).	RNA	was	collected	and	qRT-PCR	performed	for	CXCL8	
and	a	GAPDH	control.	Data	shown	mean	±	SEM	of	n=3	normalised	to	the	GAPDH	control	
and	media	control	(A).	Supernatant	was	collected	and	ELISA	used	to	measure	the	release	
of	CXCL8.	Data	shown	are	mean	±	SEM	of	n=3,	normalised	to	media	control.	Significance	
is	 indicated	 by	 *	 p	 ≤	 0.05	 verses	 RV16	 +	 DMSO,	 as	 measured	 by	 two-way	 ANOVA,	
Dunnett’s	post-test.	 	
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3.2.3 The	 Roles	 of	 the	 MAPKs	 in	 the	 Viability	 of	 PBECs	 in	 Response	 to	
Rhinoviral	Infection	
The	MAPK	pathways	 are	 known	 to	be	 involved	 in	many	 cellular	processes,	 including	
apoptosis	and	proliferation	(Wada	and	Penninger,	2004).	 Induction	of	apoptosis	 is	an	
important	component	of	the	innate	immune	response,	and	rhinoviral	infection	of	PBECs	
has	previously	been	shown	to	induce	apoptosis	(Wark	et	al.,	2005).		Thus,	the	effect	of	
inhibiting	 each	 of	 the	 MAPKs	 on	 cell	 viability	 in	 rhinoviral	 infection	 of	 PBECs	 was	
determined.	Infection	with	either	serotype	of	rhinovirus	did	not	affect	cell	viability,	and	
this	was	unaffected	by	treatment	with	any	of	the	MAPK	inhibitors	(Figure	3.5).		
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Figure	3.5	Treatment	of	PBECs	with	MAPK	inhibitors	does	not	affect	cell	viability.		
PBECs	 were	 treated	 with	 the	 indicated	 MAPK	 inhibitors	 (20	 µM),	 vehicle	 control	
(DMSO),	or	untreated	(media),	for	one	hour	prior	to	24	h	infection	with	RV1B	(MOI	3)	
(A)	or	RV16	(MOI	4)	(B).	Cell	titre	glo	cell	viability	assay	was	performed.	Data	shown	are	
mean	 ±	 SEM	 of	 relative	 light	 units,	 n=3.	 Significance	 was	 measured	 using	 one-way	
ANOVA,	Dunnett’s	post-test.		 	
Me
dia
Me
dia
DM
SO
PD
98
0
SB
20
3
SB
20
2
SP
60
0
0
2×107
4×107
6×107
8×107
1×108
Lu
m
in
es
ce
nc
e 
(R
LU
)
Me
dia
Me
dia
DM
SO
PD
98
0
SB
20
3
SB
20
2
SP
60
0
0
2×107
4×107
6×107
8×107
Lu
m
in
es
ce
nc
e 
(R
LU
)
A
B
RV1B             -       +       +       +        +       +       +
RV16             -       +       +       +        +       +       +
	68	
3.2.4 The	Roles	of	the	MAPK	Pathways	in	Rhinoviral	Replication	
The	MAPKs	control	many	different	processes	in	the	cell	and	therefore	may	affect	the	
viral	 life	 cycle.	 For	 example,	 p38	 can	 regulate	 the	 endocytosis	 pathway,	 and	
enteroviruses	have	been	shown	to	utilise	endocytosis	machinery	to	harvest	cholesterol	
(Ilnytska	et	al.,	2013).	Therefore,	the	effect	of	MAPK	inhibition	on	rhinoviral	replication	
was	investigated	by	qRT-PCR	for	rhinoviral	RNA	levels.	Treatment	with	the	ERK	inhibitor	
PD98059	did	not	have	any	effect	on	rhinoviral	replication	levels,	as	measured	by	RV	RNA	
(Figure	3.6).	Both	p38	inhibitors	consistently	caused	a	decrease	in	replication	of	both	
strains	of	 rhinovirus	at	24	and	48	h	post	 infection,	although	this	was	not	statistically	
significant.	Intriguingly,	inhibition	of	JNK	caused	a	large	increase	in	the	level	of	RV1B	and	
RV16	replication	at	both	time	points	(Figure	3.6).		
Due	to	the	role	of	IFNs	in	limiting	the	replication	of	rhinovirus,	it	was	hypothesised	that	
the	effect	of	MAPK	inhibition	on	rhinoviral	replication	seen	in	figure	3.6	was	due	to	an	
effect	 on	 IFN	 production.	 Thus,	 the	 effect	 of	 each	 MAPK	 inhibitor	 on	 IFN-b	 mRNA	
production	in	response	to	RV1B	and	RV16	infection	was	investigated	by	qRT-PCR.	Very	
little	IFN-b	was	present	in	all	samples,	less	than	0.1	copies	of	RNA	per	µg,	and	infection	
with	RV1B	or	RV16	did	not	cause	any	changes	(Figure	3.7).	In	RV16	infected	samples,	
treatment	with	any	of	the	MAPK	inhibitors	did	not	affect	IFN-b	mRNA	levels.	However,	
in	 RV1B	 infected	 samples,	 treatment	 with	 the	 JNK	 inhibitor	 SP600125	 consistently	
caused	around	a	5-fold	increase	in	IFN-b	mRNA	levels	(Figure	3.7	A).		 	
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Figure	 3.6	 RV	 replication	 is	 decreased	 by	 p38	 inhibition	 and	 increased	 by	 JNK	
inhibition.		
PBECs	 were	 treated	 with	 the	 indicated	 MAPK	 inhibitors	 (20	 µM),	 vehicle	 control	
(DMSO),	or	untreated	(media),	for	one	hour	prior	to	24	h	infection	with	RV1B	(MOI	3)	
(A)	or	RV16	(MOI	4)	(B).	RNA	was	collected	and	qRT-PCR	performed	for	RV	RNA	and	a	
GAPDH	control.	Data	shown	mean	±	SEM	normalised	to	the	GAPDH	control	and	RV	only	
24	h	samples,	n=4,	except	PD98059	which	is	n=3	(A)	and	n=2	(B).	Significance	is	indicated	
by	**	p	≤	0.01	and	****	p	≤	0.0001	versus	RV	only	as	measured	by	two-way	ANOVA	with	
Dunnett's	post-test	(excluding	PD98059	in	B).	 	
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Figure	3.7	RV	infection	does	not	induce	measurable	IFN-b	mRNA	levels.		
PBECs	 were	 treated	 with	 the	 indicated	 MAPK	 inhibitors	 (20	 µM),	 vehicle	 control	
(DMSO),	or	untreated	(media),	for	one	hour	prior	to	4	h	infection	with	RV1B	(MOI	3)	(A)	
or	RV16	(MOI	4)	(B).	RNA	was	collected	and	qRT-PCR	performed	for	IFN-b	and	a	GAPDH	
control.	Data	shown	mean	±	SEM	of	n=4,	normalised	to	the	GAPDH	control.	Significance	
compared	 to	 the	 RV	 +	 DMSO	 control	 was	 measured	 using	 one-way	 ANOVA	 with	
Dunnett’s	post-test.		 	
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3.3 Activation	of	the	MAPK	Pathways	in	PBECs	
As	 discussed	 above,	 NF-kB	 is	 activated	 by	 the	 MAPK	 pathways,	 and	 the	 NF-kB	
dependent	cytokine	CXCL8	was	secreted	in	response	to	infection	with	rhinovirus	(Figure	
3.1).	However,	it	is	known	that	the	IKK	pathway	also	plays	a	major	role	in	activating	NF-
kB	transcription	and	cytokine	release	in	response	to	TLR	or	IL-1RI	activation	(Figure	1.1).	
Therefore,	the	specific	activation	of	the	MAPK	pathways	in	PBECs	in	response	to	viral	
infection	 was	 examined.	 MAPK	 proteins	 are	 thought	 to	 be	 present	 but	 inactive	 in	
unstimulated	cells,	and	phosphorylated	and	activated	in	response	to	infection.	
The	level	of	phosphorylated,	active,	MAPK	proteins	was	measured	over	24	h	in	response	
to	stimulation	with	IL-1b	or	poly(I:C),	or	infection	with	RV1B	or	RV16	using	western	blot.	
Some	of	the	presented	western	blots	are	segmented,	this	is	due	to	samples	being	run	
on	separate	gels,	however,	blots	were	all	treated	the	same	and	blots	for	each	antibody	
exposed	for	the	same	amount	of	time.	Phosphorylated	ERK	protein	was	present	in	all	
media	control	samples	(Figure	3.8).	In	response	to	stimulation	with	IL-1b	or	poly(I:C),	or	
infection	with	RV1B,	the	levels	of	phospho-ERK	increased	slightly	at	0.5	h	then	gradually	
declined	over	 the	 rest	of	 the	 time	course,	 to	below	the	 level	 seen	 in	media	controls	
(Figure	3.8	A,	B,	C).	Infection	with	RV16	did	not	cause	the	initial	increase	in	phospho-
ERK	 levels,	 but	 from	 1	 h	 post	 infection	 levels	 gradually	 declined	 to	 an	 almost	
undetectable	 level	 (Figure	3.8	D).	This	work	 is	 inconclusive,	as	 it	 is	only	an	n	of	1.	As	
inhibition	of	ERK	did	not	have	an	effect	on	cytokine	release,	cell	viability,	or	rhinoviral	
replication	(Section	3.2),	the	activation	of	ERK	MAPK	was	not	investigated	any	further.		
Activation	of	the	p38	MAPK	was	then	examined.		No,	or	very	little,	p38	phosphorylation	
was	observed	in	untreated	cells,	whilst	stimulation	with	IL-1b	caused	phosphorylation	
of	 p38	 within	 30	 minutes	 before	 declining	 back	 to	 baseline	 (Figure	 3.9	 A).	
Phosphorylation	of	p38	in	response	to	stimulation	with	poly(I:C)	occurred	much	more	
gradually,	peaking	at	around	2	h,	before	declining	again.	The	increase	was	not	significant	
but	was	detected	consistently	(Figure	3.9	B).	No	p38	phosphorylation	was	observed	in	
response	 to	RV1B,	 although	 low	background	 levels	 can	be	 seen	 in	 the	densitometry	
(Figure	3.9	C),	whilst	p38	phosphorylation	in	response	to	RV16	occurred	late,	at	8	and	
24	h	(Figure	3.9	D).	As	MAPKs	are	generally	activated	rapidly	this	indicated	that	p38	may	
have	been	activated	prior	to	the	time	points	examined,	with	the	late	peak	detected	in	
response	to	RV16	potentially	due	to	a	second	round	of	infection.			
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To	 investigate	this	 further,	PBECs	were	 infected	with	RV1B	and	RV16	and	cell	 lysates	
were	 taken	 within	 the	 initial	 hour	 of	 virus	 addition,	 during	 viral	 attachment.	 p38	
activation	was	observed	in	response	to	both	viruses	within	this	hour,	peaking	at	around	
20-30	min	in	response	to	RV1B	(Figure	3.10	A)	and	40	min	in	response	to	RV16	(Figure	
3.10	B),	although	this	only	reached	statistical	significance	for	RV1B.		
The	final	MAPK	pathway,	JNK,	was	then	examined	using	the	same	technique.	Similarly	
to	p38,	JNK	was	phosphorylated	in	response	to	IL-1b	and	poly(I:C),	peaking	at	30	min	
(Figure	3.11	A)	and	2	hours	 (Figure	3.11	B)	 respectively.	However,	no	activation	was	
detected	in	response	to	either	of	the	rhinoviral	serotypes	over	24	h	(Figure	3.11	C	and	
D).	 Therefore,	 JNK	 activation	was	 investigated	during	 the	 one	hour	 viral	 attachment	
period.	During	this	hour	JNK	was	phosphorylated	by	RV1B,	gradually	increasing	up	to	40	
min,	although	this	did	not	reach	statistical	significance,	before	declining	back	to	baseline	
(Figure	 3.12	 A).	 Phosphorylation	 was	 also	 observed	 in	 response	 to	 RV16	 infection,	
occurring	at	30	min	and	remaining	up	to	60	min	(Figure	3.12	B).	
As	rhinoviral	infection	activated	the	MAPKs	much	earlier	than	poly(I:C)	this	early	signal	
is	 unlikely	 to	 be	 dependent	 on	 TLR3	 activation.	 UV-inactivated	 RV1B	 was	 used	 to	
determine	whether	the	early	MAPK	activation	was	dependent	on	rhinoviral	replication.	
Infection	with	RV1B	again	caused	activation	of	both	JNK	and	p38	by	20	minutes	post	
viral	addition	which	declined	by	60	minutes.	Stimulation	with	UV-inactivated	RV1B	also	
caused	activation	of	both	MAPKs	 (Figure	3.13).	These	data	must	be	 interpreted	with	
caution	as	they	are	only	n=1,	however	they	are	supported	by	previous	work	showing	
activation	of	p38	by	UV-inactivated	rhinovirus	(Dumitru	et	al.,	2006,	Wang	et	al.,	2006).	
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Figure	3.8	Levels	of	ERK	activation	gradually	decline	over	24	h.		
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	 (C),	 or	 RV16	 (MOI	 4)	 (D)	 and	 cell	 lysate	 collected	 at	 the	 indicated	 time	 points.	
Phosphorylated	ERK	and	total	actin	levels	were	measured	using	western	blot.	Blots	are	
shown	with	densitometry	below.	Data	shown	are	band	density	normalised	to	the	actin	
control	for	each	sample,	n=1.		
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Figure	3.9	p38	is	activated	by	stimulation	with	poly(I:C)	and	IL-1β.		
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	(C)	or	RV16	(MOI	4)	(D)	over	24	hours	and	cell	lysate	collected	at	the	indicated	time	
points.	Phosphorylated	p-38	and	total	actin	levels	were	measured	using	western	blot.	
Representative	blots	are	shown	with	densitometry	below.	Data	shown	are	mean	±	SEM	
of	band	density	normalised	 to	 the	actin	control	 for	each	sample,	n=3.	Significance	 is	
indicated	by	**	p	≤	0.01	 verses	unstimulated	 control	 (0	h)	 as	measured	by	one-way	
ANOVA,	with	Dunnett’s	post-test.	
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Figure	 3.10	 p38	 is	 activated	 by	 major	 and	 minor	 rhinoviral	 infection	 during	 viral	
attachment.		
PBECs	were	stimulated	with	RV1B	(A)	and	RV16	(B)	for	one	hour	during	viral	attachment	
and	cell	 lysate	 collected	at	 the	 indicated	 time	points.	Phosphorylated	p-38	and	 total	
actin	 levels	were	measured	using	western	blot.	Representative	blots	are	shown	with	
densitometry	below.	Data	shown	are	mean	±	SEM	of	band	density	normalised	to	the	
actin	control	for	each	sample,	n=3.	Significance	is	indicated	by	*	p	≤	0.05	and	**	p	≤	0.01	
verses	unstimulated	control	(0	h)	as	measured	by	one-way	ANOVA,	with	Dunnett’s	post-
test.	 	
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Figure	3.11	JNK	is	activated	by	stimulation	with	poly(I:C)	and	IL-1b.		
PBECs	were	stimulated	with	IL-1b	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	(C)	or	RV16	(MOI	4)	(D)	over	24	hours	and	cell	lysate	collected	at	the	indicated	time	
points.	Phosphorylated	JNK	and	total	actin	 levels	were	measured	using	western	blot.	
Representative	blots	are	shown	with	densitometry	below.	Data	shown	are	mean	±	SEM	
of	band	density	normalised	 to	 the	actin	control	 for	each	sample,	n=3.	Significance	 is	
indicated	 by	 *	 p	 £	 0.05	 and	 ****	 p	 £	 0.0001	 verses	 unstimulated	 control	 (0	 h)	 as	
measured	by	one-way	ANOVA	with	Dunnett’s	post-test.		 	
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Figure	 3.12	 JNK	 is	 activated	 by	 major	 and	 minor	 rhinoviral	 infection	 during	 viral	
attachment.		
PBECs	were	stimulated	with	RV1B	(A)	and	RV16	(B)	for	one	hour	during	viral	attachment	
and	cell	lysate	collected	at	the	indicated	time	points.	Phosphorylated	JNK	and	total	actin	
levels	 were	 measured	 using	 western	 blot.	 Representative	 blots	 are	 shown	 with	
densitometry	below.	Data	shown	are	mean	±	SEM	of	band	density	normalised	to	the	
actin	 control	 for	 each	 sample,	 n=3.	 Significance	 is	 indicated	 by	 *	 p	 £	 0.05	 verses	
unstimulated	control	(0	h)	as	measured	by	one-way	ANOVA,	with	Dunnett’s	post-test.		 	
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Figure	3.13	UV-inactivated	rhinovirus	activates	the	MAPK	proteins.		
PBECs	were	infected	with	RV1B	(MOI	3)	or	UV-inactivated	RV1B	and	cell	lysate	collected	
during	 viral	 attachment	 at	 the	 time	 points	 indicated.	 Phosphorylated	 p38,	
phosphorylated	JNK	and	total	actin	levels	were	measured	using	western	blot.	Blots	are	
shown,	n=1.	
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3.3.1 The	Role	of	Phosphatases	in	MAPK	Regulation	
The	 phosphorylated,	 activated,	 p38	 and	 JNK	MAPK	 signals	 were	 lost	 not	 long	 after	
activation	in	response	to	stimulation	with	IL-1b	or	poly(I:C)	or	infection	with	rhinovirus	
(Figures	 3.9	 –	 3.12).	 Phosphorylated	 proteins	 can	 be	 regulated	 through	
dephosphorylation	 or	 degradation.	 To	 determine	 the	 role	 of	 phosphatases	 in	 the	
regulation	of	p38	and	JNK	signalling	in	response	to	rhinovirus,	PBECs	were	treated	with	
a	 general	 phosphatase	 inhibitor,	 okadaic	 acid,	 prior	 to	 RV1B	 infection.	 Inhibition	 of	
dephosphorylation	consistently	caused	an	increase	in	the	phosphorylated	p38	and	JNK	
signals	at	both	30	and	60	minutes	after	virus	addition,	although	this	was	not	statistically	
significant	(Figure	3.14).	
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Figure	3.14	MAPKs	are	dephosphorylated.		
PBECs	were	pre-treated	with	1	µM	okadaic	acid	(OA)	or	vehicle	control	(DMSO)	for	30	
min	prior	to	RV1B	infection	and	cell	lysate	collected	at	the	indicated	time	points	during	
viral	attachment.	Phosphorylated	p38	(A)	and	phosphorylated	JNK	(B)	and	total	actin	
levels	 were	 measured	 using	 western	 blot.	 Representative	 blots	 are	 shown	 with	
densitometry	below.	Data	shown	are	mean	±	SEM	of	band	density	normalised	to	the	
actin	control	for	each	sample,	n=3.	Significance	was	measured	using	one-way	ANOVA	
with	Sidak’s	post-test.		
Me
dia
DM
SO OA
RV
1B
OA
 + 
RV
1B
RV
1B
OA
+ R
V1
B
0.0
0.5
1.0
1.5
P-
p3
8 
Pr
ot
ei
n 
Ex
pr
es
si
on
Me
dia
DM
SO OA
RV
1B
OA
 + 
RV
1B
RV
1B
OA
+ R
V1
B
0.0
0.5
1.0
1.5
2.0
2.5
P-
JN
K
 P
ro
te
in
 E
xp
re
ss
io
n
A
B
30 min 60 min
30 min 60 min
P-JNK
Actin
P-p38
Actin
	 81	
3.3.2 The	Effect	of	Viral	Filtrate	on	MAPK	Activation	
In	order	to	ensure	that	the	MAPK	activation	seen	in	response	to	infection	with	RV1B	or	
RV16	(Figure	3.10	and	3.12)	is	due	to	viral	infection,	PBECs	were	treated	with	viral	filtrate	
and	western	blot	used	to	measure	MAPK	activation.	Phosphorylated	ERK	protein	was	
present	in	media	control	and	addition	of	RV1B	or	RV16	did	not	cause	any	difference	in	
the	level	of	activated	ERK.	Phospho-ERK	was	also	present	in	samples	treated	with	viral	
filtrate,	but	to	a	lesser	extent	(Figure	3.15	A	and	B).	Addition	of	RV1B	or	RV16	to	PBECs	
for	 30	min	 caused	 an	 increase	 in	 levels	 of	 phosphorylated	p38	 and	 JNK.	Addition	of	
filtrate	from	both	serotypes	of	virus	caused	increases	in	JNK	and	p38	activation	to	the	
same	level	(Figure	3.15	A,	C	and	D).		
To	determine	whether	the	activation	of	the	MAPKs	by	the	filtrate	is	causing	any	of	the	
downstream	 effects	 seen	 in	 response	 to	 RV	 infection,	 the	 effect	 of	 viral	 filtrate	 on	
cytokine	production	was	investigated.	Infection	with	RV1B	caused	an	increase	in	CXCL8	
mRNA	and	secreted	protein	levels	at	24	and	48	h,	with	a	much	larger	effect	at	the	later	
time	point	(Figure	3.16).	Addition	of	filtrate	from	RV1B	to	PBECs	did	not	increase	CXCL8	
mRNA	or	protein	levels,	with	significant	differences	in	CXCL8	production	between	RV1B	
and	RV1B	filtrate	at	48	h	post	stimulation.	Stimulation	with	RV16	virus	or	RV16	filtrate	
did	not	cause	increases	in	CXCL8	mRNA	levels	or	CXCL8	protein	release	(Figure	3.16).		
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Figure	3.15	Rhinoviral	filtrate	activates	the	MAPK	proteins.	
PBECs	were	stimulated	with	RV1B	(MOI	3)	or	RV16	(MOI	4)	or	with	filtrate	from	either	
virus	for	30	minutes.	Cell	lysate	was	collected	during	viral	attachment.	Phosphorylated	
ERK,	 p38,	 and	 JNK	 and	 total	 actin	 levels	 were	 measured	 using	 western	 blot.	
Representative	blots	are	shown	in	A	with	densitometry	in	B,	C	and	D.	Data	shown	are	
mean	 ±	 SEM	of	 band	 density	 normalised	 to	 the	 actin	 control	 for	 each	 sample,	 n=3.	
Significance	was	measured	using	one-way	ANOVA	with	Sidak’s	post-test.		
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Figure	3.16	Rhinoviral	filtrate	does	not	induce	cytokine	production.		
PBECs	were	infected	with	RV1B	(MOI	3)	or	RV16	(MOI	4)	or	stimulated	with	filtrate	from	
both	viruses	for	24	or	48	h.	RNA	was	collected	and	qRT-PCR	performed	for	CXCL8	and	a	
GAPDH	control.	Data	shown	are	mean	±	SEM	of	n=3	normalised	to	the	GAPDH	control	
(A).	Supernatant	was	collected	and	ELISA	used	to	measure	the	release	of	CXCL8.	Data	
shown	are	mean	±	SEM	of	n=3.	Significance	is	indicated	by	***	p	≤	0.001	or	****	p	≤	
0.0001	as	measured	by	multiple	t-tests.	
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3.4 Activation	and	Roles	of	the	MAPK	Pathways	in	PBECs	-	Summary	
The	 data	 presented	 so	 far	 show	 that	 PBECs	 respond	 to	 rhinoviral	 infection	 or	 TLR3	
activation	by	releasing	inflammatory	cytokines.	This	response	is	decreased	when	p38	or	
JNK	are	inhibited,	but	inhibition	of	ERK	has	no	effect	on	cytokine	production.	The	p38	
and	JNK	pathways	were	also	found	to	have	roles	in	rhinoviral	replication,	with	inhibition	
of	p38	leading	to	decreased	viral	RNA	production,	and	inhibition	of	JNK	leading	to	the	
opposite,	 increased	 viral	 RNA.	 The	 increased	 viral	 replication	 in	 the	 absence	 of	 JNK	
signalling	was	not	found	to	be	due	to	changes	in	IFN-b	production.	These	data	suggest	
that	 the	 p38	 and	 JNK	 pathways	 have	 important	 roles	 in	 the	 response	 of	 PBECs	 to	
rhinoviral	infection.		
JNK	 and	 p38	 are	 activated	 in	 response	 to	 innate	 immune	 stimuli	 in	 PBECs.	 TLR3	
activation,	 by	 poly(I:C),	 leads	 to	 activation	 of	 both	 pathways	 with	 similar	 timings,	
peaking	 2	 h	 post	 stimulation.	 Stimulation	with	 the	 inflammatory	 cytokine	 IL-1b	 also	
leads	to	activation	of	both	pathways,	with	an	earlier	peak	activation	of	30	minutes	post	
stimulation.	 In	 response	 to	 rhinoviral	 infection,	MAPK	activation	 is	undetectable,	 the	
phosphorylation	seen	by	western	blot	being	due	to	an	unknown	molecule	present	in	the	
viral	 media.	 Inhibition	 of	 phosphatases	 increases	 the	 amount	 of	 activated	 MAPK,	
suggesting	they	are	regulated	by	dephosphorylation.	
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3.5 Expression	of	DUSPs	in	PBECs	
The	p38	and	JNK	pathways	have	important	roles	in	inducing	cytokine	release	(Figures	
3.2-3.4).	It	is	therefore	extremely	important	that	these	pathways	are	regulated	in	order	
to	control	and	limit	inflammation.	As	discussed	in	section	1.5,	DUSPs	1,	2,	4	and	10	have	
all	previously	been	shown	to	have	roles	in	regulating	the	MAPK	pathways	in	response	to	
immune	stimuli.		
To	 the	 best	 of	 my	 knowledge,	 these	 proteins	 have	 not	 yet	 been	 studied	 in	 PBECs.	
Therefore,	to	ensure	that	the	DUSPs	were	being	expressed	in	PBECs,	RT-PCR	was	used	
to	measure	the	mRNA	expression	of	DUSPs	1,	2,	4	and	10	and	a	GAPDH	control.	The	
regulation	of	 expression	of	 these	DUSPs	was	 investigated	 in	 response	 to	 stimulation	
with	poly(I:C)	or	IL-1b	over	24	h.	All	of	the	DUSPs	studied	were	expressed	at	the	mRNA	
level	 in	 PBECs,	 even	 at	 baseline	 (Figure	 3.17),	 however,	 no	 obvious	 regulation	 was	
observed	in	response	to	either	poly(I:C)	or	IL-1b.		 	
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Figure	3.17	DUSPs	1,	2,	4	and	10	are	expressed	in	PBECs.	
PBECs	 were	 stimulated	 with	 poly(I:C)	 (25	 µg/ml)	 (P),	 IL-1β	 (10	 ng/ml)	 (b)	 or	 left	
untreated	(M)	over	24	hours.	mRNA	was	collected	at	the	time	points	indicated	and	RT-
PCR	performed	using	primers	for	DUSPs	1,	2,	4	and	10	and	a	GAPDH	control.	n=2	with	a	
representative	gel	shown.	
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3.6 Expression	and	Regulation	of	DUSP1	in	PBECs	
3.6.1 DUSP1	 mRNA	 Expression	 and	 Regulation	 in	 PBECs	 in	 Response	 to	
Rhinoviral	Infection	
As	p38	and	JNK	had	the	biggest	roles	in	inducing	cytokine	release	in	PBECs	(Figures	3.2-
3.4)	one	DUSP	that	has	previously	been	shown	to	regulate	these	two	pathways,	DUSP1	
(Chi	et	al.,	2006),	was	taken	forward	for	further	investigation.	The	RT-PCR	results	(Figure	
3.17)	 did	 not	 show	 any	 clear	 regulation	 of	 the	 DUSP1	 mRNA	 levels	 in	 response	 to	
stimulation.	Thus,	a	more	sensitive	technique,	qRT-PCR,	was	utilised	to	investigate	the	
expression	in	more	detail	to	determine	if	the	mRNA	levels	were	regulated	in	response	
to	either	serotype	of	rhinovirus,	poly(I:C)	or	 IL-1b.	Stimulation	with	poly(I:C)	 for	24	h	
induced	approximately	 a	 6-fold	 increase	 in	DUSP1	mRNA	expression	 (Figure	3.18	B).	
However,	stimulation	of	PBECs	with	IL-1b,	or	infection	with	RV1B	or	RV16	did	not	alter	
the	levels	of	DUSP1	mRNA	expression	(Figure	3.18).		
As	the	MAPK	proteins	were	mainly	activated	in	the	initial	one-hour	attachment	phase	
of	 rhinoviral	 infection,	 and	 the	 MAPKs	 have	 been	 shown	 to	 be	 able	 to	 induce	
transcription	 of	 DUSP1	 (Ananieva	 et	 al.,	 2008),	 the	 expression	 of	 DUSP1	 over	 the	
attachment	period	was	investigated.	No	changes	in	DUSP1	mRNA	levels	were	observed	
in	response	to	RV1B	or	RV16	over	this	hour	(Figure	3.19).	
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Figure	3.18	DUSP1	transcription	is	induced	by	poly(I:C)	stimulation.	
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	 (C)	 or	 RV16	 (MOI	 4)	 (D)	 over	 24	 hours.	 mRNA	 was	 collected	 at	 the	 time	 points	
indicated	and	ΔΔCt	qRT-PCR	performed	for	DUSP1	and	a	GAPDH	control.	Data	shown	
are	mean	±	SEM,	n=3,	 fold	change	compared	to	unstimulated	control.	Significance	 is	
indicated	 by	 *	 p	 ≤	 0.05	 verses	 unstimulated	 control	 (0	 h)	 as	measured	 by	 one-way	
ANOVA,	with	Dunnett’s	post-test,	on	the	ΔΔCt	values.	
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Figure	3.19	DUSP1	transcription	does	not	change	over	the	one-hour	viral	attachment.	
PBECs	were	stimulated	with	RV1B	(MOI	3)	(A)	or	RV16	(MOI	4)	(B)	for	one	hour	during	
viral	attachment.	mRNA	was	collected	at	the	time	points	indicated	and	ΔΔCt	qRT-PCR	
performed	 for	DUSP1	and	a	GAPDH	control.	Data	 shown	are	mean	±	SEM,	n=3,	 fold	
change	 compared	 to	 unstimulated	 control.	 Significance	 was	 measured	 by	 one-way	
ANOVA,	with	Dunnett’s	post-test	on	the	ΔΔCt	values.	
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3.6.2 Role	of	the	MAPK	Pathways	in	Regulating	DUSP1	Expression	
Activation	of	two	of	the	MAPK	pathways,	p38	and	ERK,	has	previously	been	shown	to	
lead	 to	DUSP1	 transcription	 (Ananieva	 et	 al.,	 2008).	As	 poly(I:C)	 stimulation	 induced	
upregulation	of	DUSP1	mRNA	expression	at	24	h	(Figure	3.18	B),	PBECs	were	treated	
with	a	panel	of	MAPK	inhibitors	for	1	h	prior	to	poly(I:C)	stimulation	to	investigate	the	
role	of	the	MAPK	pathways	in	this	upregulation.		
Inhibition	of	the	p38	MAPK	pathway	led	to	a	reduction	in	DUSP1	mRNA	levels,	to	below	
the	level	in	unstimulated	cells,	which	is	indicated	by	the	dotted	line	(Figure	3.20).	This	
difference	was	significant	at	2	and	4	h	post	poly(I:C)	stimulation	and	a	similar	pattern	
was	observed	at	each	time	point.	Treatment	with	JNK	or	ERK	inhibitors	did	not	have	any	
effect	on	the	level	of	DUSP1	mRNA.		
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Figure	3.20	DUSP1	transcription	is	reduced	by	p38	inhibition.	
PBECs	were	treated	with	MAPK	inhibitor	(20	µM),	vehicle	control	or	untreated	for	one	
hour	prior	to	stimulation	with	poly(I:C)	(25	µg/ml)	over	24	hours.	mRNA	was	collected	
at	 the	 time	 points	 indicated	 and	 ΔΔCt	 qRT-PCR	 performed	 for	 DUSP1	 and	 a	GAPDH	
control.	Data	shown	are	mean	±	SEM,	n=3,	fold	change	compared	to	an	unstimulated	
control,	which	is	indicated	by	the	dotted	line.	Significance	is	indicated	by	*	p	≤	0.05	and	
***	p	≤	0.001	verses	DMSO	treated	as	measured	by	two-way	ANOVA,	with	Dunnett’s	
post-test,	on	the	ΔΔCt	values.	
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3.6.3 DUSP1	 Protein	 Expression	 and	 Regulation	 in	 PBECs	 in	 Response	 to	
Rhinoviral	Infection	
Although	DUSP1	mRNA	was	not	 regulated	 in	 response	 to	 rhinoviral	 infection	 (Figure	
3.18),	 DUSP1	 can	 be	 regulated	 post-translationally.	 For	 example,	 phosphorylation	 of	
serine	residues	296	and	323	has	been	shown	to	induce	degradation	of	DUSP1	protein	
(Lloberas	et	al.,	2016)	(Section	1.5.3).	Therefore,	the	protein	expression	of	DUSP1	was	
examined	using	western	blot	to	determine	if	expression	was	regulated	in	response	to	
infection	with	either	rhinovirus	serotype,	or	stimulation	with	poly(I:C)	or	IL-1b.		
In	accordance	with	the	DUSP1	mRNA	expression	(Figure	3.18),	PBECs	expressed	DUSP1	
protein	at	baseline	(Figure	3.21).	The	level	of	expression	was	not	altered	in	response	to	
stimulation	with	IL-1β	or	by	infection	with	either	rhinovirus	strain,	similarly	to	the	qRT-
PCR	results.	Although	the	expression	of	DUSP1	mRNA	was	increased	around	6-fold	in	
response	to	poly(I:C)	stimulation	(Figure	3.18	B),	this	was	not	observed	at	the	protein	
level,	with	expression	remaining	constant	over	24	h	stimulation	(Figure	3.21	B).		
As	discussed	in	section	1.5.3,	the	MAPK	proteins	have	previously	been	shown	to	post-
translationally	 regulate	 DUSP1	 (Brondello	 et	 al.,	 1999).	 Therefore,	 the	 protein	
expression	of	DUSP1	was	examined	during	 the	one-hour	viral	 attachment,	when	 the	
MAPK	proteins	were	activated.	DUSP1	protein	levels	were	not	altered	over	this	hour	in	
response	to	infection	with	either	serotype	of	rhinovirus	(Figure	3.22).		
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Figure	3.21	DUSP1	protein	 expression	 is	 not	 changed	by	major	 or	minor	 rhinoviral	
infection	or	stimulation	with	poly(I:C)	or	IL-1β.	
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	(C)	or	RV16	(MOI	4)	(D)	over	24	hours	and	cell	lysate	collected	at	the	indicated	time	
points.	 Total	 DUSP1	 and	 total	 actin	 levels	 were	 measured	 using	 western	 blot.	
Representative	blots	are	shown	with	densitometry	below.	Data	shown	are	mean	±	SEM	
of	band	density	normalised	to	the	actin	control	for	each	sample,	n=3.	Significance	was	
measured	verses	unstimulated	control	(0	h)	by	one-way	ANOVA,	with	Dunnett’s	post-
test.	
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Figure	 3.22	 DUSP1	 protein	 expression	 is	 not	 changed	 during	 the	 1	 hour	 viral	
attachment.	
PBECs	were	infected	with	RV1B	(A)	and	RV16	(B)	for	one	hour	during	viral	attachment	and	
cell	 lysate	collected	at	the	indicated	time	points.	Total	DUSP1	and	total	actin	levels	were	
measured	using	western	blot.	Representative	blots	are	shown	with	densitometry	below.	
Data	 shown	 are	mean	 ±	 SEM	of	 band	 density	 normalised	 to	 the	 actin	 control	 for	 each	
sample,	 n=3.	 Significance	 was	measured	 verses	 unstimulated	 control	 (0	 h)	 by	 one-way	
ANOVA,	with	Dunnett’s	post-test.	
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3.6.4 The	Effect	of	Steroid	Treatment	on	DUSP1	Expression	
It	 has	 previously	 been	 shown	 that	 corticosteroids,	 such	 as	 dexamethasone,	 induce	
upregulation	of	DUSP1	in	PBECs	at	the	mRNA	level	(Papi	et	al.,	2013).	Three	donors	of	
PBECs	were	treated	with	a	range	of	concentrations	of	dexamethasone	over	24	h	in	order	
to	determine	the	optimal	conditions	for	upregulation	of	DUSP1	at	the	mRNA	and	protein	
levels.	In	two	of	the	three	donors,	dexamethasone	stimulation	caused	no	change	in	the	
level	of	DUSP1	mRNA	or	protein	(Figure	3.23).	 In	the	other	donor,	DUSP1	mRNA	was	
upregulated	 by	 all	 concentrations	 of	 dexamethasone	 tested,	 with	 each	 incremental	
concentration	inducing	more	DUSP1	transcription	(Figure	3.23	A).	The	effect	of	10	nM	
dexamethasone	on	mRNA	expression	in	this	donor	did	not	translate	across	into	protein	
expression,	with	an	increase	in	DUSP1	levels	at	2	h	post	stimulation	which	then	declines	
back	to	baseline	levels.	The	response	of	this	donor	to	100	nM	dexamethasone	is	much	
more	 dramatic,	 with	 a	 maximum	 increase	 of	 70-fold	 at	 6	 h	 post	 stimulation.	
Interestingly,	 the	 protein	 expression	 then	 declined,	 whereas	 the	 mRNA	 expression	
peaked	at	24	h	(Figure	3.23	B).	
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Figure	3.23	The	effect	of	dexamethasone	treatment	on	DUSP1	expression.	
PBECs	were	treated	with	1-100	nM	dexamethasone	(Dex.)	over	24	h.	mRNA	or	cell	lysate	
was	collected	at	the	time	points	indicated.	ΔΔCt	qRT-PCR	was	performed	for	DUSP1	and	
a	GAPDH	control.	Data	shown	are	mean	±	SEM,	n=3,	fold	change	normalised	to	GAPDH	
and	untreated	control	(A).	Total	DUSP1	and	actin	protein	levels	were	measured	using	
western	blot.	Densitometry	for	each	donor	is	shown	below	the	blot	for	the	responsive	
donor.	 Data	 shown	 are	 mean	 ±	 SEM	 band	 density	 normalised	 to	 actin	 control	 and	
untreated	 control	 for	 each	 sample	 (B).	 Significance	 is	 indicated	by	*	p	≤	0.05	 versus	
untreated	control	as	measured	by	two-way	ANOVA	with	Dunnett’s	post-test	on	the	ΔΔCt	
values	(A)	or	band	density	(B).		
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3.7 Phosphorylation	of	DUSP1		
Phosphorylation	of	DUSP1	protein	on	serine	residues	359	and	364	has	previously	been	
shown	to	stabilise	the	protein,	prolonging	its	half-life	(Brondello	et	al.,	1999).	Although	
rhinoviral	 infection	 did	 not	 alter	 expression	 of	 DUSP1	 at	 the	mRNA	 or	 protein	 level	
(Figures	3.18	and	3.21),	DUSP1	could	be	regulated	by	post-translational	modifications.	
Thus,	 the	 level	 of	 Ser-359	 phosphorylated	DUSP1	 protein	 in	 PBECs	was	 investigated	
using	western	blot	to	determine	if	DUSP1	was	phosphorylated	at	baseline	and	whether	
this	 was	 regulated	 in	 response	 to	 infection	 with	 RV1B	 or	 RV16	 or	 stimulation	 with	
poly(I:C)	or	IL-1b.	
No,	or	 little,	phosphorylated	DUSP1	was	detected	at	baseline	 in	PBECs	 (Figure	3.24).	
Phospho-DUSP1	 levels	 gradually	 increased	 in	 response	 to	 stimulation	 with	 IL-1b,	
peaking	around	4	h	post-stimulation	before	declining	back	to	baseline	by	24	h	(Figure	
3.24	 A).	 Poly(I:C)	 stimulation	 also	 caused	 a	 gradual	 rise	 in	 phospho-DUSP1	 levels,	
peaking	later,	at	8	h	post-stimulation,	before	declining	back	to	baseline	(Figure	3.24	B).	
Infection	with	either	 rhinoviral	 strain	 caused	an	early	 increase	 in	phosphorylation	of	
DUSP1,	with	a	peak	at	1	h	before	declining	back	to	baseline,	and	a	second	peak	at	24	h	
(Figure	3.24	C	 and	D).	As	was	 suggested	 for	 the	 late	peak	 in	 p38	 activation	 in	RV16	
infection	(Figure	3.9	D),	this	second	peak	could	be	due	to	a	second	round	of	infection	by	
the	nascent	virions	produced	by	the	initially	infected	cells.	Importantly,	addition	of	viral	
filtrate	to	PBECs	for	one	hour	did	not	cause	any	upregulation	of	phosphorylated	DUSP1	
(data	not	shown).	
As	the	MAPK	proteins	were	found	to	be	activated	during	the	one-hour	viral	attachment,	
and	these	pathways	have	previously	been	shown	to	phosphorylate	DUSP1	in	negative	
feedback	mechanisms	(Brondello	et	al.,	1999),	the	level	of	phospho-DUSP1	during	this	
hour	was	investigated.	No,	or	very	little,	phospho-DUSP1	was	detected	in	response	to	
either	strain	of	rhinovirus	during	this	hour	(Figure	3.25).		
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Figure	3.24	DUSP1	phosphorylation	is	induced	by	major	and	minor	rhinoviral	infection	
and	stimulation	with	poly(I:C)	and	IL-1β.		
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	(C)	or	RV16	(MOI	4)	(D)	over	24	hours	and	cell	lysate	collected	at	the	indicated	time	
points.	Phosphorylated	DUSP1	and	total	actin	levels	were	measured	using	western	blot.	
Representative	blots	are	shown	with	densitometry	below.	Data	shown	are	mean	±	SEM	
of	band	density	normalised	to	the	actin	control	for	each	sample,	n=3	for	poly(I:C)	and	
RV16,	 and	 n=4	 for	 IL-1β	 and	 RV1B.	 Significance	 is	 indicated	 by	 *	 p	 £	 0.05	 verses	
unstimulated	control	(0	h)	as	measured	by	one-way	ANOVA,	with	Dunnett’s	post-test.	
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Figure	3.25	DUSP1	is	not	phosphorylated	during	the	hour	viral	attachment.	
PBECs	were	infected	with	RV1B	(A)	and	RV16	(B)	for	one	hour	during	viral	attachment	
and	cell	lysate	collected	at	the	indicated	time	points.	Phosphorylated	DUSP1	and	total	
actin	 levels	were	measured	using	western	blot.	Representative	blots	are	shown	with	
densitometry	below.	Data	shown	are	mean	±	SEM	of	band	density	normalised	to	the	
actin	 control	 for	 each	 sample,	 n=3.	 Significance	 was	 measured	 verses	 unstimulated	
control	(0	h)	by	one-way	ANOVA,	with	Dunnett’s	post-test.	
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3.8 Expression	and	Regulation	of	DUSP10	in	PBECs	
Another	DUSP	previously	found	to	preferentially	regulate	the	p38	and	JNK	pathways,	
DUSP10	 (Qian	 et	 al.,	 2009)	 (Section	 1.5.4),	 was	 also	 taken	 forward	 for	 further	
investigation	into	the	response	to	rhinoviral	infection.		
3.8.1 DUSP10	 mRNA	 Expression	 and	 Regulation	 in	 PBECs	 in	 Response	 to	
Rhinoviral	Infection	
DUSP10	has	previously	been	found	to	be	present	in	macrophages	at	baseline,	and	this	
expression	is	increased	in	response	to	innate	immune	stimuli,	such	as	LPS	(Zhang	et	al.,	
2004).	The	RT-PCR	data	revealed	that	DUSP10	mRNA	is	expressed	in	PBECs,	but	no	clear	
regulation	was	observed	in	response	to	poly(I:C)	or	IL-1b	(Figure	3.17).	Thus,	the	more	
sensitive	qRT-PCR	was	used	in	order	to	investigate	DUSP10	mRNA	expression	in	more	
detail.		
In	accordance	with	the	RT-PCR	data,	stimulation	with	poly(I:C)	over	24	h	did	not	alter	
DUSP10	mRNA	levels	(Figure	3.26	B).	Infection	with	RV1B	or	RV16	or	stimulation	with	
IL-1b	followed	a	similar	pattern	in	the	level	of	DUSP10	mRNA,	although	this	was	only	
statistically	significant	for	RV16,	with	an	early	increase,	peaking	at	1	h	for	IL-1b	and	2	h	
for	RV	infection,	before	declining	to	below	the	baseline	level	at	6	to	8	h,	then	coming	
back	up	to	baseline	level	by	24	h	(Figure	3.26	A,	C	and	D).	Interestingly,	this	is	similar	to	
the	pattern	seen	 in	phosphorylated	DUSP1	 levels	 in	 response	 to	RV	 infection	 (Figure	
3.24	C	and	D).		
To	the	best	of	our	knowledge,	the	pathways	responsible	for	inducing	DUSP10	expression	
have	 not	 previously	 been	 identified.	 The	 MAPK	 pathways	 are	 capable	 of	 inducing	
transcription	of	DUSPs	1,	2	and	4	(Ananieva	et	al.,	2008).	Thus,	to	investigate	whether	
they	 have	 a	 role	 in	 inducing	 transcription	 of	 DUSP10,	mRNA	 levels	 of	 DUSP10	were	
examined	during	the	one-hour	viral	attachment	phase.	Expression	of	DUSP10	was	not	
altered	over	this	hour	in	response	to	either	serotype	of	rhinovirus	(Figure	3.27).	
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Figure	 3.26	 DUSP10	 transcription	 does	 not	 change	 in	 response	 to	major	 or	minor	
rhinoviral	infection	or	stimulation	with	poly(I:C)	or	IL-1β.	
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	 (C)	 or	 RV16	 (MOI	 4)	 (D)	 over	 24	 hours.	 mRNA	 was	 collected	 at	 the	 time	 points	
indicated	and	ΔΔCt	qRT-PCR	performed	for	DUSP10	and	a	GAPDH	control.	Data	shown	
are	mean	 ±	 SEM,	 n=3,	 fold	 change	 normalised	 to	GAPDH	 and	 unstimulated	 control.	
Significance	is	indicated	by	*	p	≤	0.05	versus	unstimulated	control	(0	h),	as	measured	by	
one-way	ANOVA,	with	Dunnett’s	post-test,	on	the	ΔΔCt	values.	
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Figure	3.27	DUSP10	transcription	does	not	change	during	viral	attachment.	
PBECs	were	stimulated	with	RV1B	(A)	and	RV16	(B)	for	one	hour	during	viral	attachment.	
mRNA	was	 collected	 at	 the	 time	 points	 indicated	 and	 ΔΔCt	 qRT-PCR	 performed	 for	
DUSP10	 and	 a	 GAPDH	 control.	 Data	 shown	 are	 mean	 ±	 SEM,	 n=3,	 fold	 change	
normalised	to	GAPDH	and	unstimulated	control.	Significance	was	measured	by	one-way	
ANOVA,	with	Dunnett’s	post-test,	on	the	ΔΔCt	values.	
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3.8.2 DUSP10	 Protein	 Expression	 and	 Regulation	 in	 PBECs	 in	 Response	 to	
Rhinoviral	Infection	
The	expression	of	DUSP10	was	then	examined	further,	in	order	to	determine	whether	
the	 small,	 non-significant,	 changes	 in	 mRNA	 expression	 in	 response	 to	 rhinoviral	
infection	or	IL-1b	stimulation	(Figure	3.26)	were	observed	at	the	protein	level.		
As	in	the	qRT-PCR	data,	poly(I:C)	stimulation	did	not	alter	DUSP10	expression	over	24	h	
(Figure	3.28	B).	Stimulation	with	IL-1b	also	did	not	cause	any	changes	in	DUSP10	protein	
level,	despite	the	small	changes	 in	mRNA	expression	(Figure	3.28	A).	DUSP10	protein	
expression	remained	steady	in	response	to	infection	with	RV1B	or	RV16	up	to	around	6	
h	post-infection	(Figure	3.28	C	and	D).	In	accordance	with	the	mRNA	data	(Figure	3.26),	
the	 expression	 then	 declined	 slightly,	 although	 this	 was	 not	 statistically	 significant.	
Unlike	the	mRNA	expression,	this	decreased	expression	did	not	return	to	baseline	by	24	
h	(Figure	3.28	C	and	D).			
Expression	 of	 DUSP10	 over	 the	 1	 h	 viral	 attachment	 phase	 was	 then	 investigated.	
Addition	of	RV16	did	not	affect	the	protein	level	of	DUSP10	during	this	hour	(Figure	3.29	
B).	 Intriguingly,	stimulation	with	RV1B	consistently	caused	a	reduction	 in	the	 level	of	
DUSP10	 protein,	 decreasing	 to	 almost	 undetectable	 levels	 from	 10	 minutes	 before	
reappearing	around	60	minutes	after	virus	addition.	However,	this	was	not	statistically	
significant	(Figure	3.29	A).	
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Figure	3.28	DUSP10	protein	expression	does	not	change	in	response	to	major	or	minor	
rhinoviral	infection	or	stimulation	with	poly(I:C)	or	IL-1β.	
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	(C)	or	RV16	(MOI	4)	(D)	over	24	hours	and	cell	lysate	collected	at	the	indicated	time	
points.	 Total	 DUSP10	 and	 total	 actin	 levels	 were	 measured	 using	 western	 blot.	
Representative	blots	are	shown	with	densitometry	below.	Data	shown	are	mean	±	SEM	
of	band	density	normalised	to	the	actin	control	for	each	sample,	n=3.	Significance	verses	
unstimulated	control	(0	h)	was	measured	by	one-way	ANOVA,	with	Dunnett’s	post-test.	
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Figure	3.29	DUSP10	protein	expression	is	decreased	by	RV1B	but	not	RV16	during	the	
hour	viral	attachment.	
PBECs	were	stimulated	with	RV1B	(A)	and	RV16	(B)	for	one	hour	during	viral	attachment	
and	cell	lysate	collected	at	the	indicated	time	points.	Total	DUSP10	and	total	actin	levels	
were	measured	using	western	blot.	Representative	blots	are	shown	with	densitometry	
below.	Data	shown	are	mean	±	SEM	of	band	density	normalised	to	the	actin	control	for	
each	sample,	n=3.	Significance	verses	unstimulated	control	(0	h)	was	measured	by	one-
way	ANOVA,	with	Dunnett’s	post-test.	
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3.8.3 The	Effect	of	Steroid	Treatment	on	DUSP10	Expression	
Although	the	effect	of	steroid	treatment	on	DUSP1	expression	is	well	documented	(Papi	
et	al.,	2013),	to	the	best	of	our	knowledge,	the	effect	of	steroids	on	DUSP10	expression	
has	 not	 previously	 been	 examined.	 The	mRNA	 and	 protein	 expression	 of	DUSP10	 in	
PBECs	were	measured	over	24	h	of	1	to	100	nM	dexamethasone	treatment.	Similarly	to	
the	 results	 for	 DUSP1	 expression	 (Figure	 3.23),	 two	 out	 of	 three	 PBEC	 donors	were	
unresponsive	 to	 dexamethasone	 treatment,	 with	 no	 change	 in	 DUSP10	 levels.	 Very	
modest	changes	in	DUSP10	expression	were	observed	in	response	to	the	third	donor,	
with	24	h	treatment	causing	around	a	three-fold	increase	in	DUSP10	mRNA	levels	in	all	
three	doses.	A	similar	pattern	is	seen	in	the	protein	expression,	with	small	increases	at	
24	h	in	one	donor	in	response	to	each	dose.	In	the	10	nM	treatment,	one	donor	had	a	
large	increase	in	protein	expression	at	2	h	which	then	declined	(Figure	3.30).		
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Figure	3.30	DUSP10	expression	in	response	to	dexamethasone	treatment.	
PBECs	were	treated	with	1-100	nM	dexamethasone	(Dex.)	over	24	h.	mRNA	or	cell	lysate	
was	collected	at	the	time	points	indicated.	ΔΔCt	qRT-PCR	was	performed	for	DUSP10	
and	a	GAPDH	control.	Data	 shown	are	mean	±	SEM,	n=3,	 fold	 change	normalised	 to	
GAPDH	and	untreated	control	(A).	Total	DUSP10	and	actin	protein	levels	were	measured	
using	 western	 blot.	 A	 representative	 blot	 is	 shown	 with	 densitometry	 below.	 Data	
shown	are	mean	±	SEM,	n=3,	band	density	normalised	to	actin	control	and	untreated	
control	 for	 each	 sample	 (B).	 Significance	 is	 indicated	by	*	p	≤	0.05	 versus	untreated	
control	as	measured	by	two-way	ANOVA	with	Dunnett’s	post-test	on	the	ΔΔCt	values	
(A)	or	band	density	(B).	
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3.9 Expression	and	Regulation	of	DUSP4	in	PBECs	 in	Response	to	RV	
Infection	
DUSP4	has	also	previously	been	found	to	have	roles	in	regulating	the	innate	immune	
response	 (Section	 1.5.6).	 Although	 it	 is	 most	 commonly	 thought	 to	 act	 on	 the	 ERK	
pathway,	its	effect	on	innate	immune	signalling	is	controversial,	with	some	suggesting	
it	has	a	negative	regulatory	role	and	others	suggesting	it	has	a	positive	(Al-Mutairi	et	al.,	
2010,	 Cornell	 et	 al.,	 2012).	 In	 order	 to	 shed	 some	 light	 on	 this	 controversy,	 the	
expression	of	DUSP4	in	PBECs,	and	its	regulation	in	response	to	rhinoviral	infection	was	
investigated.	
As	discussed	above,	DUSP4	is	expressed	in	PBECs	at	the	mRNA	level	(Figure	3.17)	but	no	
clear	 regulation	 was	 observed	 in	 response	 to	 either	 poly(I:C)	 or	 IL-1b	 stimulation.	
Therefore,	the	more	sensitive	technique	qRT-PCR	was	used	to	determine	any	changes	
in	DUSP4	expression	in	response	to	stimulation	with	poly(I:C)	or	IL-1b	or	infection	with	
RV1B	or	RV16.		
DUSP4	mRNA	was	expressed	by	unstimulated	PBECs,	however,	this	expression	was	not	
altered	in	response	to	stimulation	with	IL-1b	or	poly(I:C)	or	by	infection	with	either	strain	
of	rhinovirus	(Figure	3.31).	
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Figure	 3.31	 DUSP4	 transcription	 does	 not	 change	 in	 response	 to	 major	 or	 minor	
rhinoviral	infection	or	stimulation	with	poly(I:C)	or	IL-1β.	
PBECs	were	stimulated	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	(MOI	
3)	 (C)	 or	 RV16	 (MOI	 4)	 (D)	 over	 24	 hours.	 mRNA	 was	 collected	 at	 the	 time	 points	
indicated	and	ΔΔCt	qRT-PCR	performed	for	DUSP10	and	a	GAPDH	control.	Data	shown	
are	mean	±	SEM,	n=3,	fold	change	compared	to	unstimulated	control.	Significance	was	
measured	by	one-way	ANOVA,	with	Dunnett’s	post-test,	on	the	ΔΔCt	values.	
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3.10 Discussion	
3.10.1 Aims	
The	aim	of	this	chapter	was	to	characterise	the	response	of	PBECs	to	rhinoviral	infection.	
The	MAPK	pathways	have	been	shown	to	be	important	inducers	of	inflammation	in	the	
innate	immune	response.	Therefore,	it	is	important	to	characterise	these	pathways	and	
their	regulation	in	the	response	to	rhinoviral	infection.		
The	first	aim	was	to	describe	the	activation	of	the	ERK,	p38	and	JNK	MAPK	pathways	in	
response	to	infection	with	two	strains	of	rhinovirus,	RV1B	and	RV16,	or	stimulation	with	
the	 synthetic	 TLR3	 ligand	 poly(I:C),	 or	 the	 inflammatory	 cytokine	 IL-1b.	 Inhibitors	 of	
these	 pathways	 were	 utilised	 to	 determine	 their	 role	 in	 the	 response	 of	 PBECs	 to	
rhinoviral	infection,	and	in	rhinoviral	replication.	
Potential	 regulators	 of	 these	 pathways,	 the	 DUSP	 family,	 were	 then	 examined	 to	
determine	whether	 they	were	 expressed	 in	 PBECs	 and	whether	 this	 expression	was	
regulated	by	rhinoviral	infection.	
3.10.2 The	Roles	of	the	MAPKs	in	Viral	Infection	
The	 MAPK	 signalling	 pathways	 are	 known	 to	 be	 activated	 by	 rhinoviral	 infection	
(Dumitru	et	al.,	2006,	Griego	et	al.,	2000,	Lau	et	al.,	2008,	Newcomb	et	al.,	2008,	Wang	
et	al.,	2006),	and	previous	inhibitor	studies	have	shown	the	importance	of	p38	and	ERK	
in	 the	 innate	 immune	 response	 to	 rhinovirus	 (Griego	 et	 al.,	 2000,	 Liu	 et	 al.,	 2008a).	
However,	much	of	this	work	has	been	done	in	cell	lines,	and	the	roles	of	these	pathways	
in	the	response	of	PBECs	to	rhinoviral	infection	have	not	been	well	characterised.	Figure	
3.1	 demonstrates	 that	 the	 innate	 immune	 pathways	 are	 being	 activated	 by	 TLR3	
stimulation	and	rhinoviral	infection,	leading	to	the	secretion	of	inflammatory	proteins.	
RV16	infection	induced	a	much	smaller	response	than	RV1B,	with	no	detectable	CXCL8	
release.	 However	 other	 work	 presented	 in	 this	 chapter,	 in	 particular	 figure	 3.4,	
demonstrates	that	RV16	infection	of	PBECs	does	induce	CXCL8	production.	Differences	
in	cytokine	production	in	response	to	major	and	minor	serotypes	has	been	documented	
previously;	in	2014	Schuler	et	al.	found	higher	levels	of	CCL20,	CCL2	and	IP-10	released	
by	primary	MDMs	infected	with	RV16	than	RV1A	(Schuler	et	al.,	2014).		
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Inhibition	of	each	of	the	MAPKs	is	a	useful	tool	to	delineate	the	role	of	each	pathway	
and	has	been	used	extensively.	Inhibition	of	either	p38	or	JNK	MAPK	led	to	a	consistent	
decrease	 in	CXCL8	 release	after	24	h	of	poly(I:C)	 stimulation.	As	discussed	 in	 section	
1.3.4,	Gern	et	al.	have	previously	demonstrated	that	treatment	of	PBECs	with	SB203580	
decreased	CXCL8	release	in	response	to	16	h	of	poly(I:C)	treatment	(Gern	et	al.,	2003).	
The	effect	of	 JNK	 inhibition	on	 cytokine	 release	 in	PBECs	has	not	been	well	 studied.	
However,	treatment	of	a	human	astroglioma	cell	line	with	SP600125	decreased	CXCL8	
release	in	response	to	poly(I:C)	treatment	(Park	et	al.,	2006).	Intriguingly,	in	this	thesis	
MAPK	inhibition	did	not	have	an	observable	effect	on	CXCL8	mRNA	levels	in	response	to	
24	h	of	 rhinoviral	 infection,	although	after	48	h	 infection	CXCL8	mRNA	and	secreted	
protein	 was	 decreased	 by	 p38	 or	 JNK	 inhibition.	 Previous	 studies	 have	 shown	 that	
treatment	 of	 BEAS-2B	 cells	 with	 SB203580	 caused	 a	 decrease	 in	 CXCL8	 release	 in	
response	to	rhinoviral	infection	at	40	h	(Liu	et	al.,	2008a)	or	72	h	(Griego	et	al.,	2000).	
One	potential	reason	that	the	effect	of	the	inhibitors	is	not	visible	until	later	time	points	
in	 response	 to	 rhinoviral	 infection	 could	 be	 due	 to	 the	 fact	 that	much	 less	 CXCL8	 is	
produced	in	response	to	rhinovirus	than	poly(I:C),	making	any	differences	caused	by	the	
inhibitors	harder	to	determine.	Previous	work	from	our	group	and	others	suggests	that	
rhinovirus	only	 infects	a	small	percentage,	around	10%,	of	the	PBEC	monolayer	(R.	L.	
Roberts,	 Personal	 Communication,	 Jakiela	 et	 al.,	 2008,	 Lopez-Souza	 et	 al.,	 2009),	
whereas	 poly(I:C)	 stimulation	would	 affect	 all	 cells,	 causing	 a	much	 larger	 response.	
There	are	also	other	ways,	other	than	mRNA	upregulation,	in	which	CXCL8	release	could	
be	induced.	Some	cytokines	are	stored	in	intracellular	pools,	ready	for	a	quick	response	
to	infection	(Cassatella	et	al.,	2006,	Vaday	et	al.,	2006),	and	CXCL8	mRNA	stability	has	
previously	been	shown	to	be	regulated	by	p38	(Winzen	et	al.,	1999).	These	data	suggest	
that	both	p38	and	JNK	play	important	roles	in	inducing	inflammatory	cytokine	release	
in	response	to	both	poly(I:C)	and	rhinoviral	infection.		
Inhibition	of	p38	and	JNK	also	caused	a	consistent	decrease	in	CCL5	release.	This	was	
unexpected	as	CCL5	is	generally	thought	of	as	an	interferon-stimulated	gene,	with	the	
IRF	proteins	 inducing	CCL5	 transcription.	 Furthermore,	a	decrease	 in	CCL5	 release	 in	
response	to	poly(I:C)	was	not	seen	in	the	work	of	Gern	et	al.	in	2003	when	BEAS-2B	cells	
were	 treated	 with	 SB203580	 (Gern	 et	 al.,	 2003).	 However,	 this	 could	 be	 due	 to	 a	
difference	between	primary	cells	and	a	cell	line.	Indeed,	the	MAPKs	have	been	found	to	
have	a	role	 in	 inducing	CCL5	release	in	response	to	infection	with	other	viruses:	with	
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ERK	 and	 p38	 inducing	 CCL5	 release	 in	 response	 to	 respiratory	 syncytial	 virus	 (RSV)	
(Pazdrak	et	al.,	2002),	and	p38	and	JNK	inducing	CCL5	in	response	to	influenza	infection	
(Kujime	et	al.,	2000).	CCL5	RNA	levels	also	decrease	in	the	presence	of	inhibitors	of	all	
three	MAPKs	in	response	to	infection	with	the	picornavirus,	enterovirus-71,	although	
this	was	in	a	glioblastoma	cell	line,	U251	(Wang	et	al.,	2015).	NF-kB	signalling	has	also	
previously	been	found	to	be	capable	of	inducing	CCL5	release	(Moriuchi	et	al.,	1997).	
Therefore,	the	decrease	of	CCL5	release	with	p38	or	JNK	inhibition	suggests	that	either:	
p38	and	JNK	have	important	roles	in	regulating	the	interferon	response	to	TLR3	as	well	
as	the	inflammatory	response;	NF-kB	has	a	larger	role	in	inducing	CCL5	production	in	
PBECs	than	previously	thought;	or	another	pathway	 is	 leading	to	the	release	of	CCL5	
protein.		
The	effect	of	JNK	inhibition	on	viral	replication	has	not	been	well	studied.	The	increase	
in	rhinoviral	replication	with	SP600125	treatment	suggests	that	JNK	has	an	important	
limiting	role	in	viral	replication.	As	mentioned	above,	inhibition	of	the	MAPKs	led	to	a	
decrease	 in	 CCL5	 release.	 CCL5	 is	 an	 interferon	 stimulated	 gene,	 upregulated	 by	 RV	
infection	of	PBECs	 (Khaitov	et	 al.,	 2009,	 Lin	et	 al.,	 1999).	Addition	of	 interferon-b	 to	
PBECs	significantly	reduces	replication	of	RV16	(Wark	et	al.,	2005).	Thus,	the	increase	in	
rhinoviral	 replication	 when	 JNK	 is	 inhibited	 could	 be	 due	 to	 a	 decrease	 in	 the	 IFN	
response.	 The	 JNK	 pathway	 has	 previously	 been	 reported	 to	 phosphorylate	 IRF3	 in	
response	to	poly(I:C)	signalling,	although	this	study	was	performed	in	the	293T	cell	line	
using	 over	 expression	 techniques	 (Zhang	 et	 al.,	 2009).	 This	 is	 not	 supported	 by	 the	
results	of	this	study,	where	JNK	inhibition	increased	the	expression	of	IFN-b	in	response	
to	 RV1B	 infection.	 This	 is	 likely	 to	 be	 due	 to	 the	 increased	 level	 of	 viral	 replication	
causing	more	IFN	induction,	rather	than	a	direct	effect	of	JNK.	However,	it	is	difficult	to	
draw	conclusions	from	these	data	due	to	the	limited	amount	of	IFN	produced.	It	would	
be	interesting	to	investigate	this	further	by	examining	the	expression	of	other	IFNs,	and	
determining	whether	MAPK	inhibition	affects	it.	IFN-a,	IFN-b,	and	IFN-l	are	all	released	
by	PBECs	in	response	to	infection	with	RV1B	or	RV16	(Khaitov	et	al.,	2009).	However,	as	
p38	 inhibition	 also	 led	 to	 a	 decrease	 in	 cytokine	 release	 a	 similar	 effect	 would	 be	
expected	in	response	to	p38	inhibition.	It	is	possible	that	necessity	for	p38	in	the	viral	
life	 cycle	 may	 overcome	 this	 effect.	 Additional	 investigation	 into	 the	 effect	 of	 JNK	
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inhibition	on	IFN	levels	in	rhinoviral	infection	is	of	importance	to	further	elucidate	these	
findings.		
Inhibition	of	p38	consistently	decreased	the	level	of	rhinoviral	replication	in	PBECs.	This	
indicates	that	the	p38	pathway	is	utilised	by	the	virus	in	the	replication	process.	A	study	
in	2010	showed	that	inhibition	of	p38	has	a	similar	effect	on	the	replication	of	several	
other	respiratory	viruses,	including:	adenovirus,	RSV,	coxsackie	virus	B3,	and	influenza	
virus	 (Marchant	 et	 al.,	 2010).	 Coxsackie	 virus	 B3	 is	 a	member	 of	 the	 Picornaviridae	
family,	like	rhinovirus,	and	therefore	has	a	similar	life	cycle.	The	Marchant	study	went	
on	to	determine	the	mechanism	of	p38	involvement	in	influenza	virus	replication.	They	
found	 that	 inhibition	 of	 p38	 led	 to	 a	 retention	 of	 influenza	 virus	 particles	 in	 early	
endosomes,	suggesting	that	p38	is	involved	in	the	release	of	virus	from	the	endosome.	
Another	possibility	is	that	p38	is	necessary	for	the	accumulation	of	cholesterol	within	
viral	replication	organelles,	as	discussed	in	section	1.3.4.	This	information	is	of	extreme	
importance	 and	 requires	 further	 investigation.	 If	 p38	 is	 necessary	 for	 rhinoviral	
replication,	 then	 regulation	 of	 p38	 has	 the	 potential	 for	 use	 as	 a	 future	 anti-viral	
treatment.	This	work	should	be	taken	forward	with	TCID50	assays	to	determine	whether	
the	difference	 in	 the	 level	 of	 viral	 RNA	 translates	 into	 a	 difference	 in	 the	 release	of	
productive	viral	particles.		
Although	 the	 MAPKs	 are	 known	 to	 have	 roles	 in	 processes	 such	 as	 apoptosis	 and	
proliferation	(Wada	and	Penninger,	2004),	inhibition	of	the	MAPKs	had	no	effect	on	the	
viability	of	PBECs	in	response	to	rhinoviral	infection,	suggesting	that	there	was	no	MAPK-
induced	apoptosis	or	necrosis	in	response	to	rhinovirus.	However,	visual	inspection	of	
monolayers	suggested	that	rhinoviral	infection	was	causing	some	cell	death	(data	not	
shown),	 and	 RV16	 infection	 has	 previously	 been	 shown	 to	 decrease	 cell	 viability	 of	
PBECs,	due	to	an	increase	in	apoptosis	(Wark	et	al.,	2005).	The	assay	used	to	detect	cell	
viability	measures	the	quantity	of	ATP	present,	from	which	the	number	of	metabolically	
active	cells	can	be	inferred.	PBECs	infected	with	rhinovirus	may	be	more	metabolically	
active	than	uninfected	cells,	causing	an	increase	in	ATP	levels	which	is	not	accounted	for	
by	 this	 assay.	 Another	 limitation	 of	 this	 experiment	 is	 that	 no	 positive	 control	 was	
included	to	ensure	the	assay	was	working.	Therefore,	the	effect	of	rhinoviral	infection	
on	cell	viability	and	the	role	of	the	MAPKs	in	this	process	remains	to	be	determined.	
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Overall,	these	findings	suggest	that	the	MAPKs	p38	and	JNK	have	important	roles	in	the	
response	 of	 PBECs	 to	 rhinoviral	 infection,	 including	 inducing	 inflammatory	 cytokine	
release	and	possibly	inducing	IFN	release.	The	p38	MAPK	may	also	have	an	important	
role	 in	 the	 rhinoviral	 life	 cycle.	 Thus,	 the	 investigation	 into	 the	 regulation	 of	 these	
pathways	 is	of	 importance.	One	 limitation	of	 this	 study	 is	 the	use	of	 small	molecule	
inhibitors,	which	have	some	off-target	effects	(Bain	et	al.,	2007).	In	future,	it	would	be	
important	 to	 confirm	 these	 findings	 using	 siRNA	 knock	 down	of	 the	MAPK	proteins.	
siRNA	 knock	 down	 in	 PBECs	 of	 p38	 or	 c-Jun,	 the	 JNK	 target,	 have	 been	 published	
previously	 and	 were	 shown	 to	 reduce	 CXCL8	 production	 in	 PBECs	 in	 response	 to	
lysophosphatidic	acid	(Saatian	et	al.,	2006).	 It	would	also	be	of	 interest	to	determine	
whether	 growth	 of	 PBECs	 at	 air-liquid	 interface	 would	 affect	 these	 results,	 as	
differentiated	cells	have	been	found	to	be	more	susceptible	to	RV	infection	(Jakiela	et	
al.,	2008).		
3.10.3 Activation	of	the	MAPKs	in	Viral	Infection	
ERK	phosphorylation	in	response	to	infection	with	RV39	has	previously	been	shown	in	
the	bronchial	epithelial	cell	line	16HBE14o-,	with	no	phospho-ERK	present	at	baseline,	
and	appearing	within	2	minutes	of	infection	(Newcomb	et	al.,	2007).	This	differs	from	
the	observations	in	this	study;	where	activated	ERK	is	present	in	all	media	controls	but	
then	declines	over	time.	This	could	be	due	to	treatment	of	the	cells,	by	changing	media	
and	washing	in	PBS,	activating	ERK	through	stress	pathways.	The	shortest	time	points	
would	 have	 the	 most	 recent	 media	 changes.	 There	 is	 a	 possible	 increase	 in	 ERK	
activation	30	minutes	after	stimulation	with	IL-1b,	poly(I:C)	and	RV1B,	however	these	
data	are	preliminary	and	would	need	further	repeats	to	investigate,	comparing	the	level	
of	activation	with	a	control	with	media	changes	and	washes	done	simultaneously.	As	
inhibition	of	ERK	had	no	effect	on	the	response	of	PBECs	to	RV	infection	(Section	3.2)	
investigation	of	ERK	activation	was	not	continued.		
Both	 p38	 and	 JNK	 were	 activated	 by	 IL-1b	 and	 poly(I:C),	 as	 has	 been	 previously	
demonstrated	in	the	literature	(An	et	al.,	2006,	Gern	et	al.,	2003,	Jang	et	al.,	2004,	Jung	
et	al.,	2002,	Wuyts	et	al.,	2003).	This	activation	in	response	to	poly(I:C)	demonstrates	
that	TLR3	signalling	can	lead	to	activation	of	the	MAPKs	in	primary	bronchial	epithelial	
cells,	however	it	occurs	later	than	previously	shown.	In	2003,	Gern	et	al.	showed	that	
stimulation	of	PBECs	with	poly(I:C)	activated	p38,	with	peak	phospho-p38	expression	
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seen	by	70	minutes	and	persisting	until	130	minutes	(Gern	et	al.,	2003),	whereas	in	this	
study,	peak	expression	was	not	observed	until	2	h.	This	could	be	due	to	a	much	higher	
dose	being	used	in	the	Gern	study,	of	100	µg/ml	compared	to	25	µg/ml.		
Although	MAPK	activation	is	seen	during	the	attachment	phase	of	infection,	this	is	not	
due	to	rhinoviral	infection.	No	activation	of	p38	or	JNK	MAPKs	is	observed	until	8	h	RV16	
infection,	 where	 p38	 phosphorylation	 is	 observed.	 However,	 the	 effects	 of	 MAPK	
inhibition	(Section	3.2)	demonstrate	that	the	MAPKs	are	being	activated	by	infection.	
The	lack	of	a	visible	band	by	western	blot	could	be	due	to	the	fact	that	each	cell	is	being	
infected	at	slightly	different	times,	therefore	the	MAPKs	are	activated	at	different	times,	
and	 there	 is	 not	 enough	 phosphorylated	 protein	 present	 at	 any	 one	 time	 to	 be	
detectable.	Allowing	the	virus	one	hour	to	attach	to	the	cells,	before	washing	off	any	
unbound	viral	particles	is	meant	to	ensure	that	infection	occurs	at	similar	times	in	the	
cell	monolayer.	However,	this	could	be	improved	by	incubating	the	virus	with	the	cells	
at	 4oC	 to	 allow	 attachment	 but	 prevent	 internalisation.	 Then,	when	moved	 to	 37oC,	
internalisation	occurs	 simultaneously.	 It	would	be	 interesting	 to	 investigate	whether	
utilisation	of	this	infection	method	would	lead	to	a	detectable	MAPK	signal.	As	discussed	
above,	RV	infects	around	10%	of	PBECs.	Therefore,	the	MAPK	activation	may	not	all	be	
due	to	direct	effects	of	viral	infection,	but	due	to	molecules	secreted	by	infected	cells	
signalling	 to	 the	 surrounding	 cells.	 This	 could	 be	 further	 investigated	 using	
immunofluorescence	 techniques,	 imaging	phosphorylated	MAPKs	 and	 viral	 capsid	 or	
double-stranded	 RNA.	 This	 would	 demonstrate	 whether	 MAPK	 activation	 was	 only	
occurring	in	cells	infected	with	rhinovirus.		
Activation	of	the	MAPKs	by	viral	filtrate	demonstrates	that	something	released	by	HeLa	
Ohio	cells	during	the	viral	propagation	technique	is	activating	the	cells.	This	molecule	is	
unaffected	by	UV	treatment	and	must	be	smaller	than	30	kDa.	Many	DAMPs	would	be	
too	 large	 to	 filter	 through,	 for	 example	 heat	 shock	 proteins	 are	 around	 70	 kDa	 and	
tenascin	C	is	between	250	and	300	kDa,	but	some	cytokines	would	still	be	present.	IL-
1b	is	17	kDa	so	would	pass	through	the	filter	easily,	and	previous	work	has	shown	that	
only	a	small	amount	of	IL-1b	is	necessary	to	induce	an	immune	response	(Piper	et	al.,	
2013).	 The	 presence	 of	 these	 molecules	 may	 also	 vary	 between	 batches	 of	 virus,	
depending	on	the	amount	of	cell	death	caused	by	infection.	The	MAPKs	are	known	to	
be	 activated	by	binding	of	 rhinovirus	 to	 cells	 (Dumitru	et	 al.,	 2006,	 Lau	et	 al.,	 2008,	
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Newcomb	et	al.,	2008,	Wang	et	al.,	2006).	Another	possible	cause	for	this	early	MAPK	
activation	could	be	due	to	fragments	of	virus	present	in	the	solution	binding	to	cells.	
HeLa	Ohio	cells	may	be	lysed	before	all	viral	proteins	are	assembled	into	virions,	and	
virions	may	be	degraded	by	freeze-thawing.	Viral	proteins	VP1	to	VP3	are	around	30	kDa	
so	may	not	fit	through	the	filter,	but	VP4	is	7	kDa	so	would	still	be	present.	Many	single-
stranded	RNA	viruses	are	known	to	produce	defective	viral	particles	during	replication	
(Mercado-Lopez	et	al.,	2013,	Xu	et	al.,	2017).	Although	the	MAPKs	were	activated,	this	
did	 not	 lead	 to	 any	measurable	 effect	 on	 cytokine	 production	 or	 release,	 therefore,	
would	not	affect	the	results	of	the	inhibitor	experiments.	In	future,	it	will	be	important	
to	 use	 purified	 viral	 stocks,	made	 using	 ultracentrifugation,	which	 is	 currently	 being	
optimised	in	our	group.		
MAPKs	 can	 be	 regulated	 in	 many	 different	 ways,	 including	 subcellular	 localisation,	
availability	 of	 scaffold	 proteins	 and	 post-translational	 modifications,	 as	 well	 as	
dephosphorylation	 (Reviewed	 in:	 Raman	 et	 al.,	 2007).	 Treatment	 of	 PBECs	 with	 a	
general	phosphatase	 inhibitor	 caused	an	 increase	 in	activation	of	both	p38	and	 JNK,	
suggesting	 that	 the	 main	 mechanism	 of	 MAPK	 regulation	 is	 by	 dephosphorylation.	
Although	this	activation	was	not	due	to	RV	infection,	it	still	gives	an	indication	of	how	
the	MAPK	pathways	are	being	regulated.	Several	phosphatases	are	capable	of	regulating	
the	MAPKs,	including	protein	phosphatases	2C	and	5	(PP2C	and	PP5),	however,	DUSPs	
are	thought	to	be	the	main	regulators	(Morita	et	al.,	2001,	Takekawa	et	al.,	1998,	Zhou	
et	al.,	2004).	
3.10.4 Expression	and	Regulation	of	DUSPs	in	PBECs	
Four	members	of	the	DUSP	family,	DUSPs	1,	2,	4	and	10	have	previously	been	found	to	
regulate	innate	immune	signalling	pathways,	although	their	role	in	regulating	rhinoviral	
infection	of	PBECs	has	not	yet	been	studied.	Previously	DUSP2	was	only	thought	to	be	
expressed	 by	 innate	 immune	 cells,	 such	 as	 mast	 cells,	 eosinophils,	 neutrophils	 and	
macrophages,	and	no	expression	was	detected	in	primary	human	bronchial	epithelial	
cells	 (Jeffrey	 et	 al.,	 2006).	 This	 is	 in	 contrast	 to	 this	 study,	where	DUSP2	mRNA	was	
expressed	in	PBECs,	even	at	baseline.	To	the	best	of	my	knowledge	the	expression	of	
DUSPs	1,	4	and	10	in	PBECs	has	not	yet	been	investigated.	DUSPs	1	and	4	have	previously	
been	characterised	as	early-response	genes,	with	no	expression	at	baseline	of	DUSP1	in	
primary	human	airway	smooth	muscle	cells,	or	DUSP4	in	mouse	BMDMs	or	embryonic	
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fibroblasts	(Cornell	et	al.,	2010,	Lawan	et	al.,	2011,	Manetsch	et	al.,	2012).	In	contrast,	
DUSP10	has	previously	been	observed	 to	be	 constitutively	present	 in	HeLa	 cells	 and	
murine	BMDMs,	although	it	can	be	upregulated	by	innate	immune	stimuli	(Tanoue	et	
al.,	1999,	James	et	al.,	2015).	All	three	of	these	DUSPs	were	found	to	be	expressed	at	
the	mRNA	level	in	PBECs	at	baseline.	This	may	be	a	specific	characteristic	of	bronchial	
epithelial	 cells,	 compared	 to	macrophages	or	 fibroblasts,	or	 it	 could	be	due	 to	 some	
aspect	of	 culturing	 the	PBECs	which	 is	 activating	 them,	as	discussed	above	with	ERK	
activation	levels.	The	ERK	pathway	has	previously	been	found	to	induce	transcription	of	
DUSPs	1,	2	and	4	(Ananieva	et	al.,	2008,	Brondello	et	al.,	1997,	Grumont	et	al.,	1996).	
Therefore,	the	constitutive	expression	of	these	DUSPs	may	be	due	to	the	activation	of	
ERK,	 induced	by	culturing	the	cells.	DUSP1	has	been	shown	to	be	upregulated	by	the	
presence	 of	 foetal	 calf	 serum	 in	 HeLa	 cells	 (Kwak	 et	 al.,	 1994).	 Although	 serum	 is	
removed	prior	to	infection	or	stimulation,	this	demonstrates	that	aspects	of	culturing	
the	cells	in	vitro	can	activate	these	pathways.	Therefore,	utilisation	of	in	vivo	methods	
is	necessary	to	gain	a	clearer	picture	of	DUSP	regulation.	
DUSP1	 mRNA	 expression	 has	 previously	 been	 found	 to	 be	 increased	 by	 poly(I:C)	
stimulation	in	a	bronchial	epithelial	cell	line,	NCI-H292,	with	around	a	2-fold	increase	1	
h	post	stimulation	(Golebski	et	al.,	2014).	 In	this	study,	DUSP1	mRNA	expression	was	
significantly	 increased	 by	 poly(I:C)	 stimulation	 much	 later	 on,	 at	 24	 h,	 with	 non-
significant,	 but	 consistent,	 increases	 of	 around	 2-fold	 also	 observed	 at	 4-6	 h	 post	
stimulation.	The	changes	in	DUSP1	mRNA	were	not	translated	into	an	increase	in	DUSP1	
protein	within	24	h.	However,	it	is	possible	that	changes	in	DUSP1	at	the	protein	level	
would	 occur	 post	 24	 h	 and	 this	 requires	 further	 study.	 DUSP1	 expression	 has	 also	
previously	been	found	to	be	increased	by	stimulation	with	IL-1b	in	A549	cells,	and	airway	
smooth	muscle	cells,	with	protein	levels	peaking	1	h	post	stimulation	(Issa	et	al.,	2007,	
Shah	et	al.,	2016b).	In	this	study,	no	significant	changes	in	DUSP1	expression	were	seen	
in	response	to	IL-1b	stimulation	or	rhinoviral	infection,	although	RV16	infection	causes	
a	consistent	increase	of	around	2-fold	at	0.5	h	post	infection,	however	again	this	was	
not	observed	at	the	protein	level.	This	is	consistent	with	results	from	a	microarray	study,	
comparing	 gene	expression	 from	nasal	 scrapings	of	 patients	 infected	with	RV16	and	
sham	infected,	where	infection	did	not	alter	DUSP1	expression	(Proud	et	al.,	2008).		
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p38	 and	 ERK	MAPKs	 have	 previously	 been	 shown	 to	 induce	 transcription	 of	 DUSP1	
through	 the	 MSK	 proteins	 (Ananieva	 et	 al.,	 2008).	 In	 this	 study,	 inhibition	 of	 p38	
consistently	 reduced	 levels	 of	 DUSP1	mRNA,	 whereas	 ERK	 inhibition	 had	 no	 effect.	
Intriguingly,	treatment	with	p38	inhibitors	reduced	DUSP1	expression	to	below	baseline	
levels.	This	would	suggest	that,	although	no	activated	p38	is	detectable	at	baseline,	it	is	
having	a	role	in	inducing	some	DUSP1	expression.		
Although	 no	 regulation	 of	 DUSP1	 expression	 was	 observed,	 all	 the	 stimulants	
investigated	regulated	DUSP1	through	phosphorylation.	This	has	previously	been	shown	
to	stabilise	the	protein,	prolonging	its	half-life	(Brondello	et	al.,	1999).	However,	if	the	
protein	was	more	stable,	an	increase	in	total	DUSP1	protein	would	be	predicted,	which	
was	not	observed.	DUSP1	was	phosphorylated	much	earlier	 in	response	to	rhinoviral	
infection	 than	 poly(I:C)	 stimulation.	 This	 indicates	 that	 an	 early,	 TLR3	 independent,	
signalling	 pathway	 is	 induced	 upon	 rhinoviral	 binding	 and	 internalisation,	 which	 is	
leading	to	DUSP1	phosphorylation.	It	has	previously	been	shown	that	ERK	is	capable	of	
phosphorylating	DUSP1	(Brondello	et	al.,	1999).	As	ERK	activation	was	seen	 in	media	
controls	 in	 this	 study,	phosphorylation	of	DUSP1	may	be	due	 to	 another	 kinase.	 For	
poly(I:C)	and	IL-1b,	the	peak	in	DUSP1	phosphorylation	occurs	slightly	after	the	peak	in	
p38	and	JNK	activation,	for	example	IL-1b	stimulation	causes	MAPK	activation	around	1	
h	post	stimulation,	and	DUSP1	is	phosphorylated	at	2	h	post	stimulation.	This	suggests	
that	the	MAPK	pathways	could	be	inducing	DUSP1	phosphorylation,	and	investigation	
into	whether	inhibition	of	these	pathways	affects	DUSP1	phosphorylation	would	be	of	
interest.	The	inclusion	of	inhibitors	of	other	serine	kinases	involved	in	the	response	to	
RV,	for	example	the	PI3K	pathway,	would	be	extremely	interesting,	as,	to	the	best	of	our	
knowledge,	this	has	not	been	investigated	before.		
Although	no	significant	changes	were	observed	in	DUSP10	expression,	both	RV1B	and	
RV16	caused	a	consistent	decrease	in	DUSP10	mRNA	expression	to	below	baseline	levels	
at	around	6	h	post	infection.	This	decrease	was	also	observed	at	the	protein	level,	with	
the	lowest	protein	expression	detected	at	24	h.	Interestingly,	stimulation	with	poly(I:C)	
or	IL-1b	did	not	have	this	effect.	Thus,	rhinoviral	infection	may	be	targeting	DUSP10	for	
degradation	 or	 downregulation.	 RV1B	 infection	 also	 caused	 a	 downregulation	 of	
DUSP10	protein	during	the	viral	attachment	phase,	although	no	changes	were	seen	at	
the	mRNA	level	during	this	time.	In	2008,	Proud	et	al.	performed	a	gene	expression	array	
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on	nasal	scrapings	to	identify	any	changes	induced	by	rhinoviral	infection,	they	found	
that	 at	 8	 h	 and	 48	 h	 post	 RV16	 infection	 the	 expression	 of	 many	 genes	 were	
downregulated,	 but	 DUSP10	 was	 unchanged	 (Proud	 et	 al.,	 2008).	 	 However,	 as	 the	
downregulation	observed	in	this	study	was	only	transient,	experimental	differences	may	
mean	that	any	down-regulation	of	DUSP10	could	have	been	missed	in	the	Proud	study	
as	only	two	time	points	were	investigated.	As	discussed	in	section	1.5.4,	DUSP10	has	
been	 associated	 with	 regulating	 IRF3	 phosphorylation	 and	 the	 antiviral	 response	 in	
influenza	 infection	 (James	 et	 al.,	 2015).	 If	 DUSP10	 has	 a	 role	 in	 anti-viral	 pathways,	
rhinovirus	may	 have	 developed	 a	mechanism	 to	 interfere	with	 this	 by	 degrading	 or	
down	regulating	DUSP10.	Many	viruses	 target	host	proteins	 for	degradation	 through	
host	pathways,	utilising	host	ubiquitin	ligases	or	expressing	their	own	(Barro	and	Patton,	
2005,	Okumura	 et	 al.,	 2008).	 However,	 preliminary	 data	 using	MG132	 suggests	 that	
inhibition	 of	 proteosomal	 degradation	 does	 not	 stop	 the	 loss	 of	 DUSP10	 protein	 30	
minutes	 after	 RV1B	 addition	 (data	 not	 shown).	 Rhinovirus	 also	 encodes	 its	 own	
proteinases	2A	and	3C,	which	have	previously	been	shown	to	degrade	components	of	
the	IFN	signalling	pathway	(Drahos	and	Racaniello,	2009).		
DUSP10	has	also	previously	been	found	to	be	phosphorylated	on	serine	residues	224	
and	230,	 leading	 to	 stabilisation	of	 the	protein	 (Benavides-Serrato	et	 al.,	 2014).	 This	
event	was	linked	to	the	mTORC	family	of	kinases,	a	group	of	proteins	involved	in	the	
PI3K	signalling	pathway.	As	discussed	above,	the	PI3K	pathway	has	been	found	to	be	
activated	 upon	 rhinoviral	 infection	 (Section	 1.3.4).	 It	 would	 be	 of	 interest	 to	 know	
whether	DUSP10	is	regulated	by	phosphorylation	upon	rhinoviral	infection,	similarly	to	
DUSP1.	Attempts	were	made	to	investigate	this.	As	no	antibody	against	phosphorylated	
DUSP10	 is	 commercially	 available,	 immunoprecipitation	 of	 DUSP10	 from	 PBECs	 was	
attempted,	but	was	unsuccessful	(data	not	shown).	Utilisation	of	the	PhosTag	(Wako)	
molecule,	which	 binds	 to	 phosphorylated	 proteins,	 increasing	 their	weight,	 enabling	
separation	of	phosphorylated	and	non-phosphorylated	proteins	by	western	blot	was	
also	unsuccessful	(data	not	shown).		
DUSP1	 has	 previously	 been	 shown	 to	 be	 upregulated	 in	 A549	 cells	 and	 PBECs	 by	
dexamethasone	(Keranen	et	al.,	2017,	Newton	et	al.,	2010,	Papi	et	al.,	2013).	In	A549	
cells,	a	time	course	of	dexamethasone	stimulation,	1	µM,	showed	peak	DUSP1	protein	
expression	6	h	post	stimulation	(Newton	et	al.,	2010)	and	stimulation	of	PBECs	with	10	
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nM	dexamethasone	for	4	h	caused	around	a	5-fold	increase	in	DUSP1	mRNA	levels	(Papi	
et	al.,	2013).	DUSP10	expression	in	response	to	dexamethasone	stimulation	has,	to	the	
best	of	my	knowledge,	not	been	studied	previously.	 In	this	study,	changes	 in	protein	
expression	of	DUSPs	1	and	10	in	response	to	dexamethasone	were	only	observed	in	one	
out	of	three	donors,	and	only	at	the	highest	dose	used,	100	nM.	Higher	doses	may	have	
caused	a	response	in	all	donors,	however,	100	nM	caused	some	toxicity	to	PBECs,	as	can	
be	 observed	 by	 the	 decline	 in	 actin	 protein	 levels.	 It	 is	well	 documented	 that	 some	
patients	are	naturally	steroid	resistant	(Schwartz	et	al.,	1968),	therefore	 it	 is	possible	
that	the	two	donors	which	do	not	upregulate	DUSP	expression	may	be	steroid	resistant.	
Smoking	is	known	to	reduce	the	efficacy	of	corticosteroids	(Chalmers	et	al.,	2002),	and	
the	responsive	donor	is	a	non-smoker,	whereas	one	of	the	non-responsive	donors	is	a	
smoker	 and	 the	 smoking	 status	 of	 the	 other	 is	 unknown	 (Table	 7.1).	 This	 could	 be	
investigated	by	the	inclusion	of	a	larger	number	of	donors	with	an	equal	ratio	of	smokers	
and	non-smokers	in	this	experiment.				
3.10.5 Conclusions	
The	data	presented	in	this	chapter	demonstrate	that	two	of	the	MAPK	pathways,	p38	
and	 JNK,	 play	 potentially	 important	 roles	 in	 rhinoviral	 infection	 of	 PBECs.	 TLR3	
stimulation	induces	activation	of	the	p38	and	JNK	MAPK	proteins,	and,	while	activated	
protein	 is	 undetectable	 in	 response	 to	 RV,	 inhibition	 of	 the	 pathways	 has	 an	 effect,	
demonstrating	 that	 they	 are	being	 activated.	 Both	pathways	 contribute	 towards	 the	
inflammatory	response,	inducing	production	and	release	of	neutrophil	and	eosinophil	
chemoattractants.	 They	 also	 play	 opposing	 roles	 in	 rhinoviral	 replication:	 p38	 being	
necessary	 for	 replication	 and	 JNK	 limiting	 it.	 The	mechanisms	 for	 this	 remain	 to	 be	
elucidated,	although	JNK	does	not	seem	to	be	acting	through	induction	of	IFN-b.	
Two	proteins	previously	found	to	have	important	roles	in	regulating	p38	and	JNK,	DUSP1	
and	DUSP10,	are	expressed	 in	PBECs.	 Infection	with	RV	also	 regulates	both	proteins,	
although	in	different	ways.	DUSP1	is	phosphorylated	in	response	to	infection,	which	has	
previously	been	demonstrated	to	stabilise	the	protein,	and	further	work	is	necessary	to	
determine	whether	DUSP10	is	also.	DUSP10	expression	is	downregulated	in	response	to	
RV	infection,	possibly	through	protein	degradation.	There	are	many	other	ways	DUSPs	
may	 be	 regulated,	 which	 remain	 to	 be	 investigated,	 for	 example	 oxidation	 and	
acetylation.	 The	 differences	 in	 regulation	 of	 these	 proteins	 suggests	 they	may	 have	
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different	 roles	 in	 regulating	 the	 response	 to	 RV	 infection.	 This	 will	 be	 further	
investigated	in	chapter	4.		
These	findings	are	summarised	in	figure	3.32.	
These	data	support	 the	hypothesis	 that	 regulating	the	MAPK	pathways	 is	a	potential	
therapeutic	target	for	the	management	of	asthma	and	COPD	exacerbations.		
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Figure	3.32	Summary	of	findings	presented	in	chapter	3.	
The	p38	and	JNK	MAPK	pathways	are	activated	in	PBECs	in	response	to	infection	with	
rhinovirus	 and	 poly(I:C)	 through	 several	 pattern	 recognition	 receptors	 or	 ICAM-1	
binding.	IL-1b	binding	IL-1RI	also	leads	to	MAPK	activation.	The	JNK	pathway	leads	to	
production	of	 inflammatory	cytokines,	and	possibly	 interferon	which	limits	rhinovirus	
replication.	The	p38	pathway	leads	to	production	of	inflammatory	cytokines,	and	DUSP1	
which	 is	 subsequently	 phosphorylated.	 p38	 activation	 positively	 regulates	 rhinovirus	
replication,	which	leads	to	downregulation	of	DUSP10.		
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4 Chapter	Four	–	Results:	The	Roles	of	DUSPs	in	Rhinoviral	
Infection	
4.1 Introduction	
The	results	presented	in	chapter	3	suggest	that	p38	and	JNK	play	important	roles	in	the	
inflammatory	 response	 of	 PBECs	 to	 rhinoviral	 infection.	 Therefore,	 two	 DUSPs	
previously	 shown	 to	 regulate	 these	 pathways,	 and	 reduce	 inflammatory	 responses,	
were	taken	forward	for	investigation	into	their	role	in	rhinoviral	infection:	DUSP1	and	
DUSP10.		
As	discussed	in	chapter	1,	DUSP1	has	been	shown	to	regulate	p38	and	JNK	activation,	
and	 thus	 inflammatory	 cytokine	 release,	 in	 the	 response	 to	 bacterial	 infection	 of	
macrophages	(Chi	et	al.,	2006,	Hammer	et	al.,	2006,	Frazier	et	al.,	2009,	McGuire	et	al.,	
2017,	Talwar	et	al.,	2017,	Zhao	et	al.,	2005).	DUSP1	has	also	been	shown	to	regulate	
inflammatory	cytokine	release	in	response	to	poly(I:C)	and	vaccinia	virus	and	to	regulate	
the	interferon	response	to	HCV	(Caceres	et	al.,	2013,	Choi	et	al.,	2015,	Golebski	et	al.,	
2015).		
In	 2015,	 James	 et	 al.	 studied	 the	 role	 of	 DUSP10	 in	 viral	 infection.	 They	 found	 that	
DUSP10	knock	out	mice	showed	increased	viral	titres	when	infected	with	influenza	virus	
compared	to	wild-type	mice.	This	was	associated	with	increased	inflammatory	cytokines	
and	type	I	IFNs	in	BAL,	BMDMs	and	bone	marrow	derived	dendritic	cells	(BMDCs).	When	
the	MAPK	activation	was	examined,	ERK	phosphorylation	in	response	to	influenza	was	
prolonged	 in	knock	out	BMDMs,	but	activated	p38	and	 JNK	 levels	were	comparable.	
Type	I	 IFN	expression	was	also	 increased	 in	knock	out	BMDMs	when	stimulated	with	
poly(I:C),	or	the	RIG-I	substrate	5’-tri-phosphorylated	double-stranded	RNA,	or	infected	
with	vesicular	stomatitis	virus	or	sendai	virus.	This	increase	in	IFN	production	correlated	
with	an	 increase	 in	phosphorylated	IRF3	expression,	and,	using	 immunoprecipitation,	
they	showed	a	direct	interaction	between	DUSP10	and	IRF3	(James	et	al.,	2015).	This	
suggests	that	in	RNA	virus	infection,	DUSP10	dephosphorylates	IRF3,	regulating	the	anti-
viral	IFN	response.		
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4.1.1 Aims	
The	p38	and	JNK	MAPK	pathways	are	important	inducers	of	inflammation	in	response	
to	rhinoviral	infection.	Previous	work	has	demonstrated	that	two	proteins,	DUSPs	1	and	
10,	regulate	inflammation	through	dephosphorylating	p38	and	JNK,	although	their	roles	
in	rhinoviral	infection	have	not	yet	been	studied.	The	results	presented	in	chapter	three	
show	that	both	DUSPs	1	and	10	are	expressed	in	PBECs	and	are	regulated	by	rhinoviral	
infection.	The	aim	of	this	chapter	was	to	determine	the	roles	of	DUSPs	1	and	10,	using	
siRNA	knock	down,	in	rhinoviral	infection	of	PBECs.	This	included	their	roles	in	rhinoviral	
replication,	cytokine	production	and	MAPK	activation.			
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4.2 Knock	Down	of	DUSP1	Expression	
To	the	best	of	my	knowledge	DUSP1	knock	down	has	never	been	successfully	attempted	
in	PBECs,	although	it	has	been	accomplished	in	airway	epithelial	cell	lines,	such	as	A549	
and	NCI-H292	(Golebski	et	al.,	2015,	Shah	et	al.,	2016a).	In	order	to	determine	the	role	
of	 DUSP1	 in	 rhinoviral	 infection	 of	 PBECs,	 siRNA	 knock	 down	 of	 DUSP1	 protein	was	
attempted.	 BEAS-2B	 cells	 were	 initially	 used	 to	 optimise	 the	 siRNA	 knock	 down.	
Transfection	of	BEAS-2Bs	with	four	different	siRNA	targeting	DUSP1,	listed	in	table	2.7,	
did	not	 lead	 to	measurable	differences	 in	DUSP1	protein	 levels	after	24	h	 treatment	
(data	not	shown)	or	48	h	treatment	(Figure	4.1	A).	DUSP1	siRNA	number	4	had	been	
optimised	 in	 BEAS-2B	 cells	 previously	 by	 another	 group	 (S.	 V.	 Shah,	 Personal	
Communication),	however	in	this	study,	this	was	unsuccessful	in	BEAS-2Bs,	HeLa	Ohio,	
and	PBECs.	DUSP1	mRNA	levels	were	also	measured	and	no	differences	were	detected	
between	 control	 and	 DUSP1	 siRNA	 treatments	 (data	 not	 shown).	 CXCL8	 release	 in	
response	to	poly(I:C)	stimulation	was	also	quantified,	to	investigate	whether	the	DUSP1	
siRNA	 treatment	 had	 measurable	 consequences	 despite	 uncertain	 knock	 down.	 No	
differences	 in	 CXCL8	 production	 were	 observed	 between	 control	 and	 DUSP1	 siRNA	
treatments	(Figure	4.1	B).	DUSP1	knock	down	was	also	attempted	in	PBECs	using	all	four	
siRNAs,	with	 Lipofectamine	 transfection	 reagent,	using	a	variety	of	 conditions	 (Table	
4.1),	with	no	observable	knock	down	(Figure	4.1	C).		
In	order	to	optimise	the	DUSP1	knock	down,	BEAS-2B	cells	were	treated	with	a	variety	
of	concentrations	of	siRNA	and	Lipofectamine	transfection	reagent.	Lipofectamine	was	
chosen	initially	as	it	is	regularly	used	to	successfully	transfect	PBECs.	As	knock	down	was	
unsuccessful,	different	transfection	reagents	were	then	tested.	Sigma-Aldrich	Mission	
siRNA	transfection	reagent	was	chosen	as	it	has	been	validated	in	a	variety	of	cell	lines	
and	 primary	 cells.	 Viromer	 Blue	 was	 also	 selected	 as	 it	 has	 been	 designed	 for	
transfection	 of	 hard-to-transfect	 primary	 cells.	 However,	 neither	 led	 to	 measurable	
knock	down	of	DUSP1	mRNA	or	protein	levels	(data	not	shown).	All	conditions	tested	
are	listed	in	table	4.1.		
Dexamethasone	 treatment	 causes	 upregulation	 of	 DUSP1	 protein	 expression	 (Figure	
3.23).	Any	small	differences	 in	DUSP1	expression	caused	by	siRNA	treatment	may	be	
more	 detectable	 when	 DUSP1	 is	 upregulated	 by	 dexamethasone.	 However,	 DUSP1	
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siRNA	 treatment	did	not	 knock	down	DUSP1	expression	 in	 cells	 treated	with	 vehicle	
control	or	dexamethasone	(data	not	shown).		 	
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Figure	4.1	Attempted	DUSP1	knock	down.	
BEAS-2B	cells	were	untransfected	(U),	mock	transfected	(M)	or	transfected	with	control	
siRNA	(Ctrl)	or	four	different	DUSP1	siRNA:	1-3	at	0.1	µM	and	4	at	0.075	µM,	and	cell	
lysate	collected	at	48	h.	Total	DUSP1	and	total	actin	levels	were	measured	using	western	
blot.	A	representative	blot	is	shown,	n=1-2	(A).	After	48	h	knock	down	with	DUSP1	siRNA	
4,	 BEAS-2Bs	 were	 stimulated	 with	 poly(I:C)	 (25	 µg/ml)	 for	 24	 h	 and	 supernatant	
collected.	CXCL8	was	detected	using	ELISA,	n=1	(B).	PBECs	were	untransfected,	mock	
transfected	or	transfected	with	control	siRNA	or	DUSP1	siRNA	1	and	cell	lysate	collected	
at	24	h,	or	transfected	with	control	or	DUSP1	siRNA	2-4	for	48	h,	n=1-2	(C).		 	
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Table	4.1:	Conditions	for	Attempted	DUSP1	Knock	Down		
Cell	Type	 Conditions	 siRNA	
1	 2	 3	 4	
PBECs	 1X	Lipo.	24	h		 X	 		 X	 		
1X	Lipo.	48	h	 		 X	 X	 X	
2X	Lipo.	24	h	 		 X	 		 		
2X	Lipo.		48	h		 		 X	 X	 		
1X	siRNA	24	h	 		 		 		 		
1X	siRNA	48	h	 		 X	 		 X	
2X	siRNA	48	h	 		 X	 		 X	
PIC	Stimulation	 X	 		 X	 		
Different	Confluencies	 X	 X	 X	 		
BEAS-2B	 1X	Lipo.	24	h		 X	 		 		 X	
1X	Lipo.	48	h	 X	 		 X	 X	
2X	Lipo.	24	h	 X	 X	 		 X	
2X	Lipo.		48	h		 X	 X	 X	 X	
1X	siRNA	24	h	 		 X	 		 X	
1X	siRNA	48	h	 X	 X	 X	 X	
2X	siRNA	24	h	 		 		 		 X	
2X	siRNA	48	h	 X	 		 X	 X	
Mission	1X	siRNA	 X	 X	 X	 		
Mission	2X	siRNA	 X	 X	 X	 		
Viromer	1X	siRNA	 X	 X	 X	 		
Viromer	2X	siRNA	 X	 X	 X	 		
PIC	Stimulation	 X	 		 		 X	
Dex.	Treatment	 		 X	 X	 X	
Different	Confluencies	 X	 X	 X	 X	
Different	Media	 X	 X	 X	 X	
HeLa	Ohio	 2X	Lipo.	24	h		 X	 		 X	 X	
2X	Lipo.	48	h	 		 		 X	 X	
1X	siRNA	24	h	 X	 		 X	 X	
1X	siRNA	48	h	 		 		 X	 X	
Dex.	Treatment	 		 		 X	 X	
DUSP1	knock	down	was	attempted	in	the	cell	types	shown	using	four	different	siRNAs	
targeting	DUSP1	(siRNA	1-4).	The	conditions	attempted	for	each	siRNA	in	each	cell	type	
are	marked	with	an	X.	Lipo.	=	Lipofectamine,	PIC	=	poly(I:C),	and	Dex.	=	dexamethasone.		
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4.3 Knock	Down	of	DUSP10	Expression	in	PBECs	
In	 order	 to	 determine	 the	 role	 of	 DUSP10	 in	 regulating	 the	 response	 of	 PBECs	 to	
rhinoviral	 infection,	DUSP10	expression	was	 successfully	 knocked	down	using	 siRNA.	
DUSP10	expression	was	knocked	down	at	both	the	protein	level	and	the	RNA	level	with	
an	average	knock	down	efficiency	of	78.14%	and	88.96%	respectively	(Figure	4.2).		
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Figure	4.2	DUSP10	knock	down	in	PBECs.	
PBECs	 were	 untransfected	 (Un)	 or	 treated	 with	 DUSP10	 siRNA	 (DUSP10)	 or	 control	
siRNA	(Ctrl)	(100	nM)	and	cell	lysate	collected	at	48	h.	Total	DUSP10	and	total	actin	levels	
were	measured	using	western	blot.	A	representative	blot	is	shown	with	densitometry	
below.	Data	shown	are	mean	±	SEM	band	density	normalised	to	actin	control	for	each	
sample	(A).	ΔΔCt	qRT-PCR	was	performed	for	DUSP10	and	a	GAPDH	control.	Data	shown	
are	mean	±	SEM	of	fold	change	normalised	to	GAPDH	and	untransfected	(B).	Significance	
is	indicated	by	**	p	≤	0.01,	****	p	≤	0.0001	as	measured	by	one-way	ANOVA,	Dunnett’s	
post-test	to	compare	siRNA	treatments,	on	band	density,	n=3	(A)	or	ΔΔCt	values,	n=7	
(B).	
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4.4 The	Role	of	DUSP10	in	Rhinoviral	Infection	of	PBECs	
4.4.1 The	Effect	of	DUSP10	Knock	Down	on	RV	Replication	
A	lack	of	DUSP10	protein	has	previously	been	associated	with	reduced	influenza	virus	
replication,	 and	 increased	 interferon	 production	 (James	 et	 al.	 2015).	 The	 effect	 of	
reduced	 DUSP10	 protein	 levels	 on	 replication	 of	 rhinovirus	 was	 investigated.	 After	
treatment	with	DUSP10	or	control	siRNA,	replication	of	both	RV1B	and	RV16	in	PBECs	
was	determined	by	qRT-PCR	with	primers	specific	 for	rhinoviral	RNA.	Both	RV1B	and	
RV16	 replicated	 in	 PBECs,	 although	 the	 level	 of	 replication	 varied	 greatly	 between	
donors,	and	the	level	of	replication	was	unaffected	by	treatment	with	either	control	or	
DUSP10	siRNA	(Figure	4.3).		
The	 effect	 of	 knocking	 down	 DUSP10	 on	 IFN	 production	 was	 then	 investigated.	
Treatment	 with	 control	 siRNA	 caused	 increases	 in	 IFN-b	 mRNA	 levels	 and	 cytokine	
release	 compared	 to	 untransfected	 cells	 in	 some	 donors,	 suggesting	 that	 siRNA	
treatment	was	inducing	an	anti-viral	response,	as	has	been	observed	previously	(Kariko	
et	al.,	2004)	(Figures	4.4	and	4.5).	Loss	of	DUSP10	did	not	cause	any	differences	in	IFN-
b	mRNA	levels	in	response	to	infection	with	either	serotype	of	rhinovirus	or	poly(I:C),	
although	very	small	amounts	of	IFN-b	were	present	(Figure	4.4).		
Knock	down	of	DUSP10	did	not	have	an	observable	effect	on	release	of	the	interferon-
stimulated	gene	CCL5	 in	 response	 to	either	 strain	of	 rhinovirus	 (Figure	4.5	A	and	B).	
However,	in	response	to	stimulation	with	poly(I:C),	DUSP10	siRNA	treatment	caused	a	
statistically	significant	decrease	in	CCL5	release	compared	to	control	siRNA	treatment.	
Although	 this	 is	 statistically	 significant,	 the	 level	 of	 CCL5	 released	 by	 DUSP10	 knock	
down	cells	is	very	similar	to	untransfected	cells	(Figure	4.5	C).	
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Figure	4.3	DUSP10	knock	down	does	not	affect	RV	replication.	
PBECs	were	untransfected	(Un)	or	treated	with	DUSP10	or	control	siRNA	(Ctrl)	(100	nM)	
for	48	h	prior	to	infection	with	RV1B	(MOI	3)	(A)	or	RV16	(MOI	4)	(B)	for	24	h.	RNA	was	
collected	and	qRT-PCR	performed	for	RV	RNA	and	a	GAPDH	control.	Data	shown	mean	
±	SEM	normalised	to	the	GAPDH	control,	n=3.	Significance	between	control	and	DUSP10	
siRNA	was	measured	by	paired	t-test.	
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Figure	4.4	DUSP10	knock	down	does	not	affect	IFN-b	expression.	
PBECs	were	untransfected	(Un)	or	treated	with	DUSP10	or	control	siRNA	(Ctrl)	(100	nM)	
for	48	h	prior	to	stimulation	with	poly(I:C)	(25	µg/ml)	(A),	RV1B	(MOI	3)	(B)	or	RV16	(MOI	
4)	 (C)	 for	 4	 h.	mRNA	was	 collected	 and	 qRT-PCR	performed	 for	 IFN-β	 and	 a	GAPDH	
control.	 Data	 shown	 are	 mean	 ±	 SEM	 normalised	 to	 the	 GAPDH	 control,	 n=3.	
Significance	between	control	and	DUSP10	siRNA	was	measured	by	paired	t-test.	
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Figure	 4.5	 DUSP10	 knock	 down	 decreases	 CCL5	 release	 in	 response	 to	 poly(I:C)	
stimulation,	but	not	RV	infection.	
PBECs	were	untransfected	(Un)	or	treated	with	DUSP10	or	control	(Ctrl)	siRNA	(100	nM)	
for	48	h	prior	to	stimulation	with	poly(I:C)	(25	µg/ml)	(A),	RV1B	(MOI	3)	(B)	or	RV16	(MOI	
4)	 (C)	 for	24	h.	Supernatant	was	collected	and	ELISA	used	to	measure	 the	release	of	
CCL5.	 Data	 shown	 are	 mean	 ±	 SEM,	 n=4	 for	 poly(I:C)	 and	 3	 for	 RV1B	 and	 RV16.	
Significance	between	DUSP10	and	control	siRNA	treatment	is	indicated	by	*	p	≤	0.05	as	
measured	by	paired	t-test.	
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4.5 The	Role	of	DUSP10	in	Cytokine	Production	
4.5.1 The	Effect	of	DUSP10	Knock	Down	on	CXCL8	Production	in	PBECs	
DUSP10	 knock	 out	 mice	 have	 previously	 been	 found	 to	 show	 increased	 cytokine	
generation	in	response	to	influenza	infection,	as	well	as	other	innate	immune	stimuli,	
such	as	poly(I:C),	LPS,	and	bacterial	infection	(Section	1.5.4).	Thus,	the	effect	of	DUSP10	
knock	 down	 on	 cytokine	 generation	 in	 PBECs	 in	 response	 to	 rhinoviral	 infection,	 or	
poly(I:C),	 or	 IL-1β	 stimulation	was	 investigated.	 There	was	 a	 large	 amount	 of	 donor	
variation,	making	it	difficult	to	draw	conclusions	from	replicates	of	n=	3	or	4.	In	response	
to	rhinoviral	infection,	loss	of	DUSP10	did	not	affect	levels	of	CXCL8	mRNA	or	secreted	
protein,	compared	to	cells	treated	with	control	siRNA	(Figures	4.6	and	4.7	C	and	D).	In	
response	to	poly(I:C)	stimulation,	the	mean	CXCL8	mRNA	level	increased	in	cells	treated	
with	DUSP10	siRNA,	however,	in	two	out	of	four	donors	the	level	decreased	compared	
to	control	siRNA	treatment	(Figure	4.6	B).	 In	addition,	CXCL8	release	 is	not	 increased	
with	DUSP10	knock	down	in	poly(I:C)	treated	cells	(Figure	4.7	B).		
In	 response	 to	 stimulation	 with	 IL-1β,	 cells	 treated	 with	 DUSP10	 siRNA	 showed	
consistently	 higher	 CXCL8	mRNA	 levels	 than	 untransfected	 or	 control	 siRNA	 treated	
cells,	 although	 this	 was	 not	 statistically	 significant,	 likely	 consequent	 upon	 a	 large	
amount	of	donor	variation	(Figure	4.6	A).	This	difference	was	not	evident	in	the	levels	
of	CXCL8	release	(Figure	4.7	A).		
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Figure	4.6	The	effect	of	DUSP10	knock	down	on	CXCL8	mRNA	production.	
PBECs	were	untransfected	(Un)	or	treated	with	DUSP10	or	control	siRNA	(Ctrl)	(100	nM)	
for	48	h	prior	to	stimulation	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	
(MOI	3)	(C)	or	RV16	(MOI	4)	(D)	for	24	h.	RNA	was	collected	and	qRT-PCR	performed	for	
CXCL8	 and	 a	 GAPDH	 control.	 Data	 shown	 mean	 ±	 SEM	 normalised	 to	 GAPDH	 and	
unstimulated	 (media)	 control,	 n=4	 for	 A	 and	 B,	 and	 n=3	 for	 C	 and	 D.	 Significance	
between	DUSP10	and	control	siRNA	treatments	was	measured	by	paired	t-test.	
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Figure	4.7	The	effect	of	DUSP10	knock	down	on	CXCL8	release.	
PBECs	were	untransfected	(Un)	or	treated	with	DUSP10	or	control	(Ctrl)	siRNA	(100	nM)	
for	48	h	prior	to	stimulation	with	IL-1β	(100	ng/ml)	(A),	poly(I:C)	(25	µg/ml)	(B),	RV1B	
(MOI	3)	(C)	or	RV16	(MOI	4)	(D)	for	24	h.	Supernatant	was	collected	and	ELISA	used	to	
measure	 the	 release	 of	 CXCL8.	 Data	 shown	 are	 mean	 ±	 SEM,	 n=3,	 normalised	 to	
unstimulated	 (media)	 control.	 Significance	 between	 DUSP10	 and	 control	 siRNA	
treatments	was	measured	by	paired	t-test.	
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4.5.2 The	Effect	of	DUSP10	Knock	Down	on	CXCL8	Production	in	Response	to	
IL-1b	
In	order	to	investigate	the	role	of	DUSP10	in	the	response	to	IL-1b	in	more	detail,	CXCL8	
mRNA	production	was	 investigated	 at	 an	 earlier	 time	 point,	 of	 6	 h.	 Loss	 of	 DUSP10	
caused	an	increase	in	the	mean	level	of	CXCL8	mRNA	compared	to	control	siRNA	treated	
cells	from	58.6	to	90.2	fold	(Figure	4.8	A).	 In	two	out	of	three	donors,	DUSP10	knock	
down	caused	a	large	increase	in	CXCL8	mRNA	levels	(Figure	4.8	B).	In	the	third	donor,	
CXCL8	levels	were	much	lower,	with	a	small	increase	in	cells	treated	with	DUSP10	siRNA.		
PBECs	 with	 confirmed	 DUSP10	 knock	 down	 were	 treated	 with	 a	 range	 of	 IL-1β	
concentrations.	 At	 each	 concentration	 of	 IL-1β,	 DUSP10	 knock	 down	 consistently	
resulted	in	an	increase	in	CXCL8	mRNA	levels,	with	significant	differences	in	cells	treated	
with	10	and	100	ng/ml	(Figure	4.9	A).	However,	when	measured	by	ELISA,	this	difference	
was	 not	 observed,	 with	 decreases	 in	 CXCL8	 release	 in	 DUSP10	 knock	 down	 cells	
observed	in	many	of	the	donors	(Figure	4.9	B).	DUSP10	knock	down	had	been	observed	
to	cause	cell	death,	hence	the	different	patterns	in	qRT-PCR	and	ELISA	results	could	be	
due	to	the	fact	that	qRT-PCR	data	is	normalised	to	housekeeping	RNA,	whereas	ELISA	
data	 is	 not	 normalised.	 Therefore,	 the	 number	 of	 cells	 per	 well	 at	 the	 time	 of	
supernatant	collection	was	determined	(Figure	4.10	A),	and	CXCL8	release	normalised	
to	cell	number.	Cells	treated	with	DUSP10	siRNA	had	on	average	40.5%	less	cells	than	
those	treated	with	control	siRNA	(Figure	4.10	A).	At	each	concentration	of	IL-1b,	DUSP10	
knock	down	caused	an	increase	in	CXCL8	release	per	105	cells	(Figure	4.10	B).		 	
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Figure	4.8	DUSP10	knock	down	increases	CXCL8	mRNA	production	in	response	to	IL-
1b.	
PBECs	were	untransfected	(Un)	or	treated	with	DUSP10	or	control	siRNA	(Ctrl)	(100	nM)	
for	48	h	prior	to	stimulation	with	IL-1β	(100	ng/ml)	for	6	h.	RNA	was	collected	and	qRT-
PCR	 performed	 for	 CXCL8	 and	 a	 GAPDH	 control.	 Data	 shown	mean	 ±	 SEM	 (A)	 and	
individual	donors	 (B)	normalised	 to	GAPDH	and	media	control,	n=3.	Significance	was	
measured	by	one-way	ANOVA,	Dunnett’s	post-test	to	compare	siRNA	treatments	(A)	or	
paired	t-test	(B).			
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Figure	4.9	DUSP10	knock	down	increases	CXCL8	mRNA	production,	but	not	release,	in	
response	to	IL-1b.	
PBECs	were	 treated	with	DUSP10	 or	 control	 siRNA	 (Ctrl)	 (100	 nM)	 for	 48	 h	 prior	 to	
stimulation	 with	 IL-1β	 (1-100	 ng/ml)	 for	 24	 h.	 mRNA	 was	 collected	 and	 qRT-PCR	
performed	for	CXCL8	and	a	GAPDH	control.	Data	shown	are	each	donor	normalised	to	
the	 GAPDH	 control	 and	 unstimulated	 (0	 ng/ml)	 Ctrl	 cells	 n=4	 (A).	 Supernatant	 was	
collected	 and	 ELISA	 used	 to	 measure	 the	 release	 of	 CXCL8,	 n=3	 (B).	 Significance	 is	
indicated	 by	 *	 p	 ≤	 0.05	 as	 measured	 by	 two-way	 ANOVA	 with	 Sidak's	 post-test,	 to	
compare	between	control	and	DUSP10	siRNA	at	each	dose.	
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Figure	4.10	DUSP10	knock	down	increases	CXCL8	release	per	cell	in	response	to	IL-1b.		
PBECs	were	 treated	with	DUSP10	 or	 control	 siRNA	 (Ctrl)	 (100	 nM)	 for	 48	 h	 prior	 to	
stimulation	with	IL-1β	(1-100	ng/ml)	for	24	h.	Cells	were	detached	and	counted	using	a	
haemocytometer.	Data	shown	are	mean	±	SEM,	n=8.	Significance	is	indicated	by	***	p	
≤	0.001	as	measured	by	t-test	(A).	Supernatant	was	collected	and	ELISA	used	to	measure	
the	release	of	CXCL8.	Each	donor	is	shown,	normalised	to	cell	counts,	n=3.	Significance	
was	measured	using	 two-way	ANOVA,	Sidak’s	post-test	 to	compare	between	control	
and	DUSP10	siRNA	at	each	dose	(B).		
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4.5.3 The	Effect	of	DUSP10	Knock	Down	on	MAPK	Activation	in	Response	to	
IL-1b	
Cells	taken	from	DUSP10	knock	out	mice	have	previously	been	found	to	have	increased	
MAPK	activation,	in	particular	p38	and	JNK,	in	response	to	a	range	of	stimuli	(Section	
1.5.4).	Inhibition	of	p38	and	JNK	caused	a	significant	decrease	in	CXCL8	production	in	
response	to	poly(I:C)	and	RV	infection	(Figures	3.2-3.4).	Therefore,	it	was	hypothesised	
that	 any	 increase	 in	 CXCL8	 production	 in	 DUSP10	 knock	 down	 in	 response	 to	 IL-1b	
(Figure	4.9	and	4.10)	would	be	due	to	increased	MAPK	activation.	This	was	investigated	
using	western	blot	 for	 the	phosphorylated,	 activated	p38	 and	 JNK	proteins.	DUSP10	
knock	down	did	not	affect	the	level	of	phosphorylated	p38	or	JNK	30	minutes	post	IL-1b	
stimulation	(Figure	4.11).		 	
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Figure	4.11	DUSP10	knock	down	does	not	affect	MAPK	activation	in	response	to	IL-1b.		
PBECs	were	treated	with	DUSP10	siRNA	(DUSP10)	or	control	siRNA	(Ctrl)	(100	nM)	for	
48	 h	 before	 stimulation	 with	 IL-1b	 (100	 ng/ml)	 and	 cell	 lysate	 collected	 at	 30	min.	
Phosphorylated	p38	and	JNK	and	total	actin	levels	were	measured	using	western	blot.	A	
representative	blot	 is	shown	(A)	with	densitometry	below	(B	and	C).	Data	shown	are	
mean	 ±	 SEM	 band	 density	 normalised	 to	 actin	 control,	 n=3.	 Significance	 between	
DUSP10	and	control	siRNA	treatments	was	measured	by	paired	t-test.	
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4.5.4 The	Effect	of	DUSP10	Knock	Down	on	Cytokine	Release	in	Response	to	
IL-1b	
As	DUSP10	knock	down	caused	increases	in	CXCL8	production	and	release	in	response	
to	 IL-1b	but	not	rhinoviral	 infection,	the	role	of	DUSP10	 in	 IL-1b	 signalling	was	taken	
forward	for	further	investigation.	In	order	to	gain	a	wider	view	of	the	role	of	DUSP10	in	
epithelial	responses	to	IL-1b,	an	array	was	used	to	determine	the	effect	of	DUSP10	knock	
down	on	the	release	of	a	variety	of	cytokines.	The	chosen	array	contained	antibodies	
for	 36	 human	 cytokines,	 chemokines	 and	 proteins	 known	 to	 be	 upregulated	 by	
inflammation,	enabling	a	broad	view	of	the	effect	of	the	loss	of	DUSP10.		
IL-1b	 stimulation	 caused	 an	 upregulation	 in	 the	 release	 of	 several	 cytokines:	 CXCL1,	
CXCL10,	G-CSF,	GM-CSF,	IL-1b,	IL-6,	and	CXCL8.	IL-1ra	was	secreted	by	PBECs,	but	the	
level	 was	 unaffected	 by	 IL-1b	 stimulation.	 Two	 molecules	 with	 roles	 in	 airway	
remodelling	were	secreted	by	PBECs	in	both	stimulated	and	unstimulated	cells:	MIF	and	
Serpin1	 (Chen	 et	 al.,	 2010,	Oh	 et	 al.,	 2002).	 CXCL12	 release	was	 decreased	by	 IL-1b	
stimulation	 compared	 to	 media	 only	 controls.	 (Table	 4.2).	 	 Some	 proteins	 that	 are	
known	 to	be	 released	by	epithelial	 cells	 in	 response	 to	 rhinoviral	 infection	or	dsRNA	
were	not	released	in	response	to	IL-1b,	including:	CXCL1,	ICAM-1,	IL-1a,	IL-2,	IL-16,	IL-
17E	and	IL-18	(Beale	et	al.,	2014,	Papadopoulos	et	al.,	2000,	Piper	et	al.,	2013,	Schneider	
et	 al.,	 2010,	 Sha	 et	 al.,	 2004,	 Terajima	 et	 al.,	 1997,	 Xu	 et	 al.,	 2010).	 As	 observed	
previously,	 IL-1b	 stimulation	 did	 not	 induce	 the	 production	 of	 IFN	 or	 IFN-stimulated	
genes,	such	as	CCL5	and	CXCL11,	which	are	known	to	be	produced	in	response	to	RV	
infection	(Chen	et	al.,	2006,	Lin	et	al.,	1999,	Piper	et	al.,	2013).		
DUSP10	 knock	 down	 caused	 some	 changes	 in	 levels	 of	 cytokine	 release.	 Release	 of	
CXCL1	and	IL-1b	were	both	increased	in	DUSP10	knock	down	compared	to	control	siRNA	
treated	 cells,	with	 IL-1b	 levels	 almost	 doubling	 (Table	 4.2).	When	normalised	 to	 cell	
number,	CXCL8	 levels	were	also	 increased	by	DUSP10	siRNA	treatment	 (Figure	4.13).	
Intriguingly,	CXCL10	levels	were	decreased	in	DUSP10	knock	down.		
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4.6 IL-1b	Potentiation	of	the	Response	to	RV	Infection	
IL-1b	 has	 previously	 been	 shown	 to	 potentiate	 the	 response	 of	 epithelial	 cells	 to	
rhinoviral	infection	(Stokes	et	al.,	2011).	Therefore,	the	effect	of	dual	stimulation	with	
IL-1b	and	rhinovirus	on	cytokine	release	by	epithelial	cells	was	investigated.	PBECs	were	
stimulated	with	10	or	100	ng/ml	IL-1b,	with	and	without	RV16	infection,	and	mRNA	and	
secreted	protein	levels	of	CXCL8	measured.	Infection	with	RV16	caused	small	increases	
in	CXCL8,	which	was	increased	by	stimulation	with	IL-1b.	At	the	mRNA	level,	only	the	
highest	 IL-1b	 concentration	 caused	 observable	 increases	 in	 CXCL8	 production,	
compared	to	RV16	alone.	However,	as	measured	by	ELISA,	both	IL-1b	concentrations	
caused	incremental	increases	in	CXCL8	release.	This	response	was	further	potentiated	
by	DUSP10	knock	down,	with	significantly	higher	CXCL8	levels	released	in	cells	treated	
with	DUSP10	siRNA	(Figure	4.14).		
In	order	to	determine	whether	the	potentiation	of	the	response	to	RV16	with	IL-1b	was	
due	to	an	effect	on	rhinoviral	replication,	RV	RNA	levels	were	measured	using	qRT-PCR.	
Each	concentration	of	IL-1b	did	not	affect	the	amount	of	RV	RNA	present	(Figure	4.15).	
As	seen	previously	(Figure	4.3),	this	was	unaffected	by	DUSP10	knock	down.		
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Figure	 4.14	 IL-1b	 potentiates	 CXCL8	 production	 in	 response	 to	 RV16,	 and	 DUSP10	
knock	down	potentiates	it	further.	
PBECs	were	treated	with	DUSP10	siRNA	(DUSP10)	or	control	siRNA	(Ctrl)	(100	nM)	for	
48	h	prior	to	stimulation	with	IL-1β	(1-10	ng/ml)	and/or	RV16	infection	(MOI	4).	qRT-
PCR	 was	 performed	 for	 CXCL8	 and	 a	 GAPDH	 control.	 Data	 shown	 are	 fold	 change	
normalised	 to	GAPDH	control	 and	media	 control	 (A).	 Supernatant	was	 collected	and	
ELISA	 performed	 for	 CXCL8.	 Data	 shown	 are	 ng/ml	 normalised	 to	 cell	 counts	 (B).	
Significance	is	indicated	by	*	p	≤	0.05,	**	p	≤	0.01,	***	p	≤	0.001	between	control	and	
DUSP10	 siRNA,	 as	 measured	 by	 two-way	 ANOVA,	 Sidak’s	 post-test,	 or	 #	 between	
stimulants,	as	measured	by	two-way	ANOVA,	Tukey’s	post-test,	n=3.	
Me
dia
IL-
1β
 1 
ng
/m
l
IL-
1β
 10
 ng
/m
l
RV
16
RV
16
 + 
IL-
1β
 1 
ng
/m
l
RV
16
 + 
IL-
1β
 10
 ng
/m
l
0
100
200
300
400
C
XC
L8
 m
R
N
A 
Fo
ld
 C
ha
ng
e
N
or
m
al
is
ed
 to
 G
A
PD
H
Ctrl
DUSP10
Me
dia
IL-
1β
 1 
ng
/m
l
IL-
1β
 10
 ng
/m
l
RV
16
RV
16
 + 
IL-
1β
 1 
ng
/m
l
RV
16
 + 
IL-
1β
 10
 ng
/m
l
0
50
100
150
200
C
XC
L8
 R
el
ea
se
 n
g/
m
l 
pe
r 1
x1
0^
5 
ce
lls
 
Ctrl
DUSP10
A
B
*
*
**
*
###
##
##
#
##
##
###
##
	 151	
	
Figure	4.15	IL-1b	stimulation	does	not	affect	RV	replication.	
PBECs	were	treated	with	DUSP10	siRNA	(DUSP10)	or	control	siRNA	(Ctrl)	(100	nM)	for	
48	h	prior	to	stimulation	with	IL-1β	(1-10	ng/ml)	and/or	RV16	infection	(MOI	4).	qRT-
PCR	was	performed	for	RV	RNA	and	a	GAPDH	control.	Data	shown	are	mean	±	SEM,	n=3,	
normalised	 to	 GAPDH	 control.	 Significance	 was	 measured	 by	 two-way	 ANOVA,	
Dunnett’s	post-test,	to	compare	between	RV16	and	RV16+IL-1b	treatments.	
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4.7 The	Role	of	DUSP10	in	Steroid	Treatment	
DUSP1	 is	 known	 to	 contribute	 significantly	 to	 the	 restriction	 of	 cytokine	 release	 by	
dexamethasone	(Papi	et	al.,	2013).	However,	to	the	best	of	my	knowledge,	the	role	of	
DUSP10	in	dexamethasone	treatment	has	not	previously	been	investigated.	In	order	to	
determine	whether	DUSP10	contributes	to	the	effect	of	dexamethasone,	PBECs	were	
treated	 with	 DUSP10	 or	 control	 siRNA	 48	 h	 before	 simultaneous	 treatment	 with	
dexamethasone	and	poly(I:C),	and	the	level	of	CXCL8	mRNA	determined	by	qRT-PCR.	As	
seen	previously,	 in	 the	absence	of	dexamethasone,	poly(I:C)	 stimulation	upregulated	
CXCL8	mRNA	 and	 secreted	 protein	 levels	 (Figure	 4.16).	 In	 cells	 treated	with	 control	
siRNA	 dexamethasone	 treatment	 significantly	 reduced	 CXCL8	 mRNA	 production,	
whereas	 in	DUSP10	knock	down	cells	 there	was	no	difference	 in	CXCL8	mRNA	 levels	
when	dexamethasone	was	present	(Figure	4.16	A).	However,	when	CXCL8	release	was	
measured	by	ELISA,	dexamethasone	treatment	did	not	induce	any	differences	between	
control	or	DUSP10	siRNA	treatments	(Figure	4.16	B).		
As	the	dexamethasone	treatment	may	not	have	had	time	to	act	before	upregulation	of	
CXCL8	mRNA	by	poly(I:C),	the	experiment	was	repeated	with	a	4	h	dexamethasone	pre-
treatment	before	stimulation.	As	in	figure	4.16,	dexamethasone	treatment	consistently	
caused	a	 small	 reduction	 in	CXCL8	mRNA	production	 in	 response	 to	poly(I:C)	 in	 cells	
treated	with	control	siRNA,	although	this	was	not	statistically	significant	(Figure	4.17	A).	
This	difference	was	not	observed	in	cells	treated	with	DUSP10	siRNA.	The	same	pattern	
was	observed	in	secreted	protein	levels,	although	also	not	statistically	significant	(Figure	
4.17	B).		
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Figure	4.16	Dexamethasone	treatment	does	not	reduce	CXCL8	production	in	response	
to	poly(I:C).	
PBECs	were	treated	with	DUSP10	siRNA	(DUSP10)	or	control	siRNA	(Ctrl)	(100	nM)	for	
48	h,	prior	to	stimulation	with	poly(I:C)	(PIC)	(25	µg/ml)	and	dexamethasone	(Dex)	(10	
nM).	qRT-PCR	was	performed	for	CXCL8	and	a	GAPDH	control.	Data	shown	are	mean	±	
SEM	of	fold	change	normalised	to	GAPDH	and	media	control,	n=4	(A).	Supernatant	was	
collected	 and	ELISA	performed	 for	 CXCL8.	Data	 shown	are	 fold	 change	 compared	 to	
media	control,	n=3	(B).	Significance	between	treatments	is	indicated	by	#	p	≤	0.05,	as	
measured	by	two-way	ANOVA,	Dunnett’s	post-test.	Significance	between	control	and	
DUSP10	siRNA	was	measured	using	two-way	ANOVA,	Sidak’s	post-test.	
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Figure	4.17	Dexamethasone	treatment	does	not	reduce	CXCL8	production	in	response	
to	poly(I:C)	with	4	h	pre-treatment.	
PBECs	were	treated	with	DUSP10	siRNA	(DUSP10)	or	control	siRNA	(Ctrl)	(100	nM)	for	
48	 h,	 then	 treated	 with	 dexamethasone	 (10	 nM)	 for	 4	 h	 prior	 to	 stimulation	 with	
poly(I:C)	 (25	µg/ml).	 qRT-PCR	was	 performed	 for	 CXCL8	 and	 a	 GAPDH	 control.	 Data	
shown	are	mean	±	SEM	of	 fold	change	normalised	 to	GAPDH	and	media	control	 (A).	
Supernatant	was	collected	and	ELISA	performed	for	CXCL8.	Data	shown	are	fold	change	
compared	to	media	control	(B).	Significance	between	treatments	was	measured	by	two-
way	ANOVA,	Dunnett’s	post-test.	Significance	between	control	and	DUSP10	siRNA	was	
measured	using	two-way	ANOVA,	Sidak’s	post-test,	n=3.	
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4.8 Discussion	
4.8.1 Aims	
The	 aims	 of	 this	 chapter	 were	 to	 determine	 whether	 DUSPs	 1	 and	 10	 had	 roles	 in	
regulating	responses	of	airways	epithelial	cells	to	rhinoviral	infection.	Both	DUSPs	have	
previously	been	shown	to	have	roles	in	regulating	innate	immune	signalling	pathways,	
in	particular	p38	and	JNK,	in	response	to	infection	with	bacteria	and	other	viruses.	Their	
role	in	rhinoviral	infection	has	not	yet	been	studied,	and	it	was	deemed	likely	they	would	
be	 important	as	the	results	presented	 in	chapter	three	show	p38	and	JNK	are	strong	
inducers	of	inflammation	in	RV	infection.	
4.8.2 DUSP1	
Although	DUSP1	is	the	most	well	studied	protein	from	the	DUSP	family,	there	is	little	
known	 about	 its	 role	 in	 viral	 infection.	 Previous	work	 has	 suggested	 it	may	 have	 an	
important	role	in	viral	infection	of	the	airway,	as	siRNA	knock	down	in	the	epithelial	cell	
line	NCI-H292	increases	production	of	IL-6	and	CXCL8	in	response	to	poly(I:C)	stimulation	
(Golebski	et	al.,	2015).	 In	order	 to	 take	this	work	 further,	and	 investigate	the	role	of	
DUSP1	 in	 rhinoviral	 infection	of	epithelial	 cells,	 siRNA	knock	down	was	attempted	 in	
PBECs	and	the	epithelial	cell	lines	BEAS-2B	and	HeLa	Ohio.		
Four	 different	 DUSP1	 siRNA	mixtures	 were	 utilised,	 with	many	 different	 techniques	
attempted	to	optimise	knock	down	of	DUSP1.	This	included	altering	the	concentrations	
of	siRNA	and	Lipofectamine	transfection	reagent,	incubation	times,	cell	media,	and	cell	
confluencies.	Although	Lipofectamine	is	routinely	used	successfully	in	our	group,	other	
transfection	reagents,	shown	to	work	well	in	hard	to	transfect	cells,	were	also	utilised.	
Under	all	conditions	tested,	DUSP1	knock	down	was	unsuccessful.	Knock	down	of	DUSP1	
in	PBECs	has	never	been	published.	Although	it	has	been	reported	in	BEAS-2B	cells	(S.	V.	
Shah,	Personal	Communication),	we	were	unable	to	replicate	this.		
Knock	down	of	other	genes	using	the	same	techniques	were	run	alongside	DUSP1	knock	
down	attempts	and	were	successful	(data	not	shown),	suggesting	that	the	transfection	
was	 productive	 and	 the	 siRNA	 complexes	 were	 entering	 the	 cells.	 The	 knock	 down	
efficiency	 was	 measured	 at	 the	 mRNA	 level,	 as	 well	 as	 the	 protein	 level,	 and	 no	
differences	were	 found.	As	 the	data	presented	 in	 chapter	 three	 shows	 low	 levels	 of	
DUSP1	mRNA	 are	 constitutively	 expressed,	 the	 inability	 to	 knock	 DUSP1	 expression	
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down	in	unlikely	to	be	due	to	the	protein	having	a	long	half-life.	One	possibility	is	that	
loss	of	DUSP1	protein	is	fatal,	and	any	cells	with	a	successful	knock	down	died.	DUSP1	
has	previously	been	found	to	inhibit	apoptosis	(MagiGalluzzi	et	al.,	1997).	Although	no	
significant	cell	death	was	observed	by	eye	when	highly	confluent	monolayers,	80-90%,	
were	transfected,	when	lower	confluencies,	60-70%,	were	used,	a	large	amount	of	cell	
death	was	seen.	However,	this	was	seen	with	both	DUSP1	and	control	siRNA	treatments,	
suggesting	it	was	due	to	the	transfection	itself	rather	than	the	loss	of	DUSP1.	Another	
common	reason	for	inefficient	knock	down	is	due	to	secondary	structures	in	the	mRNA	
blocking	siRNA	binding	(Bohula	et	al.,	2003,	Holen	et	al.,	2002).	However,	the	utilisation	
of	 four	 different	 siRNA	mixtures,	 two	 of	 which	were	 pools	 containing	 three	 or	 four	
different	sequences,	means	a	wide	range	of	target	sites	were	included.		
In	future,	the	role	of	DUSP1	in	rhinoviral	infection	could	be	determined	by	other	means,	
for	example	by	over	expressing	DUSP1	in	an	airway	epithelial	cell	line,	or	utilising	DUSP1	
knock	out	mice.	Mice	cannot	be	infected	with	major	group	strains	of	rhinovirus	as	they	
do	not	express	the	receptor	ICAM-1.	Infection	models	utilising	minor	group	strains	have	
been	reported,	but	replication	of	the	virus	is	variable	(Newcomb	et	al.,	2008).	A	more	
promising	method	could	be	to	generate	knock	out	human	epithelial	cells	using	CRISPR-
Cas9	technology.	CRISPR-Cas9	has	been	widely	used	to	make	knock	outs	in	cell	lines,	and	
has	been	recently	reported	to	have	worked	in	primary	nasal	epithelial	cells	(Chu	et	al.,	
2015).	
4.8.3 DUSP10	and	Viral	Replication	
Knock	down	of	DUSP10	protein	in	PBECs	was	successful,	with	around	80%	of	the	protein	
removed.	This	allowed	the	investigation	into	the	role	of	DUSP10	in	rhinoviral	infection	
of	PBECs.	Loss	of	DUSP10	did	not	affect	replication	of	rhinovirus	or	production	of	IFN-b.	
This	is	in	contrast	to	the	results	of	a	study	from	2015,	where	DUSP10	knock	out	mice	
had	much	lower	levels	of	influenza	replication,	due	to	an	increase	in	IFN	levels	(James	
et	al.,	2015).	The	difference	between	these	two	studies	could	be	due	to	DUSP10	having	
different	 roles	 in	 response	 to	 different	 viruses,	 for	 example	 both	 viruses	 have	 very	
different	replication	cycles	and	influenza	is	thought	to	signal	through	TLR7	more	than	
TLR3	(Diebold	et	al.,	2004).	However,	 the	James	et	al.	paper	also	stimulated	BMDMs	
from	DUSP10	knock	out	mice	with	poly(I:C)	and	found	an	increase	in	IFN	production;	
whereas	in	this	study,	there	was	no	difference	in	IFN-b	levels	in	PBECs	in	response	to	
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poly(I:C)	between	cells	treated	with	control	or	DUSP10	siRNA.	This	could	be	due	to	the	
difference	 in	 cell	 types,	 the	 influenza	 paper	 examining	 murine	 BMDMs	 rather	 than	
human	epithelial	 cells.	DUSP10	may	have	specific	 roles	 in	different	cell	 types,	as	has	
been	 suggested	 for	DUSP1	 (Zhang	et	 al.,	 2015,	 Zhao	et	 al.,	 2017).	 It	 could	 also	be	 a	
species	 dependent	 phenotype,	 it	 would	 be	 interesting	 to	 determine	 the	 effect	 of	
DUSP10	knock	down	on	influenza	replication	in	human	PBECs.	
IFN-b	 mRNA	 levels	 were	 low	 in	 response	 to	 infection	 with	 RV	 or	 stimulation	 with	
poly(I:C),	making	any	differences	caused	by	DUSP10	knock	down	difficult	to	determine.	
However,	DUSP10	knock	down	also	caused	no	change	in	the	level	of	CCL5,	an	interferon-
stimulated	gene,	in	response	to	RV	and	caused	a	significant	downregulation	in	response	
to	poly(I:C).	This	indicates	that	DUSP10	knock	down	is	not	upregulating	ISG	expression,	
and	thus	IFN	production,	in	response	to	rhinoviral	infection.	Consequently,	investigation	
into	 the	 effect	 of	 DUSP10	 knock	 down	 on	 other	 IFNs	 may	 not	 be	 worthwhile.	 The	
significant	decrease	in	CCL5	production	in	DUSP10	knock	down	cells	seen	in	response	to	
poly(I:C)	 is	 likely	 due	 to	 the	 cell	 death	 observed	 in	 cells	 treated	with	DUSP10	 siRNA	
(discussed	below),	rather	than	a	positive	regulatory	role	for	DUSP10	in	CCL5	production,	
although	other	DUSPs	have	been	shown	to	have	positive	regulatory	roles	by	acting	as	
scaffold	proteins	(Ju	et	al.,	2016,	Takagaki	et	al.,	2004,	Zama	et	al.,	2002).	One	study	has	
previously	suggested	that	DUSP10	can	act	as	a	scaffold	protein	for	ERK	signalling	in	the	
fibroblast	cell	line	COS-7	(Nomura	et	al.,	2012).	
4.8.4 The	Role	of	DUSP10	in	Cell	Viability	
DUSP10	knock	down	caused	cell	death	in	around	40%	of	the	PBEC	monolayer.	DUSPs	
have	been	shown	to	have	roles	in	cell-cycle	pathways,	with	many	of	them	implicated	in	
several	cancers.	DUSP10	itself	is	upregulated	in	tumours	taken	from	colon	cancers	and	
glioblastomas,	 and	 an	 SNP	 in	 the	 DUSP10	 gene	 is	 associated	with	 colorectal	 cancer	
(Benavides-Serrato	et	al.,	2014,	Nomura	et	al.,	2012,	Zhang	et	al.,	2014).	However,	 it	
seems	 that	 DUSP10	 has	 a	 protective	 role	 in	 cancer,	with	 overexpression	 of	 DUSP10	
decreasing	proliferation	of	an	adenocarcinoma	cell	line,	BxPC3	(He	et	al.,	2014).	Some	
cancer	therapies	upregulate	DUSP10	expression,	contributing	to	the	anti-tumour	effect	
through	inactivating	p38	(Krishnan	et	al.,	2007,	Nonn	et	al.,	2006).	Similarly	to	this	study,	
MacKeigan	et	al.	performed	an	siRNA	screen	for	proteins	important	for	survival	of	HeLa	
cells,	and	found	that	siRNA	knock	down	of	DUSP10	reduced	cell	survival	(MacKeigan	et	
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al.,	2005).	This	demonstrates	that	DUSP10	has	an	important	role	in	regulating	the	cell	
cycle,	and	knocking	down	its	expression	may	be	detrimental	to	the	cell.	This	is	supported	
by	 the	 fact	 that	DUSP10	 is	 phosphorylated	 and	 stabilised	 by	mTORC2,	 an	 important	
regulator	of	cell	growth	(Benavides-Serrato	et	al.,	2014).	The	role	of	DUSP10	in	the	cell	
cycle	is	thought	to	be	through	regulation	of	the	MAPKs	(He	et	al.,	2014).	JNK	is	known	
to	 be	 involved	 in	 cell	 growth,	 as	 inhibition	 of	 the	 protein	 leads	 to	 cell	 cycle	 arrest	
(Takahashi	et	al.,	2013).	However,	DUSP10	knock	down	did	not	affect	activation	of	the	
MAPKs.	Therefore,	more	work	is	necessary	to	investigate	how	loss	of	DUSP10	is	causing	
cell	death,	the	first	step	being	to	determine	the	type	of	cell	death:	apoptosis,	necrosis	
or	pyroptosis	(discussed	below).		
The	MAPKs	 also	have	 roles	 in	 regulating	 tight	 junctions	between	 the	epithelial	 cells.	
Inhibition	of	either	ERK	or	JNK	has	been	shown	to	prevent	tight	junction	disassembly	in	
response	to	various	stimuli	 (Cohen	et	al.,	2010,	Petecchia	et	al.,	2012).	Disruption	of	
tight	 junctions	 is	 another	possible	mechanism	by	which	 loss	of	DUSP10	 leads	 to	 cell	
death;	 DUSP10	 knock	 down	 increasing	 MAPK	 activity	 leading	 to	 the	 loss	 of	 tight	
junctions.	 This	 has	 implications	 in	 rhinoviral	 infection,	 as	 infection	 also	 leads	 to	
disruption	of	tight	junctions	(Sajjan	et	al.,	2008,	Yeo	and	Jang,	2010).	Rhinoviral	infection	
causes	significant	damage	to	the	airway	epithelium	(Bossios	et	al.,	2005,	Wark	et	al.,	
2002).	 The	 role	 of	 DUSP10	 in	 regulation	 of	 the	 cell	 cycle	 or	 tight	 junctions	may	 be	
important	in	recovery	of	the	epithelium	after	infection.		
4.8.5 The	Role	of	DUSP10	in	Inflammatory	Cytokine	Release	
DUSP10	knock	down	did	not	affect	 inflammatory	cytokine	production	 in	 response	 to	
infection	 with	 either	 strain	 of	 rhinovirus,	 or	 poly(I:C)	 stimulation,	 suggesting	 that	
DUSP10	is	not	negatively	regulating	the	TLR3	signalling	pathway	in	PBECs.	It	is	possible	
that	 there	 could	 be	 redundancy	 between	 the	 DUSP	 proteins,	 with	 another	 protein	
compensating	 for	 the	 loss	 of	 DUSP10.	 Preliminary	 data	 suggests	 that	DUSP10	 knock	
down	 does	 not	 affect	 the	 mRNA	 expression	 of	 DUSP1	 (data	 not	 shown),	 but	 other	
studies	 have	 found	 altered	 expression	 of	 other	 DUSPs,	 including	 DUSPs	 2	 and	 4,	 in	
response	to	loss	of	DUSP1	(Maier	et	al.,	2007).	It	could	also	be	due	to	this	being	a	knock	
down	rather	 than	a	knock	out.	Small	amounts	of	DUSP10	protein	may	be	enough	 to	
regulate	signalling	pathways,	knock	out	models	would	have	to	be	utilised	to	investigate	
this	further.	However,	the	effect	of	knock	down	on	cell	viability	suggests	enough	protein	
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has	been	removed	for	the	effect	to	be	seen.	The	variability	between	donors	also	makes	
results	difficult	to	interpret,	and	greater	n	numbers	would	be	necessary	to	make	a	firm	
conclusion.	These	were	not	included	in	this	study	as	the	results	did	not	suggest	DUSP10	
caused	a	difference	in	CXCL8	expression	in	RV	infection.		
In	 response	 to	 IL-1b	 stimulation,	 DUSP10	 knock	 down	 increased	 CXCL8	 mRNA	
production	 and	 protein	 release,	 suggesting	 an	 important	 role	 in	 the	 regulation	 of	
inflammatory	cytokine	release.	In	order	to	gain	a	wider	picture	of	the	effect	of	DUSP10	
knock	down	on	IL-1b	signalling,	a	cytokine	array	was	used.	Although	this	technique	is	
only	semi-quantitative,	and	only	includes	samples	from	one	donor,	it	gives	an	indication	
of	which	cytokines	are	good	candidates	to	follow	up	in	future.	IL-1b	stimulation	of	PBECs	
induced	release	of	several	cytokines.	DUSP10	knock	down	did	not	affect	the	release	of	
many	of	these	cytokines,	unless	the	results	were	normalised	to	cell	number,	as	observed	
previously.	This	array	confirmed	the	upregulation	of	CXCL8	in	DUSP10	knock	down	cells,	
and	showed	increased	release	of	another	neutrophil	chemoattractant,	CXCL1	(Nagarkar	
et	al.,	2009).	This	endorses	the	anti-inflammatory	function	of	DUSP10,	and	suggests	an	
important	role	in	regulating	damaging	neutrophilia	in	the	airway.	Other	cytokines	with	
differential	 expression	 in	DUSP10	knock	down	cells	 included	 IL-1b	 itself	 and	CXCL10,	
each	of	which	are	discussed	in	more	detail	below.		
The	greatest	difference	between	control	and	DUSP10	siRNA	treated	cells	was	in	IL-1b	
release.	This	implies	that,	in	addition	to	regulating	a	pathway	that	leads	to	production	
of	 inflammatory	 cytokines,	 DUSP10	 is	 also	 regulating	 a	 pathway	 specific	 to	 IL-1b	
production.	IL-1b	is	produced	in	response	to	infection	or	stimulation	by	transcription	of	
pro-IL-1b,	 which	 is	 then	 cleaved	 into	 the	 active	 protein	 by	 the	 inflammasome.	 The	
inflammasome	consists	of	a	 sensor	protein,	 the	adaptor	protein	ASC,	and	caspase-1.	
There	 are	 several	 different	 sensor	 proteins,	 most	 being	 members	 of	 the	 Nod-like	
receptor	(NLR)	family.	Rhinoviral	infection	of	PBECs	is	known	to	induce	IL-1b	release	in	
a	caspase-1	dependent	manner	(Piper	et	al.,	2013).	Triantafilou	et	al.	demonstrated	that	
the	RV	protein	2B	induces	inflammasome	activation	in	PBECs	by	forming	pores	in	the	
endoplasmic	reticulum	and	Golgi,	releasing	Ca2+	ions	(Triantafilou	et	al.,	2013).	The	NLRs,	
NLRP3	 and	 NLRC5	 sense	 the	 changes	 in	 ion	 concentration,	 leading	 to	 activation	 of	
caspase-1,	and	 IL-1b	production.	As	 IL-1b	 is	differentially	expressed	 in	DUSP10	knock	
down	 cells,	 one	 possibility	 is	 that	 DUSP10	 is	 regulating	 inflammasome	 activation.	
	160
DUSP10	has	previously	been	linked	to	the	inflammasome	adaptor,	ASC,	as	THP-1	cells	
treated	 with	 ASC	 shRNA	 had	 increased	 DUSP10	 mRNA	 levels,	 suggesting	 that	 ASC	
supresses	DUSP10	production	(Taxman	et	al.,	2011).	The	interplay	between	DUSP10	and	
the	 inflammasome	 requires	 further	 investigation,	 for	 example	 measuring	 levels	 of	
caspase-1	activation	in	DUSP10	knock	down	cells.	The	levels	of	IL-1b	in	DUSP10	knock	
down	 in	 response	 to	 rhinovirus	 should	 also	 be	 determined,	 to	 see	 whether	 this	
phenotype	is	a	specific	response	to	activation	with	IL-1b.		
Prolonged	stimulation	of	the	inflammasome	can	lead	to	cell	death	through	pyroptosis	
(Brough	and	Rothwell,	2007).	Pyroptosis	is	a	mechanism	of	cell	death	with	aspects	of	
both	apoptosis	and	necrosis.	 It	 is	highly	 inflammatory,	resulting	from	cell	 lysis,	unlike	
apoptosis,	but	is	dependent	on	caspase-1	activation,	unlike	necrosis	(Fink	and	Cookson,	
2006).	 Infection	 of	 the	 neuroblastoma	 cell	 line	 SK-N-SH	 with	 the	 picornavirus,	
enterovirus-71	has	been	 found	 to	activate	 the	 inflammasome	and	 lead	 to	 cell	 death	
through	 pyroptosis	 (Yogarajah	 et	 al.,	 2017).	 If	 DUSP10	 does	 regulate	 inflammasome	
activation,	pyroptosis	could	be	another	mechanism	by	which	loss	of	DUSP10	leads	to	
cell	 death.	 One	 way	 in	 which	 to	 investigate	 whether	 DUSP10	 knock	 down	 induces	
pyroptosis	 is	 utilisation	 of	 the	 stain	 7-aminoactinomycin	 D	 (7-AAD)	 which	 binds	 to	
extracellular	DNA.		
Although	DUSP10	knock	down	increased	production	of	IL-1b,	it	did	not	affect	release	of	
the	receptor	antagonist	IL-1ra,	nor	did	stimulation	with	IL-1b.	The	balance	between	IL-
1b	and	IL-1ra	is	important	in	preventing	excessive,	damaging	inflammatory	responses.	
Stimuli	 that	 induce	 production	 of	 IL-1b	 generally	 also	 induce	 IL-1ra,	 and	 IL-1b	
stimulation	 has	 been	 shown	 to	 induce	 release	 of	 IL-1ra	 (Gabay	 et	 al.,	 1997).	
Experimental	human	RV16	infection	showed	a	positive	correlation	between	levels	of	IL-
1b	 and	 IL-1ra	 in	 nasal	 lavage	 (de	 Kluijver	 et	 al.,	 2003).	 The	 fact	 that	 IL-1ra	 is	 not	
upregulated	by	DUSP10	knock	down,	but	IL-1b	is,	suggests	that	loss	of	DUSP10	leads	to	
an	excessive	IL-1b	mediated	inflammatory	response.	
CXCL10	was	released	in	response	to	IL-1b	stimulation.	CXCL10	has	been	shown	to	be	
induced	in	PBECs	by	RV16	infection,	and	levels	in	nasal	lavage	correlate	with	symptom	
severity,	 viral	 titre	 and	 lymphocyte	 number	 (Spurrell	 et	 al.,	 2005).	 It	 has	 also	 been	
associated	 with	 asthma	 and	 COPD,	 with	 cells	 taken	 from	 these	 patients	 expressing	
higher	protein	levels	(Miotto	et	al.,	2001,	Saetta	et	al.,	2002).	CXCL10	has	been	shown	
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to	be	an	important	chemoattractant	for	Th1	cells	(Hyun	et	al.,	2005,	Sallusto	et	al.,	1998,	
Xie	et	al.,	2003).	Knock	down	of	DUSP10	decreased	release	of	CXCL10	in	response	to	IL-
1b	 stimulation.	 This	 suggests	 that	DUSP10	positively	 regulates	 its	 release,	 and	 could	
have	 an	 important	 role	 in	 regulating	 the	 Th1/Th2	 axis	 in	 airway	 inflammation.	 The	
balance	 between	 Th1	 and	 Th2	 responses	 is	 an	 important	 component	 of	 asthma	
exacerbations,	and	therapies	targeting	this	have	had	promising	results	in	recent	clinical	
trials	(Corren	et	al.,	2017).	Inhibition	of	the	ERK	or	p38	pathways,	using	inhibitors	U0126,	
PD98059	and	SB203580,	has	previously	been	shown	to	increase	CXCL10	production	in	
PBECs	 in	 response	 to	 RV16	 infection	 (Zaheer	 et	 al.,	 2009).	 This	 increase	 in	 CXCL10	
transcription	was	due	to	increased	activity	of	the	transcription	factor	IRF1.	IL-1	signalling	
has	 previously	 been	 found	 to	 induce	 IRF1	 activation	 and	 production	 of	 CXCL10	 in	
primary	 human	 astrocytes	 (Harikumar	 et	 al.,	 2014).	 The	 decrease	 in	 CXCL10	 in	 cells	
treated	with	DUSP10	siRNA	suggests	that	DUSP10	is	negatively	regulating	this	pathway.	
It	would	be	important	to	determine	the	effect	of	DUSP10	knock	down	on	the	activation	
of	IRF1	in	PBECs,	as	this	could	help	identify	the	point	at	which	DUSP10	is	acting.	
Interestingly,	 IL-1b	 stimulation	was	 found	to	decrease	production	of	CXCL12.	CXCL12	
has	an	important	role	in	the	neutrophil	life	cycle,	regulating	their	release	from	the	bone	
marrow,	and	their	return	once	senescent	(Martin	et	al.,	2003,	Petit	et	al.,	2002,	Suratt	
et	al.,	2004).	CXCL12	has	also	been	shown	to	have	a	role	in	the	lung.	Experimental	RV16	
infection	increased	CXCL12	levels	in	nasal	secretions	(Branigan	et	al.,	2014),	and	blocking	
CXCL12	signalling	reduced	neutrophil	numbers	 in	the	murine	 lung	 in	response	to	LPS	
(Petty	 et	 al.,	 2007).	 In	 2011,	 Yamanda,	 et	 al.	 demonstrated	 that	 CXCL12	 expression	
increased	 lung	 neutrophil	 numbers	 by	 acting	 as	 a	 retention	 signal,	 rather	 than	 a	
chemoattractant,	and	protected	neutrophils	from	apoptosis	(Yamada	et	al.,	2011).	This	
implies	that	IL-1b	signalling	in	PBECs	reduces	the	production	of	a	neutrophil	retention	
signal,	perhaps	as	a	negative	 feedback	mechanism	to	 reduce	 the	amount	of	damage	
done	by	inflammation.	
The	fact	that	DUSP10	regulated	the	response	to	IL-1b,	but	not	to	RV	infection	suggests	
that	DUSP10	has	a	role	in	regulating	part	of	the	pathway	induced	by	IL-1b	which	is	not	
involved	 in	 the	 TLR3	 signalling	 cascade.	 For	 example,	 IL-1b	 activates	 the	 MyD88	
pathway,	which	involves	phosphorylation	of	IRAK1	and/or	IRAK2,	which	are	not	involved	
in	 the	 TLR3-TRIF	 pathway.	DUSP10	 could	 be	 dephosphorylating	 these	 IRAK	proteins,	
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blocking	 this	 signalling	 pathway.	 However,	 activation	 of	 p38	 and	 JNK,	 which	 are	
downstream	of	the	IRAK	proteins,	in	response	to	IL-1b	was	unaffected	by	DUSP10	knock	
down.	 DUSP10	 could	 also	 be	 regulating	 these	 pathways	 in	 ways	 other	 than	
dephosphorylation;	 DUSP16	 has	 been	 demonstrated	 to	 negatively	 regulate	 ERK	 by	
anchoring	it	in	the	cytoplasm	(Masuda	et	al.,	2010).			
These	findings,	and	the	potential	sites	at	which	DUSP10	may	be	acting,	are	summarised	
in	figure	4.18.		
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Figure	4.18	The	Role	of	DUSP10	in	IL-1b	signalling	in	PBECs.	
IL-1b	binds	IL-1RI	on	the	epithelial	surface	triggering	activation	of	the	MAPK	and	NF-kB	
pathways.	These	pathways	lead	to	the	production	of	pro-IL-1b,	IRF1	and	inflammatory	
cytokines.	Pro-IL-1b	is	cleaved	to	mature	IL-1b	by	the	inflammasome,	composed	of	an	
NLR	sensor,	ASC	and	caspase-1.	Mature	IL-1b	is	secreted.	IRF1	induces	transcription	of	
cytokines,	including	CXCL10,	this	is	negatively	regulated	by	the	MAPKs.	Red	lines	indicate	
potential	sites	at	which	DUSP10	may	be	negatively	regulating	these	pathways.		
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Co-stimulating	PBECs	with	RV	and	 IL-1b	dramatically	potentiated	 the	 response	 to	RV	
alone.	 As	monocytes	 release	 IL-1b	 in	 response	 to	 infection	with	 RV	 (Ganesan	 et	 al.,	
2016);	 monocytes	 present	 in	 the	 infected	 airway	 would	 potentiate	 the	 response	 of	
PBECs	to	rhinoviral	 infection.	The	response	was	further	 increased	by	 loss	of	DUSP10.	
This	suggests	that	DUSP10	would	have	a	role	in	the	response	to	rhinoviral	infection	in	
the	airway;	RV	inducing	IL-1b	release	by	monocytes,	which	would	act	on	epithelial	cells	
to	 induce	 cytokine	 release,	 which	 is	 regulated	 by	 DUSP10.	 As	 discussed	 above,	 the	
results	obtained	using	a	cytokine	array	suggest	DUSP10	also	has	an	important	role	 in	
regulating	release	of	IL-1b	in	PBECs,	therefore	loss	of	DUSP10	would	further	potentiate	
the	inflammatory	response.	
4.8.6 The	Role	of	DUSP10	in	Steroid	Treatment	
Dexamethasone	 treatment	 is	 known	 to	 reduce	 the	 production	 of	 inflammatory	
cytokines	in	response	to	a	range	of	stimuli	(Abraham	et	al.,	2006,	Goleva	et	al.,	2013,	
Harada	et	al.,	2011,	Keranen	et	al.,	2017,	Newton	et	al.,	2010,	Papi	et	al.,	2013,	Rahman	
et	 al.,	 2016,	 Rider	 et	 al.,	 2013,	 Shah	 et	 al.,	 2016a).	 In	 response	 to	 poly(I:C),	
dexamethasone	reduces	the	production	of	the	inflammatory	cytokines	TSLP	and	CXCL8	
in	PBECs	and	BEAS-2Bs	respectively	(Harada	et	al.,	2011,	Rider	et	al.,	2013).	This	 is	 in	
contrast	to	the	results	found	in	the	present	study,	as	dexamethasone	treatment	did	not	
have	much	 of	 an	 effect	 on	 CXCL8	 production	 or	 release,	with	 or	without	 a	 4	 h	 pre-
treatment.	This	is	unexpected	as	dexamethasone	is	a	commonly	used	steroid	with	well	
documented	anti-inflammatory	effects.	 In	 future,	 this	 experiment	 could	be	 repeated	
using	a	higher	concentration	of	dexamethasone	than	10	nM.	The	dose	of	10	nM	was	
selected	as	the	higher	concentration	of	100	nM	led	to	cell	death	in	PBECs	(Figure	3.23),	
however	inclusion	of	a	dose	response	curve	could	indicate	whether	dexamethasone	was	
having	 an	 effect.	 Many	 of	 the	 papers	 discussed	 above	 used	 1	 µM	 dexamethasone,	
including	 those	 studying	 PBECs,	 the	 effect	 of	 this	 on	 cell	 death	 was	 not	 presented	
(Harada	 et	 al.,	 2011,	 Papi	 et	 al.,	 2013).	 If	 this	 experiment	 was	 to	 be	 repeated,	 the	
inclusion	of	a	positive	control,	to	ensure	dexamethasone	was	working,	would	be	useful.	
For	example,	reductions	in	cytokine	release	in	response	to	LPS	by	dexamethasone	have	
been	widely	published	(Abraham	et	al.,	2006,	Keranen	et	al.,	2017,	Newton	et	al.,	2010,	
Papi	et	al.,	2013,	Shah	et	al.,	2016a).	Therefore,	the	inclusion	of	cells	treated	with	LPS	
alone	 and	 in	 combination	 with	 dexamethasone	 would	 indicate	 whether	 the	
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dexamethasone	was	 having	 an	 effect.	 This	 could	 also	 be	 repeated	 using	 a	 different	
steroid,	for	example	budesonide	has	been	shown	to	reduce	CXCL8	production	in	BEAS-
2B	cells	and	PBECs	in	response	to	RV	infection	(Skevaki	et	al.,	2009).	
Once	steroid	treatment	has	been	established	to	reduce	inflammatory	cytokine	release,	
the	effect	of	DUSP10	knock	down	can	be	investigated.	Although	there	is	a	slight	trend	
towards	less	CXCL8	mRNA	with	dexamethasone	treatment	in	cells	treated	with	control	
siRNA,	 it	 is	small	and	variable.	This	makes	 it	difficult	 to	conclude	whether	the	 loss	of	
DUSP10	affects	it.		
4.8.7 Conclusions	
The	work	presented	in	this	chapter	suggests	that	DUSP10	has	a	regulatory	role	in	PBECs.	
Although	not	directly	regulating	the	release	of	inflammatory	cytokines	or	interferons	to	
rhinoviral	infection	of	PBECs,	DUSP10	does	regulate	cytokine	production	in	response	to	
IL-1b,	an	important	molecule	in	inflammation.	DUSP10	knock	down	increased	secretion	
of	two	neutrophil	chemoattractants,	CXCL8	and	CXCL1,	in	response	to	IL-1b	signalling,	
suggesting	 it	 may	 contribute	 to	 the	 regulation	 of	 neutrophil	 influx	 into	 the	 lung,	 a	
damaging	response	to	rhinoviral	infection.	DUSP10	may	also	play	a	role	in	regulating	the	
Th1/Th2	axis,	with	decreased	secretion	of	a	Th1	cytokine	in	response	to	IL-1b	 in	cells	
treated	with	DUSP10	siRNA.	DUSP10	also	negatively	regulates	the	release	of	IL-1b	itself,	
suggesting	a	possible	role	in	inflammasome	regulation.		
These	data	demonstrate	that	DUSP10	has	an	important	role	in	regulating	inflammatory	
cytokine	release	in	response	to	IL-1b	stimulation.	Previous	work	has	demonstrated	an	
important	 role	 for	 IL-1b	 in	 cross-talk	 between	 macrophages	 and	 epithelial	 cells	 in	
rhinoviral	 infection	 (Stokes	 et	 al.,	 2011),	 and	 IL-1b	 was	 found	 to	 potentiate	 the	
inflammatory	response	to	RV.	Thus,	DUSP10	may	have	a	role	in	regulating	inflammation	
in	response	to	rhinoviral	infection	of	the	airway.		
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5 Chapter	 Five:	 Rhinoviral	 Infection	 of	 Monocytes	 and	
Macrophages	
5.1 Introduction	
During	rhinoviral	infection,	many	different	cell	types	are	present	in	the	inflamed	airway.	
Therefore,	to	understand	the	pathogenesis	of	rhinoviral	infections,	it	may	be	important	
to	study	the	responses	of	these	different	cells	to	RV	and	their	 interactions	with	each	
other.	The	results	presented	in	chapter	four	suggest	an	important	role	for	DUSP10	in	
the	 response	 to	 IL-1b.	 An	 important	 source	 of	 IL-1b	 in	 the	 inflamed	 airway	 are	
macrophages	and	monocytes	(Netea	et	al.,	2009).	Therefore,	 in	this	chapter,	I	will	be	
focusing	on	the	roles	of	macrophages	and	monocytes	 in	rhinoviral	 infection,	and	the	
role	of	DUSP10	in	their	interactions	with	PBECs.	
Resident	macrophages	are	present	in	the	airway,	capable	of	phagocytosing	and	killing	
pathogens,	 and	 secreting	 inflammatory	 mediators.	 During	 an	 immune	 response,	
monocytes	 are	 recruited	 from	 the	 blood	 vessels	 into	 the	 respiratory	 tract	 by	
chemotactic	cytokines.	These	monocytes	play	 important	roles	 in	pathogen	control	by	
secreting	inflammatory	cytokines	and	nitric	oxide	(Jagannath	et	al.,	1998,	Jakubzick	et	
al.,	2013).	They	have	a	greater	ability	to	release	some	pro-inflammatory	mediators,	such	
as	IL-1β,	than	macrophages	(Netea	et	al.,	2009).	These	infiltrating	monocytes	can	also	
differentiate	 into	 recruited	 macrophages,	 including	 M1	 cells,	 which	 release	 pro-
inflammatory	mediators,	and	M2	cells	which	are	thought	to	have	an	anti-inflammatory	
resolution	 role	 and	 play	 a	 part	 in	 tissue	 remodelling	 (Van	 den	 Bossche	 et	 al.,	 2012,	
Verreck	et	al.,	2004).	Monocytes	can	also	differentiate	into	antigen	presenting	cells	and	
migrate	to	the	lymph	nodes	(Jakubzick	et	al.,	2013).		
Some	of	the	cytokines	released	by	macrophages	and	monocytes	can	act	on	epithelial	
cells	and	potentiate	their	response.	In	vitro	co-culture	models	have	demonstrated	that	
this	 cooperative	 signalling	 between	 epithelial	 cells	 and	 monocytes	 can	 dramatically	
exacerbate	the	inflammatory	response	to	many	different	stimuli	(Chaudhuri	et	al.,	2010,	
Haller	et	al.,	2000,	Ishii	et	al.,	2005,	Morris	et	al.,	2006,	Stokes	et	al.,	2011,	Tsutsumi-Ishii	
and	 Nagaoka,	 2003).	 Previous	 work	 from	 our	 group	 has	 shown	 that	 addition	 of	
monocytes	to	BEAS-2B	cultures	considerably	increases	the	release	of	CXCL8	in	response	
to	RV1B	infection,	when	the	monocytes	are	activated	by	LPS	(Stokes	et	al.,	2011).	Co-
	168
cultures	 of	 primary	 monocytes	 and	 PBECs	 have	 also	 been	 found	 to	 have	 increased	
production	 of	 CCL2	 and	 CXCL10	 in	 response	 to	 RV16	 infection	 (Korpi-Steiner	 et	 al.,	
2010).	IL-1β	has	been	shown	to	be	particularly	important	in	this	signalling	network,	as	
blocking	 IL-1β	signalling	using	blocking	antibodies	or	 the	 IL-1	 receptor	antagonist	 (IL-
1Ra)	inhibited	this	increased	cytokine	generation	(Chaudhuri	et	al.,	2010,	Morris	et	al.,	
2005,	Stokes	et	al.,	2011,	Tsutsumi-Ishii	and	Nagaoka,	2003).	
Monocytes	produce	a	wide	range	of	inflammatory	cytokines	in	response	to	stimulation	
with	rhinovirus,	including:	IL-1b,	IL-6,	CXCL8,	CXCL10,	and	TNFa	(Ganesan	et	al.,	2016,	
Gern	et	al.,	1994,	Johnston	et	al.,	1997,	Karta	et	al.,	2014,	Saba	et	al.,	2014).	Much	of	
this	expression	is	not	affected	by	UV	inactivation	of	the	virus,	suggesting	replication	is	
unnecessary	for	the	response.	 Indeed,	many	studies	suggest	that	rhinovirus	does	not	
replicate	within	monocytes	or	macrophages.	In	1994,	Gern	et	al.	infected	macrophages	
taken	from	BAL	with	RV16,	they	found	viral	RNA	within	the	macrophages,	suggesting	
the	virus	was	entering	the	cells,	but	the	viral	titres	declined	over	time	(Gern	et	al.,	1994).	
Saba	 et	 al.	 found	 a	 similar	 result	 in	 response	 to	 infection	 with	 the	 minor	 group	
rhinovirus,	RV1B,	with	bone	marrow	macrophages,	and	monocytes	isolated	from	BAL	
both	showing	no	increase	in	viral	titre	over	25	h	(Saba	et	al.,	2014).	Although	rhinovirus	
does	not	seem	to	replicate	in	primary	monocytic	cells,	some	replication	of	major	group	
rhinoviruses,	RV9	and	RV16,	is	detectable	in	the	monocyte	cell	line	THP-1	(Johnston	et	
al.,	1997,	Laza-Stanca	et	al.,	2006).		
5.1.1 Aims	
The	 results	 summarised	 in	 chapter	 four	 show	 that	 DUSP10	 negatively	 regulates	 the	
inflammatory	response	to	IL-1b	stimulation	of	epithelial	cells.	IL-1b	has	been	shown	to	
be	 an	 important	 molecule	 in	 the	 cross-talk	 between	 monocytes/macrophages	 and	
epithelial	cells	in	response	to	rhinoviral	infection	(Stokes	et	al.,	2011).	Therefore,	it	was	
hypothesised	that	DUSP10	would	have	an	important	role	in	the	response	to	rhinovirus	
in	the	airway,	where	epithelial	cells,	monocytes	and	macrophages	are	all	present.	
The	aim	of	this	chapter	was	to	determine	the	role	of	DUSP10	in	rhinoviral	infection	in	a	
multi-cellular	 environment.	 The	 first	 aim	 was	 to	 determine	 whether	 rhinovirus	
replicated	in	monocytes	or	macrophages	and	characterise	their	response	to	the	virus.	
The	 second	 aim	 was	 to	 determine	 the	 effect	 on	 PBECs	 of	 factors	 released	 by	
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macrophages	or	monocytes	 in	response	to	rhinovirus,	and	the	role	of	DUSP10	in	this	
response.		
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5.2 Rhinoviral	Replication	in	Monocytes	and	Macrophages	
As	discussed	in	section	5.1,	macrophages	and	monocytes	have	previously	been	found	to	
respond	to	rhinoviral	infection,	but	replication	of	the	virus	in	these	cells	has	not	been	
detected.	 Therefore,	 replication	 of	 both	 serotypes	 of	 rhinovirus	 was	 measured	 in	
monocytes	and	monocyte-derived	macrophages	(MDMs).		
Rhinovirus	did	not	replicate	well	in	MDMs	cultured	for	either	7	or	14	days,	with	very	low	
copy	numbers	of	rhinoviral	RNA	per	µg,	although	these	data	are	preliminary	(Figure	5.1).	
In	monocytes,	rhinovirus	replication	was	more	productive,	with	both	RV1B	and	RV16	
reaching	around	1,500	 copies	per	µg	by	48	h	when	 cells	were	 infected	 in	0%	 serum	
media	 (Figure	 5.2	 A).	 However,	 when	monocytes	were	 infected	 in	 2%	 serum	media	
rhinovirus	did	not	replicate	well,	with	the	highest	level	reached	136	copies	per	µg	in	48	
h	RV1B	infection	(Figure	5.2	B).		
This	was	confirmed	by	measuring	the	number	of	virions	released	by	monocytes	infected	
in	0%	and	2%	media,	using	the	TCID50	assay.	In	0%	media	RV1B	reached	a	TCID50/ml	of	
35933.33	by	24	h,	and	RV16	reached	the	slightly	lower	titre	of	250633.33	(Figure	5.3	A).	
At	48	h	this	decreased,	in	contrast	to	the	qRT-PCR	results	which	showed	higher	titres	at	
the	later	time	point	(Figure	5.2	A).	 In	2%	media,	the	rhinoviral	titres	are	much	lower,	
only	reaching	8000-9000	TCID50/ml	by	24	h,	and	again	decreasing	by	48	h	post	infection	
(Figure	5.3	B).	 	
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Figure	5.1	RV	does	not	replicate	well	in	MDMs.	
MDMs	were	differentiated	for	7	or	14	days	prior	to	RV1B	(MOI	4)	(A)	or	RV16	(MOI	4)	
(B)	 infection	 in	 serum	 free	 media.	 RNA	 was	 collected	 at	 24	 and	 48	 h	 and	 qRT-PCR	
performed	 for	RV	RNA	and	a	GAPDH	control.	Data	 shown	normalised	 to	 the	GAPDH	
control,	n=1.	
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Figure	5.2	RV	replicates	in	monocytes	when	no	serum	is	present.	
Monocytes	were	infected	with	RV1B	(MOI	4)	or	RV16	(MOI	4)	infection	in	0%,	n=3	(A)	or	
2%	serum,	n=4	(B).	RNA	was	collected	at	24	and	48	h	and	qRT-PCR	performed	for	RV	
RNA	and	a	GAPDH	control.	Data	shown	mean	±	SEM	normalised	to	the	GAPDH	control.	
Significance	is	indicated	by	*	p	≤	0.05	compared	to	uninfected	(0	h)	control	as	measured	
by	two-way	ANOVA,	Dunnett’s	post-test.	
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Figure	5.3	RV	replicates	in	monocytes	when	no	serum	is	present.	
Monocytes	were	infected	with	RV1B	(MOI	4)	or	RV16	(MOI	4)	infection	in	0%	(A)	or	2%	
serum	(B).	Supernatant	was	collected	at	24	and	48	h	and	TCID50	assay	performed.	Data	
shown	mean	±	SEM,	n=3.		
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5.2.1 Cytokine	Production	in	Monocytes	in	Response	to	RV	Infection	
As	 rhinovirus	 appeared	 to	 replicate	more	 efficiently	 in	monocytes,	 these	 cells	 were	
taken	forward	for	investigation	into	cytokine	release	in	response	to	rhinoviral	infection.	
CXCL8	and	IL-1b	release	in	response	to	infection	with	RV1B	and	RV16	in	both	0%	and	2%	
media	was	measured	by	ELISA.		
Monocytes	released	high	amounts	of	CXCL8	at	baseline,	to	comparable	levels	in	both	
0%	and	2%	media.	 The	amount	of	CXCL8	 released	was	not	 altered	by	 infection	with	
either	RV1B	or	RV16	(Figure	5.4).		
IL-1b	was	also	released	by	monocytes	at	baseline,	this	was	slightly	lower	in	cells	infected	
in	2%	media	than	0%	media	(Figure	5.5).	In	0%	media,	infection	with	RV1B	or	RV16	did	
not	alter	the	level	of	IL-1b	released	by	monocytes.	In	2%	media,	both	RV1B	and	RV16	
infection	 significantly	 increased	 IL-1b	 release	at	 24	h	post	 infection,	 this	was	 slightly	
higher	 in	 response	 to	 RV1B	 than	 RV16	 (Figure	 5.5	 B).	 All	 samples	 were	 above	 the	
minimum	level	of	detection.		
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Figure	5.4	CXCL8	is	constitutively	released	by	monocytes	in	culture.	
Monocytes	were	infected	with	RV1B	(MOI	4)	or	RV16	(MOI	4)	infection	in	0%	(A)	or	2%	
serum	(B).	Supernatant	was	collected	at	24	and	48	h	and	ELISA	used	to	measure	the	
release	of	CXCL8.	Data	shown	are	mean	±	SEM,	n=3.	Significance	is	indicated	by	*	p	≤	
0.05	compared	to	uninfected	(0	h)	as	measured	by	two-way	ANOVA,	Dunnett’s	post-
test.	
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Figure	5.5	IL-1b	is	constitutively	released	by	monocytes	in	culture.	
Monocytes	were	infected	with	RV1B	(MOI	4)	or	RV16	(MOI	4)	infection	in	0%	(A)	or	2%	
serum	(B).	Supernatant	was	collected	at	24	and	48	h	and	ELISA	used	to	measure	the	
release	of	IL-1β.	Data	shown	are	mean	±	SEM,	n=3.	Significance	is	indicated	by	*	p	≤	0.05,	
**	p	≤	0.01	compared	to	uninfected	(0	h)	as	measured	by	two-way	ANOVA,	Dunnett’s	
post-test.	
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5.3 The	Activation	of	PBECs	by	Monocytes	in	RV	Infection	
The	cross-talk	between	monocytes	and	epithelial	cells	in	response	to	rhinoviral	infection	
was	then	investigated.	Supernatant	from	infected	monocytes	was	transferred	to	PBECs	
to	 determine	 whether	 factors	 released	 by	 monocytes,	 in	 response	 to	 rhinoviral	
infection,	 could	 activate	 epithelial	 cells.	 Monocytes	 were	 infected	 with	 RV	 and	
supernatant	collected	at	24	and	48	h.		Supernatant	was	filtered	to	remove	viral	particles	
before	 diluting	 1:2	 with	 PBEC	 recovery	 media,	 hereafter	 called	 conditioned	 media.	
PBECs	were	pre-treated	with	DUSP10	or	control	siRNA	before	addition	of	conditioned	
media	 for	24	h,	methodology	 is	 shown	 in	 figure	5.6	A.	CXCL8	mRNA	production	and	
protein	secretion	was	measured.		
Transfer	of	supernatant	from	uninfected	monocytes	to	PBECs	caused	some	CXCL8	mRNA	
production	 and	 protein	 release	 (Figure	 5.6	 and	 5.7).	 This	 level	 was	 not	 affected	 by	
infection	of	the	monocytes	with	RV1B	(Figure	5.6)	or	RV16	(Figure	5.7).	CXCL8	mRNA	
production	was	consistently	higher	in	DUSP10	knock	down	cells	than	cells	treated	with	
control	siRNA,	and	this	was	statistically	significant	 in	RV16	 infection	(Figure	5.7).	This	
effect	was	not	seen	by	ELISA;	however,	the	results	were	not	normalised	by	cell	number.	
The	CXCL8	release	measured	by	ELISA	will	 include	CXCL8	released	by	the	monocytes,	
carried	over	in	the	conditioned	media.	However,	mRNA	expression	data	indicates	that	
PBECs	are	producing	CXCL8.		 	
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Figure	 5.6	 Supernatant	 from	 monocytes	 infected	 with	 RV1B	 can	 induce	 CXCL8	
production	in	PBECs.		
Monocytes	 were	 infected	 with	 RV1B	 (MOI	 4)	 for	 0,	 24	 or	 48	 h,	 in	 0%	 serum,	 and	
supernatant	 collected.	 Supernatant	 was	 filtered	 and	 diluted	 1:2	 in	 recovery	 media	
before	addition	to	PBECs	pre-treated	with	DUSP10	or	control	(Ctrl)	siRNA	(100	nM)	for	
48	h.	The	time	line	of	the	experiment	is	shown	in	A.	RNA	was	collected	and	qRT-PCR	
performed	for	CXCL8	and	GAPDH.	Data	shown	are	mean	±	SEM	normalised	to	GAPDH	
control	(B).	Supernatant	was	collected	and	ELISA	used	to	measure	the	release	of	CXCL8.	
Data	shown	are	mean	±	SEM	(C).	Significance	between	siRNA	treatments	was	measured	
by	two-way	ANOVA,	Sidak’s	post-test.	Significance	between	time	points	was	measured	
by	two-way	ANOVA,	Dunnett’s	post-test.	n=3.	
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Figure	 5.7	 Supernatant	 from	 monocytes	 infected	 with	 RV16	 can	 induce	 CXCL8	
production	in	PBECs.	
Monocytes	 were	 infected	 with	 RV16	 (MOI	 4)	 for	 0,	 24	 or	 48	 h,	 in	 0%	 serum	 and	
supernatant	 collected.	 Supernatant	 was	 filtered	 and	 diluted	 1:2	 in	 recovery	 media	
before	addition	to	PBECs	pre-treated	with	DUSP10	or	control	(Ctrl)	siRNA	(100	nM)	for	
48	h.	The	time	line	of	the	experiment	is	shown	in	A.	RNA	was	collected	and	qRT-PCR	
performed	for	CXCL8	and	GAPDH.	Data	shown	are	mean	±	SEM	normalised	to	GAPDH	
control	(B).	Supernatant	was	collected	and	ELISA	used	to	measure	the	release	of	CXCL8.	
Data	shown	are	mean	±	SEM	(C).	Significance	between	siRNA	treatments	is	indicated	by	
*	p	≤	0.05	as	measured	by	two-way	ANOVA,	Sidak’s	post-test.	Significance	between	time	
points	was	measured	by	two-way	ANOVA,	Dunnett’s	post-test.	n=3.	
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5.4 Discussion	
5.4.1 Aims	
The	 aim	 of	 this	 chapter	 was	 to	 characterise	 the	 response	 of	 monocytes	 and	
macrophages	to	rhinoviral	infection,	in	terms	of	cytokine	release	and	viral	replication	in	
these	cells.	The	role	of	these	cells	in	the	airway	was	then	investigated,	by	examining	the	
effect	of	factors	released	by	these	cells	in	response	to	RV	on	PBECs,	and	determining	the	
role	of	DUSP10	in	this	setting.		
5.4.2 Rhinovirus	Replication	in	Monocytes	and	Macrophages	
Rhinovirus	was	found	to	replicate	well	in	monocytes,	as	demonstrated	by	increases	in	
rhinoviral	RNA	and	released	virions.	Rhinovirus	replicated	much	more	effectively	when	
no	 serum	was	 present.	 As	 discussed	 in	 section	 4.1,	 several	 groups	 have	 shown	 that	
rhinovirus	does	not	replicate	in	monocytes	(Gern	et	al.,	1994,	Johnston	et	al.,	1997,	Laza-
Stanca	et	al.,	2006,	Saba	et	al.,	2014).	In	each	of	these	studies,	serum	was	present,	at	
different	concentrations,	during	infection.	The	decreased	replication	in	the	presence	of	
serum	could	be	due	to	factors	within	the	serum	which	prevent	replication.	Although	FCS	
is	heat	inactivated	to	remove	immune	factors	such	as	complement,	there	may	still	be	
anti-viral	 factors	 present.	 For	 example,	 FCS	 is	 known	 to	 contain	 low	 levels	 of	 IgG	
(ThermoFisher).	Cows	and	humans	come	into	close	contact	so	 it	could	be	speculated	
that	they	make	antibodies	to	human	rhinovirus	which	are	present	in	the	FCS.		
The	lack	of	serum	would	cause	stress	in	the	cells,	as	is	seen	by	the	release	of	cytokines	
at	baseline.	It	may	be	that	stressed	cells	are	more	permissive	to	infection.	Recent	work	
in	keeping	with	my	findings	has	just	been	published.	Zhou	et	al.	demonstrated	that	RV16	
is	capable	of	replicating	in	PBMCs	or	THP-1	cells	when	co-cultured	with	A549	cells.	This	
was	thought	to	be	due	to	a	product	secreted	by	the	epithelial	cells,	as	infecting	THP-1	
cells	in	“conditioned	media”	taken	from	A549	cells	or	PBECs	also	had	this	effect	(Zhou	
et	al.,	2017).		The	conditioned	media	was	generated	by	incubating	serum	free	RPMI	with	
A549	cells	for	24	h.	This	was	in	comparison	to	non-conditioned	media:	RPMI	containing	
10%	FCS.	Therefore,	the	increased	rhinoviral	replication	in	conditioned	media	observed	
by	 Zhou	 et	 al.	may	 be	 due	 to	 the	 lack	 of	 serum,	 rather	 than	 a	 product	 secreted	 by	
epithelial	cells.	In	the	Zhou	paper,	they	postulate	that	the	increased	replication	is	due	to	
an	increase	in	ICAM-1	expression.	It	would	therefore	be	of	interest	to	examine	whether	
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culturing	monocytes	without	serum	increases	expression	of	 ICAM-1.	However,	 in	this	
study,	both	RV1B	and	RV16	replicated	 in	the	absence	of	serum.	RV1B	belongs	to	the	
minor	group	rhinoviruses,	and	therefore	does	not	bind	ICAM-1.	Cellular	stress	has	been	
demonstrated	to	upregulate	both	ICAM-1	and	LDLR	(Ma	et	al.,	2008,	Tumur	et	al.,	2010).	
Perhaps	the	lack	of	serum	induces	stress	pathways	which	upregulate	receptors	for	both	
major	and	minor	group	rhinoviruses.	To	the	best	of	our	knowledge	this	is	the	first	study	
to	demonstrate	replication	of	a	minor	group	rhinovirus	in	monocytes.		
Rhinovirus	did	not	replicate	well	in	MDMs,	even	though	these	were	infected	in	0%	serum	
media.	It	would	also	be	of	interest	to	examine	ICAM-1	and	LDLR	expression	in	MDMs,	as	
this	may	also	be	the	reason	for	these	cells	being	less	permissive	to	rhinoviral	infection.	
Differentiation	 of	 monocytes	 into	 MDMs	 has	 previously	 been	 shown	 to	 change	
expression	levels	of	many	adhesion	molecules	(Prieto	et	al.,	1994).	Prieto	et	al.	showed	
similar	expression	levels	of	ICAM-1	on	the	surface	of	monocytes	and	MDMs,	however	
they	utilised	a	different	method	of	macrophage	differentiation	to	that	used	this	study,	
which	may	affect	 results.	 For	 example,	 they	 treated	monocytes	with	 concanavolin	A	
during	the	differentiation	process,	which	has	previously	been	found	to	affect	expression	
of	surface	ligands	(Krause	et	al.,	2001).	Replication	of	human	cytomegalovirus	in	MDMs	
has	previously	been	found	to	differ	depending	on	whether	the	cells	were	differentiated	
in	the	presence	of	concanavolin	A	(Soderberg-Naucler	et	al.,	2001).	
Rhinovirus	has	been	 shown	 to	 induce	 secretion	of	 CXCL8	 and	 IL-1b	 in	monocytes	or	
macrophages	 previously.	 Infection	 of	 PBMCs	 with	 RV9	 induced	 CXCL8	 release,	 and	
infection	of	MDMs	with	RV16	induced	IL-1b	release	(Ganesan	et	al.,	2016,	Johnston	et	
al.,	1997).	In	this	study,	monocytes	released	both	cytokines	at	baseline,	and	expression	
was	not	altered	by	RV16	or	RV1B	 infection,	except	 for	slight	 increases	 in	 IL-1b	when	
infected	in	2%	serum.	This	implies	that	due	to	the	stress	caused	by	reduced	serum	levels,	
as	discussed	above,	cytokine	expression	is	already	at	its	peak	and	cannot	be	increased	
by	infection.	The	amount	of	CXCL8	released	by	monocytes	was	similar	to	the	expression	
previously	found	at	48	h	post	infection,	of	between	20	and	30	ng/ml	(Johnston	et	al.,	
1997).	The	release	of	IL-1b	in	this	study	was	much	lower	than	that	found	by	Ganesan	et	
al.,	with	around	30	pg/ml	compared	to	100	ng/ml	(Ganesan	et	al.,	2016).	This	could	be	
due	to	the	examination	of	different	time	points,	16	h	compared	to	24	or	48,	or	the	use	
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of	differentiated	cells.	However,	in	this	study,	preliminary	data	found	release	of	IL-1b	by	
MDMs	to	be	undetectable,	with	or	without	RV	infection	(data	not	shown).		
5.4.3 Activation	of	PBECs	by	Monocytes	
As	the	data	presented	in	chapter	four	demonstrated	that	IL-1b	potentiates	the	response	
of	PBECs	 to	 rhinoviral	 infection,	 the	cross-talk	between	monocytes	and	PBECs	 in	 the	
response	to	RV	was	then	investigated.	Supernatant	transfer	from	monocytes	to	PBECs	
induced	small	amounts	of	CXCL8	production	and	release.	This	showed	that	molecules	
released	by	 the	monocytes	 are	 able	 to	 stimulate	 cytokine	production	by	PBECs,	 and	
CXCL8	 mRNA	 levels	 were	 consistently	 higher	 in	 cells	 treated	 with	 DUSP10	 siRNA.	
However,	this	CXCL8	production	was	not	upregulated	by	rhinoviral	infection,	likely	due	
to	 the	 high	 baseline	 levels	 of	 cytokine	 production	 in	 monocytes.	 This	 experiment	
demonstrates	that	the	presence	of	monocytes	could	potentiate	the	response	of	PBECs	
to	RV,	however	more	optimisation	 is	needed	to	minimise	stress	 in	 the	monocytes	at	
baseline.		
5.4.4 Conclusions	
As	IL-1b	is	known	to	play	an	important	role	in	the	cross-talk	between	epithelial	cells	and	
monocytes,	 the	 role	 of	 DUSP10	 in	 the	 interplay	 between	 the	 two	 cells	 types	 was	
investigated.	 Rhinovirus	 replicated	 well	 in	 monocytes,	 although	 under	 stressed	
conditions,	and	supernatants	taken	from	monocytes	did	induce	cytokine	production	by	
epithelial	cells,	which	was	increased	by	DUSP10	knock	down.		
	 	
	 183	
6 Chapter	Six:	Final	Discussion	
6.1 How	Does	This	Thesis	Add	to	the	Current	Knowledge?	
This	 is	 the	 first	 study	 to	 investigate	 DUSP	 regulation	 of	 epithelial	 inflammatory	
responses	 to	 respiratory	 viral	 infection.	 Respiratory	 inflammation	 is	 a	 damaging	
response	 to	 rhinoviral	 infection	 and	 can	 cause	 severe	 complications,	 especially	 in	
patients	with	asthma	or	COPD.	DUSPs	represent	a	possible	future	therapeutic	target	for	
limiting	excessive	inflammation.	
The	MAPK	pathways	are	known	to	induce	the	production	of	inflammatory	cytokines	in	
response	to	a	variety	of	stimuli,	 including	rhinovirus.	However,	previous	studies	have	
focused	on	the	roles	of	p38	and	ERK	(Griego	et	al.,	2000,	Liu	et	al.,	2008a).	This	study	
reinforces	the	role	of	p38	in	the	inflammatory	response	to	rhinoviral	infection,	but	also	
demonstrates	 a	 similar	 role	 for	 JNK,	 with	 inhibition	 of	 either	 dramatically	 reducing	
CXCL8	production.		
Although	the	role	of	the	MAPKs	in	cytokine	induction	has	been	investigated	previously,	
their	impact	on	rhinoviral	replication	has	not.	This	was	the	first	study	to	demonstrate	
that	 the	p38	pathway	 is	necessary	 for	 replication	of	RV,	although	this	has	previously	
been	shown	 for	other	viruses	 (Marchant	et	al.,	2010).	 In	opposition	 to	 this,	 JNK	was	
found	 to	 limit	 rhinoviral	 replication,	 although	 the	 mechanism	 by	 which	 it	 acts	 is	
unknown.	These	findings	have	important	implications	for	any	future	therapeutics,	if	JNK	
was	to	be	targeted	to	reduce	inflammation,	this	may	have	detrimental	effects	on	the	
immune	control	of	rhinoviral	replication.	
DUSPs	1	and	10	were	expressed	in	PBECs	at	baseline.	The	expression	of	these	proteins	
in	PBECs,	and	their	regulation	in	response	to	RV	have	not	previously	been	investigated.	
Rhinoviral	infection	did	not	alter	expression	of	DUSP1	but	did	induce	phosphorylation	
of	the	protein,	previously	shown	to	stabilise	it	(Brondello	et	al.,	1999).	DUSP10	was	also	
regulated	in	response	to	rhinoviral	infection,	although	in	a	different	way:	RV1B	addition	
caused	a	rapid	downregulation	of	DUSP10	protein	which	recovered	by	60	minutes.	Both	
serotypes	 of	 rhinovirus	 also	 caused	 a	 later	 decrease	 in	 DUSP10	 by	 around	 4	 h	 post	
infection.	These	data	demonstrate	that	both	proteins	are	being	regulated	by	infection,	
suggesting	an	important	role	in	the	response	of	PBECs	to	RV.		
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Although	DUSP10	did	not	have	a	direct	role	in	regulating	the	response	of	PBECs	to	RV	
infection,	 in	contrast	to	previous	work	with	influenza	virus	(James	et	al.,	2015),	 it	did	
regulate	the	response	to	IL-1b.	IL-1b	has	previously	been	shown	to	have	an	important	
role	in	potentiating	the	inflammatory	response	of	epithelial	cells	to	rhinoviral	infection	
(Morris	 et	 al.,	 2005,	 Stokes	 et	 al.,	 2011).	 This	 suggests	 that	 DUSP10	would	 have	 an	
important	anti-inflammatory	role	in	rhinoviral	infection	of	the	airway.	This	is	reinforced	
by	 the	 data	 showing	 that	 co-stimulation	 of	 PBECs	 with	 RV	 and	 IL-1b	 increases	 the	
production	of	CXCL8,	and	loss	of	DUSP10	potentiates	this	still	further.	
Activation	of	epithelial	cells	by	IL-1b	is	not	only	important	in	rhinoviral	infection	but	has	
roles	in	many	different	settings.	For	example,	IL-1b	is	known	to	have	roles	in	asthma	and	
COPD,	with	levels	correlating	to	exacerbation	severity	(Ackerman	et	al.,	1994,	Botelho	
et	al.,	2011).	In	murine	asthma	models,	knock	out	of	the	IL-1b	receptor	leads	to	much	
lower	levels	of	pulmonary	eosinophilia	(Schmitz	et	al.,	2003).	IL-1b	also	has	an	important	
role	in	other	respiratory	viral	infections,	for	example	blocking	IL-1b	signalling	decreases	
inflammation	 in	 response	 to	 influenza	 virus	 (Kim	 et	 al.,	 2015,	 Thomas	 et	 al.,	 2009).	
Clinical	 trials	have	demonstrated	 the	effect	of	 the	 IL-1b	 antagonist	 IL-1Ra	 in	 treating	
several	inflammatory	disorders	(Abbate	et	al.,	2010,	Cohen	et	al.,	2002,	Hawkins	et	al.,	
2004).	This	demonstrates	that	the	role	of	DUSP10	in	regulating	the	epithelial	response	
to	IL-1b	would	have	import	in	a	wide	range	of	settings,	and	could	be	utilised	as	a	target	
for	future	anti-inflammatory	treatments.		
The	data	put	forward	in	this	work	propose	a	new	mechanism	by	which	inflammation	is	
regulated	within	 the	 infected	airway.	This	 is	 summarised	 in	 figure	6.1.	 In	 this	model,	
rhinovirus	infects	epithelial	cells	lining	the	airway	where	it	activates	pattern	recognition	
receptors	and	innate	immune	signalling	pathways,	including	the	MAPK	pathways.	This	
leads	 to	 the	 production	 of	 inflammatory	 cytokines	 which	 are	 secreted,	 recruiting	
immune	 cells	 such	 as	 monocytes	 to	 the	 site	 of	 infection.	 Rhinovirus	 infects	 and	
replicates	within	 these	monocytes,	 causing	 them	 to	 release	 inflammatory	 cytokines,	
including	 IL-1b.	 IL-1b	 binds	 to	 the	 receptor	 IL-1Ra	 on	 the	 surface	 of	 epithelial	 cells	
activating	 innate	 immune	 signalling	 pathways	 and	 the	 production	 of	 cytokines,	
potentiating	 the	 inflammatory	 response	 to	 rhinovirus.	 The	 response	 to	 IL-1b	 is	
negatively	regulated	by	DUSP10.	Therefore,	DUSP10	has	an	important	role	 in	 limiting	
the	inflammatory	response	in	rhinoviral	infected	airways.		 	
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Figure	6.1	The	role	of	DUSP10	in	the	rhinovirus	infected	airway.	
Rhinovirus	 binds	 to	 the	 epithelial	 cell	 surface	 triggering	 internalisation.	 Pattern	
recognition	receptors	recognise	aspects	of	RV	and	trigger	signalling	pathways	leading	to	
transcription	factor	(TF)	activation	and	the	production	and	secretion	of	 inflammatory	
cytokines.	Immune	cells,	including	monocytes,	move	towards	the	released	cytokines	by	
chemotaxis.	 Rhinovirus	 infects	 and	 replicates	within	monocytes.	 Infected	monocytes	
release	 IL-1b	 which	 binds	 IL-1RI	 on	 the	 epithelial	 surface.	 This	 triggers	 activation	 of	
signalling	pathways	 leading	to	the	production	and	release	of	 inflammatory	cytokines,	
which	is	regulated	by	DUSP10.		
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6.2 Limitations	of	the	Study	
The	major	limitation	of	this	work	is	the	inclusion	of	only	three	to	four	donors	in	each	
figure	as	the	donors	are	so	variable.	The	variability	between	donors	 is	expected,	and	
represents	the	differences	you	would	predict	within	the	population.	Although	a	wide	
age	range	was	included,	the	majority	of	donors	were	between	50	and	70	years	of	age	
and	11	out	of	13	donors	were	male.	The	smoking	status	was	known	for	8	donors	and	out	
of	these,	only	one	was	a	non-smoker	(Table	7.1).	This	makes	it	very	difficult	to	determine	
any	 patterns	 caused	 by	 donor	 characteristics.	 This	 donor	 variability	makes	 the	 data	
difficult	to	interpret	and	changes	may	be	missed	due	to	large	error	bars.	The	application	
of	 statistical	 tests	 to	 small	 numbers	 of	 replicates	 is	 also	 difficult	 and	 statistical	
significance	is	less	likely	to	be	found.	Therefore,	the	data	presented	here	would	be	made	
much	 more	 robust	 by	 the	 inclusion	 of	 a	 larger	 number	 of	 donors.	 However,	 the	
interesting	findings	within	this	study,	for	example	the	increase	in	CXCL8	production	in	
response	to	IL-1b	when	DUSP10	is	knocked	down,	are	clear.		
Another	 limitation	 is	 the	 use	 of	 small	 molecule	 inhibitors	 against	 the	 MAPKs.	 As	
discussed	 in	 section	 3.10.2,	 these	 inhibitors	 have	 many	 off-target	 effects.	 The	
concentrations	used	are	high,	well	above	the	IC50	values.	This	could	have	been	improved	
by	the	inclusion	of	dose	response	curves,	as	lowering	the	concentrations	would	reduce	
off-target	effects	and	allow	the	delineation	of	each	pathway	more	successfully.		
This	study	could	also	be	improved	by	the	use	of	purified	rhinovirus.	The	effect	of	viral	
filtrate	on	MAPK	activation	demonstrates	that	other	molecules	within	the	solution	are	
having	effects	on	the	cells,	although	this	does	not	lead	to	cytokine	release.	This	effect	
may	also	vary	between	batches	of	virus.	Although	each	figure	was	completed	using	the	
same	batch	of	virus,	this	adds	more	variability	into	the	study.		
6.3 Future	Work	
If	 DUSPs	 are	 to	 be	 used	 as	 future	 therapeutic	 targets	 for	 rhinoviral	 infection,	 it	 is	
important	 that	 they	 are	 fully	 understood.	 This	 includes	 characterising	 the	 pathways	
DUSPs	regulate	and	how	they	regulate	them,	and	how	these	pathways	impact	on	the	
expression	and	regulation	of	the	DUSPs	themselves.	Therefore,	validation	of	the	results	
presented	in	this	thesis,	for	example	the	data	generated	using	MAPK	inhibitors,	using	
alternative	techniques	and	purified	viral	stocks	is	of	importance.		
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The	regulation	of	DUSPs	1	and	10	in	response	to	rhinoviral	infection	should	be	further	
investigated.	DUSPs	can	be	post-translationally	regulated	in	a	number	of	ways,	including	
phosphorylation,	acetylation	and	oxidation	(Benavides-Serrato	et	al.,	2014,	Cao	et	al.,	
2008,	Kamata	et	al.,	2005).	Therefore,	the	effect	of	rhinoviral	 infection	on	DUSPs	has	
only	been	partially	investigated	so	far.	RV	infection	induces	an	earlier	phosphorylation	
of	 DUSP1	 than	 poly(I:C),	 suggesting	 that	 this	 is	 independent	 of	 TLR3.	 The	 pathway	
leading	to	this	phosphorylation	event	and	the	kinase	responsible	are	unknown.	An	early	
signalling	 pathway	 is	 also	 responsible	 for	 the	 loss	 of	 DUSP10	 in	 RV1B	 infection.	 To	
investigate	both	of	these	events,	a	panel	of	small	molecule	inhibitors	could	be	used	to	
block	a	range	of	signalling	pathways	to	narrow	down	the	protein	responsible.		
As	discussed	in	chapter	four,	siRNA	knock	down	of	DUSP1	was	unsuccessful.	Therefore,	
the	role	of	DUSP1	in	the	response	to	rhinoviral	infection	remains	to	be	understood.	The	
utilisation	of	overexpression	techniques	or	generation	of	CRISPR	knock	out	cells	could	
be	used	to	investigate	this	in	the	future.		
Rhinovirus	was	found	to	replicate	best	in	monocytes	when	no	serum	was	present.	The	
reason	for	this	remains	to	be	explored.	Initially	the	expression	of	ICAM-1	and	LDLR	on	
the	cell	surface	should	be	determined.	It	would	also	be	of	interest	to	learn	whether	the	
monocytes	infected	in	2%	serum	are	acting	as	a	reservoir	of	rhinovirus.	This	could	be	
determined	by	infecting	in	2%	serum	for	a	period	of	time	before	removing	the	serum	
and	measuring	whether	rhinovirus	replication	then	increases.		
The	major	findings	of	this	thesis	suggest	a	new	mechanism	by	which	DUSP10	regulates	
the	 inflammatory	 response	 to	 rhinovirus.	 This	mechanism	 is	 presented	 in	 figure	 6.1,	
however,	the	point	in	the	IL-1b	signalling	pathway	at	which	DUSP10	is	acting	remains	
unknown.	Potential	sites	at	which	DUSP10	may	act	are	presented	in	figure	4.18.	Data	
presented	 in	 this	 thesis	 suggests	 that	 DUSP10	 is	 not	 dephosphorylating	 the	 MAPK	
proteins	p38	or	JNK,	as	DUSP10	knock	down	did	not	increase	p38	or	JNK	activation	levels,	
however	 it	 is	 possible	 that	 the	 activation	 could	 be	 prolonged.	While	 this	 should	 be	
further	investigated,	it	would	also	be	interesting	to	investigate	whether	DUSP10	is	acting	
at	a	different,	novel,	point.	 If	 funding	were	available,	 it	would	be	exciting	to	utilise	a	
commercially	available	antibody	screen,	specific	to	phosphorylated	proteins.	This	would	
enable	the	identification	of	any	unknown	targets	of	DUSP10.	Expression	of	CXCL10	in	
response	 to	 IL-1b	 was	 decreased	 when	 DUSP10	 was	 knocked	 down.	 CXCL10	 is	
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transcriptionally	 induced	 by	 IRF1.	 Although	 this	 finding	 should	 be	 confirmed	using	 a	
more	 quantitative	 technique,	 such	 as	 ELISA,	 and	 samples	 from	 multiple	 donors,	 it	
suggests	a	point	at	which	DUSP10	may	be	acting	and	 investigation	 into	 the	effect	of	
DUSP10	knock	down	on	IRF1	activation	would	be	of	 interest.	Knock	down	of	DUSP10	
also	affected	expression	of	IL-1b	itself.	This	identifies	another	potential	role	for	DUSP10	
in	inflammasome	regulation.	This	also	links	 in	with	the	fact	that	DUSP10	knock	down	
causes	 significant	 cell	 death.	 Further	 investigation	 is	 required	 to	 determine	 the	
mechanism	of	cell	death:	pyroptosis,	apoptosis	or	necrosis.		
IL-1b	is	known	to	have	an	important	role	in	the	cross-talk	between	epithelial	cells	and	
monocytes	 in	 rhinoviral	 infection	 (Section	 5.1).	 This	 suggests	 that	 DUSP10	 has	 an	
important	 role	 in	 regulating	 the	 response	 to	 rhinovirus	 in	 the	 airway.	 Transfer	 of	
supernatants	from	monocytes	to	PBECs	was	found	to	induce	some	cytokine	secretion,	
suggesting	that	factors	secreted	by	monocytes	are	able	to	induce	inflammation	in	PBECs.	
It	would	be	of	interest	to	move	this	forward	into	a	co-culture	model,	as	previous	studies	
have	shown	that	it	is	not	only	secreted	factors	that	influence	cellular	communication,	
but	 cell-cell	 contacts	 (Lee	 and	 Rannels,	 1996,	 Tao	 and	 Kobzik,	 2002).	 However,	
monocytes	released	high	levels	of	cytokines	at	baseline,	likely	due	to	the	stress	caused	
by	a	 lack	of	serum.	 In	order	 to	move	forward	 into	co-culture	models,	optimisation	 is	
necessary	 to	 reduce	 this	 stress.	 Once	 optimised,	 the	 role	 of	 DUSP10	 in	 rhinoviral	
infection	can	be	 investigated	 in	a	multi-cellular	environment,	more	representative	of	
the	infected	airway.		
This	work	has	identified	DUSP10	as	an	important	regulator	of	airway	inflammation.	This	
could	lead	to	the	future	development	of	new	treatments	for	viral	induced	asthma	and	
COPD	exacerbations.	However,	more	work	is	required	in	order	to	fully	understand	these	
pathways	 before	 they	 can	 be	 manipulated	 for	 therapeutic	 use.	 This	 includes	
identification	of	the	proteins	targeted	by	DUSP10,	further	characterisation	of	regulation	
of	 DUSP10	 expression,	 and	 investigation	 into	 the	 role	 of	 DUSP10	 in	 a	multi-cellular	
environment.		
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6.4 Conclusions	
Exacerbations	 of	 asthma	 and	 COPD	 caused	 by	 rhinoviral	 infections	 represent	 a	
significant	cause	of	morbidity	and	mortality.	It	is	therefore	important	to	develop	new	
therapeutics	aimed	at	limiting	the	excessive	inflammatory	response	to	RV.	In	order	to	
do	 this,	 the	 pathways	 leading	 to	 this	 response	 and	 their	 regulation	 need	 to	 be	 fully	
characterised.	 This	 study	 has	 identified	 two	 pathways,	 p38	 and	 JNK,	 as	 important	
inducers	of	 inflammation	 in	response	to	RV,	and	characterised	the	expression	of	two	
potential	 regulators,	 DUSPs	 1	 and	 10.	 Both	 proteins	 were	 expressed	 in	 PBECs	 and	
regulated	by	RV	infection.	A	novel	role	for	DUSP10	was	characterised	in	limiting	cytokine	
production	in	response	to	IL-1b	alone,	and	in	combination	with	RV.	Therefore,	DUSP10	
plays	 an	 important	 negative	 regulatory	 role	 in	 the	 inflammatory	 response	 of	 airway	
epithelial	cells.	This	study	has	identified	DUSP10	as	a	potential	future	therapeutic	target	
for	exacerbations	of	asthma	and	COPD.		
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